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ABSTRACT 
 
The µ opioid receptor (µOR) exerts a powerful excitatory effect in cortical circuits and 
cultured neurons by promoting glutamatergic activity after binding endogenous or 
exogenous opioids. While most research indicates that the receptor does this by 
decreasing activity or output of GABAergic interneurons that inhibit glutamate-releasing 
Pyramidal Neurons, other experiments suggest that the µOR directly upregulates 
excitatory Pyramidal Neurons instead. Thus, the cellular target of cortical opioid agonists 
remains unclear, and the µOR’s net excitatory mechanisms are not fully understood. 
Consequently, utilizing electrophysiology to detect µOR responses to the specific agonist 
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin (DAMGO) has yielded incomplete 
information on its effects. This receptor has been shown to modulate both αDTX 
sensitive and insensitive currents in thalamic neurons to exert its effects, but this has not 
been investigated in cortical neurons. Here, we utilized a combination of calcium-
imaging and patch-clamp electrophysiology in cultured rat neocortical neurons to 
investigate the network and cellular effects of the µOR to understand its mechanisms and 
their consequences. With our experiments testing its effects on spontaneous calcium 
oscillations, we found that the µOR exerts its net excitatory effects through inhibition of 
GABAergic interneurons. Our separate set of studies using patch-clamp 
electrophysiology reveals that the µOR has multiple inhibitory effects on firing frequency 
and action potential kinetics, including αDTX-sensitive and insensitive ones. Thus, 
opioids suppress GABAergic interneurons to promote net excitation in cortical circuits. 
Collectively, these findings  promote our understanding of effects of endogenous or 
exogenous opioids on cortical networks, as well as provide robust analyses of the 
electrophysiological effects of the µOR which could provide insight into further studies 
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
 
1.1 Opioids and neuropharmacology 
Our understanding of neuroscience has been profoundly shaped by the pharmacological 
tools we have available. This is particularly true for the development and research in 
opioids, which have been used for thousands of years for both recreational and medicinal 
purposes (Santella & Triggle, 2007). Opium’s active component, morphine, was 
successfully isolated from the plant product by the mid-19th century (Blakemore & 
White, 2002). Since then, this chemical has been successfully modified to enhance its 
properties; in some instances, to enhance its pain-killing properties, and in other cases for 
nefarious purposes by leveraging its addictive and euphoric qualities. Codeine, 
papaverine, buprenorphine, fentanyl, methadone, and diamorphine (heroin) are all 
opioids – either natural or synthetic that have been developed over the generations 
(Brownstein, 1993; Pathan & Williams, 2012). These drugs are all exogenous opioids that 
are ingested, injected, or inhaled by the subject and they are not normally found in 
humans or other animals. 
Chemists eventually discovered drugs (such as naloxone and naltrexone) that can 
be co-administered to reverse the effects of morphine. But the mechanisms that all these 
opioid-derived drugs used to induce their effects on living beings remained a mystery for 
several generations. Some of earliest studies in modern neuropharmacology were 
dedicated to determining how these drugs physically interact with our physiology to 
produce their characteristic pain relief and euphoria. 
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Over 100 years later, in the 1970s, researchers identified the means that opioids 
use to exert their chemical effects using radio-labelled ligands; these drugs interacted 
with various receptor proteins located on cell membranes and were distributed unevenly 
in the brain and body (Goldstein, Lowney, & Pal, 1971; Kuhar, Pert, & Snyder, 1973; 
Pert & Snyder, 1973; E. J. Simon, Hiller, & Edelman, 1973; Terenius, 1973). The µ 
Opioid Receptor (µOR) is presently known to be the main target of these drugs and is the 
principal opioid receptor (OR) that mediates pain analgesia and euphoric effects of opioid 
drugs (Valentino & Volkow, 2018).  
Since it seemed unlikely that animals produce the µOR specifically for exogenous 
opiates, scientists predicted that these receptors were evolved for unidentified natural, 
neurotransmitters that may fulfill a pain-killing role in the brain (Brownstein, 1993). 
These hypothesized neurotransmitters were called endogenous opioids because they were 
believed to occur naturally within animals and bind to the same opioid receptors that the 
exogenous opioids were already known to target. Their existence was shown in 
experiments in the 1970s; it was discovered naloxone, which can reverse the effects of 
morphine, could also reverse the analgesia seen after repeated, painful shocks (Akil, 
Mayer, & Liebeskind, 1976). Thus, it appeared that animals secrete endogenous opioids 
which can be reversed the same way that an administered opioid drug could also be 
reversed. 
Several different endogenous opioids, and a few receptors for those endogenous 
opioids, were subsequently discovered over the decades. Fascinatingly, consuming opioid 
drugs are not the only means that the opioid neurotransmitter system can be disrupted; 
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several neuropsychiatric conditions are shown to feature a disrupted endogenous opioid 
system, which can lead then to aberrations in pain-sensitivity, and deficient motivation 
and poor mood (Ashok, Myers, Reis Marques, Rabiner, & Howes, 2019; Der-Avakian & 
Markou, 2012). The endogenous opioid neurotransmitter system is now a target for 
treatment in mood disorders exhibiting these symptoms (Butelman & Kreek, 2015; Lutz 
& Kieffer, 2013; Valentino & Volkow, 2018). The endogenous opioid system is also 
implicated in binge-eating disorders, which arise from defective reward-valuation 
processes by drive satiated animals to consume food (Giuliano & Cottone, 2015). Much 
of this research has centered on the neocortex, the center of higher-function and decision-
making. 
Yet despite the long history of medical opioids, the usage of opioids is perilous. 
Specifically, the addictiveness and rapid accumulation of tolerance to the drug has 
birthed the “opioid epidemic” of abuse. Some opioids, like heroin, originally were 
developed for medical applications but rapidly became popular as a drug of abuse 
(Hosztafi, 2001). Heroin is one of the most addictive substances in human history. In 
addition to the addictiveness and tolerance issues, opiates can induce respiratory 
depression through the µOR and, ultimately, to death in high doses (Valentino & 
Volkow, 2018). 
Around 750,000 Americans have died since 1999 from opioid overdose; about 
2/3rds of all drug overdoses are associated with opioids. This problem is also attributed 
partly to abuse of prescription opioids, which accounted for about 1/3rd of opioid-related 
deaths in 2018 (Services, 2020). Currently, there has been an interest in developing new 
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opioidergic drugs that can treat depression, impulsivity, and paradoxically, to also 
prevent addictions (Shippenberg, 2009; Sullivan, 2018). There is a critical need to 
understand how the µOR and opioidergic drugs function to exert their effects on brains. 
1.2 Overview of the cerebral cortex 
The human cortex constitutes almost half of the human brain and is associated with 
higher-order functions, such as perception, cognition, and voluntary movements (Molnár 
& Pollen, 2014; Rakic, 2009). This region of the brain has expanded immensely over 
mammalian evolution leading to greater brain complexity and is crucial for the 
intellectual capability and flexibility (Lui, Hansen, & Kriegstein, 2011). However, this 
greater complexity has been accompanied by greater vulnerability; this vast brain region 
is implicated in schizophrenia (Hashimoto et al., 2008; David A. Lewis, Curley, Glausier, 
& Volk, 2012), autism (Amaral, Schumann, & Nordahl, 2008; Carper & Courchesne, 
2005; Courchesne & Pierce, 2005; Zilbovicius et al., 1995), major depressive disorder 
(Bremner et al., 2002; Drevets, 2007; George et al., 2000; Lemogne, Delaveau, Freton, 
Guionnet, & Fossati, 2012), and attention-deficit hyperactivity disorder (Rubia et al., 
2010; Wolf et al., 2009).  
The human cerebral cortex encompasses the “wrinkly” superficial surface of the 
brain and is heavily gyrated (Lui et al., 2011). This region includes about 50 Brodmann’s 
Areas that often have differences in their cytoarchitecture, depending on their function 
and connections (Johns, 2014; Rakic, 2009). All cortical areas are constituted of several 
layers of neurons, and the various types of neurons can be distributed unevenly through 
the layers and region of cortex (Lui et al., 2011). 
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The cerebral cortex can be divided into 3 major components; firstly, the neocortex 
(also called isocortex); secondly, the allocortex, constituted of the paleocortex (primary 
olfactory cortex) and the archicortex (the hippocampus); and thirdly, the mesocortex 
(cingulate cortex and parahippocampal gyrus) (Johns, 2014). The neocortex usually has 6 
layers of stratified cortical neurons while the allocortex has 3 layers. The mesocortex, 
which is found between the allocortex and neocortex, has between 3-6 layers (Johns, 
2014). This dissertation project deals exclusively with the neocortex (specifically the 
frontal cortex), but the hippocampus expresses similar cell types, and they are sometimes 
used as models for each other. However, some differences between the neurons of the 
hippocampus and neocortex will be noted in this text. Whenever possible, I have cited 
experiments done in neocortical neurons, but I cite hippocampal studies in lieu of 
neocortical studies because of the sometimes-disproportionate volume of relevant 
research done on hippocampal neurons. 
All branches of science have benefited greatly from animal models. Animal 
models for neuroscience is particularly important because only animals possess brains, 
and brain research is sometimes a dangerous endeavor for the subject. While modern 
brain scans (PET, fMRI) are virtually harmless in moderation, much of neuroscience 
research requires “breaking” certain pathways and genes, or by introducing toxic reagents 
to understand how neurons work and interact with each other. Otherwise, all of 
neuroscience would strictly be correlational. Indeed, most every branch of science 
therefore requires models to serve as a stand-in for human participants, so that 
researchers can conduct science as ethically as possible. These findings can eventually be 
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translated into human medical science and improve the lives of humans (and nonhuman 
animals). However, neuroscience has a unique problem when compared to other branches 
of science; the brains of humans are incredibly complex when compared to other animals. 
Thus, while the genes of a fruit fly and a human may be sufficiently similar with genetics 
research - but the structure of their brains are not similar enough for most brain research. 
This problem is especially true for the neocortex of the human brain, which is uniquely 
complex and therefore difficult to compare with other animals.  
Our fellow primates (for example, chimpanzees) have well-developed 
neocortices, but they are difficult to handle and carry serious ethical ramifications. 
Rodents are a sensible starting point for studying neocortex because they are a model that 
are frequently used, and they can be handled relatively easily. Therefore, when scientists 
notice things about the brain that are initially observed in the brain scans of human 
subjects, other scientists can follow up on this research with studies done in rodents. 
1.3 Cortical neuroanatomy of the endogenous opioid system 
Much of the discussion in the literature about the roles of the endogenous opioid system 
revolves around several regions in the frontal cortex of humans. This region, fortunately, 
has homologs that can be studied in rats, and so I will delineate the relevant components. 
This includes the prefrontal cortex (PFC), the orbitofrontal cortex (OFC), and the anterior 
cingulate cortex (ACC). In humans, the PFC is the dorsolateral prefrontal cortex (dlPFC), 
ventrolateral prefrontal cortex (vlPFC), the medial prefrontal cortex (mPFC) and the 
ventral prefrontal cortex (vPFC) (Striedter, 2005).  
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But do rats have a region homologous to the human PFC? At first, the consensus 
was that rats do not, because their own medial PFC was agranular; it lacked a layer of 
small (Pyramidal) neurons that populated the middle cortical layers that was present in 
humans. But, with the evolution of techniques that allowed scientists to trace afferent and 
efferent fiber pathways in the brain, more attention was devoted to their connections than 
their histology. The functions of the human prefrontal cortex are present in rats as the 
mPFC in a simplified form. Currently the use of rat mPFC as a model for human PFC is 
justified for several reasons, including being targeted by fibers from the mediodorsal 
nucleus of the thalamus, which is a thalamic region associated with memory and planning 
– thus suggesting that rat mPFC was involved in these “higher functions” (Funahashi, 
2013; Rose & Woolsey, 1948). Similarities are also expressed on the neurotransmitter 
receptors; both human prefrontal cortex and rat mPFC have reciprocal connections of 
cholinergic fibers from basal forebrain nuclei, and as well reciprocal dopaminergic fibers 
to/from the ventral tegmental area (the VTA is part of the opioidergic reward system) 
(Carr & Sesack, 2000). The mPFC is also well-connected with the periaqueductal gray, a 
pain-killing neuroanatomical region that I will be discussing later (An, Bandler, Öngür, & 
Price, 1998; Hardy & Leichnetz, 1981; Ong, Stohler, & Herr, 2019; Y.-f. Xie, Huo, & 
Tang, 2009). Lesion studies also indicate that the human dlPFC and rat mPFC both 
mediate executive functions, such as decision-making, directing attention, and working 
memory (Hoover & Vertes, 2007). Therefore, the complex “human” brain functions that 
are distributed throughout a relatively large area, but can be found in a small, simplified 
form in the rat mPFC where it fulfills a similar function to humans.  
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Whether rats have a PFC has been a contentious topic, but the mPFC in rats is 
also intimately related to decision-making and the endogenous opioid system. This region 
expresses opioid receptors and opioid peptides (C. Jiang et al., 2019). This region is 
involved in suppressing impulsivity, binge-eating, mood disorders, reactivity to fear 
(Blasio, Steardo, Sabino, & Cottone, 2014; Selleck et al., 2015; Tejeda et al., 2015). In 
rats, the ORs in this region can instigate overeating with a preference for carbohydrate-
enriched foods(Mena, Sadeghian, & Baldo, 2011; Mena, Selleck, & Baldo, 2013).  
Like the mPFC, the orbitofrontal cortex (OFC) in rats is also connected with the 
mediodorsal nucleus and subcortical structures associated with the endogenous opioid 
system in humans and rats, which will be discussed later in this review (Heilbronner, 
Rodriguez-Romaguera, Quirk, Groenewegen, & Haber, 2016; Rose & Woolsey, 1948). 
This includes afferents from the ventral tegmental area, a region associated with the 
reward system (M. J. M. Murphy & Deutch, 2018). The OFC is implicated in addiction, 
decision-making, and depression (Bremner et al., 2002; Rolls & Grabenhorst, 2008; 
Volkow & Fowler, 2000). 
The ACC is located along the medial surface of the brain and consists of a ribbon 
of tissue that encloses the anterior portion of the corpus callosum. The OFC and ACC 
also play an important role in decision-making, attention, and behavior. They show 
prominent expression of opioid receptors and endogenous opioids in both humans and 
rodents (Lau, Ambrose, Thomas, Qiao, & Borgland, 2020; Mitchell et al., 2012). Rat 
neurons cultured from the ACC also express these receptors in vitro (E. Tanaka & North, 
1994). The ACC is implicated in behavior, affective disorders, schizophrenia and effort-
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related decisions (Benes, McSparren, Bird, SanGiovanni, & Vincent, 1991; Devinsky, 
Morrell, & Vogt, 1995; Elston, Croy, & Bilkey, 2019; Schweimer, Saft, & Hauber, 
2005). This region also interacts with the reward and antinociceptive systems(Narita et 
al., 2010; Navratilova et al., 2015).  
Although the hippocampal formation is not a neocortical region, this literature 
review will frequently reference their µORs. Some hippocampal neurons express µORs 
and endogenous opioids that bind to the receptor (Drake & Milner, 2006; H. K. Lee, 
Dunwiddie, & Hoffer, 1980; Madison & Nicoll, 1988; Przewlocki et al., 1999; Stumm, 
Zhou, Schulz, & Höllt, 2004; M. Whittington, Traub, Faulkner, Jefferys, & Chettiar, 
1998). Interfering with the endogenous opioid system there, by direct infusion of µOR 
antagonists into the CA3, interferes with both the encoding and the retrieval of spatial 
memory (Meilandt, Barea-Rodriguez, Harvey, & Martinez, 2004). These receptors may 
also interfere with memory retrieval during stress (Shi et al., 2020). Chronic 
administration of opioids is believed to reduce neurogenesis in this region, which may 
then contribute to some of the long-lasting cognitive effects of opioid addiction (Eisch, 
Barrot, Schad, Self, & Nestler, 2000; Persson et al., 2003). Therefore, the µORs and the 
endogenous opioids of the hippocampal formation are an important feature of memory 
encoding and retrieval. 
The endogenous opioid system of the neocortex collectively modulates 
antinociception, reward valuation and reward-seeking behaviors. Disruption of this 
neurotransmitter system is believed to contribute to pathological and compulsive 
behaviors, such as behaviors eating disorders, pathological gambling, and drug-seeking 
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(B. Bencherif et al., 2005; Badreddine Bencherif et al., 2005; Joutsa et al., 2018; Mick et 
al., 2016; Mitchell et al., 2012; Qu, Huo, Huang, & Tang, 2015; Zubieta et al., 1996). 
Some neuropsychiatric disorders, such as schizophrenia are associated with abnormalities 
in the cortical opioid system, which may produce some of the cognitive symptoms 
(impairments in executive control) featured in that disorder (Volk, Radchenkova, Walker, 
Sengupta, & Lewis, 2012). People with schizophrenia also have reduced affective 
responses to pain (Ashok et al., 2019; de la Fuente-Sandoval, Favila, Gómez-Martín, 
León-Ortiz, & Graff-Guerrero, 2012; Linnman, Coombs, Goff, & Holt, 2013; Stubbs et 
al., 2015), which can also be found in animal models for the disease (Kekesi et al., 2011; 
Szűcs, Büki, Kékesi, Horváth, & Benyhe, 2016). In a broader context, poor inhibitory 
control and motivational drive is featured in many psychiatric conditions, such as 
depression, attention deficit hyperactivity disorder, and drug addiction (American 
Psychiatric Association; Jentsch & Pennington, 2014; Kaye et al., 2013; Merriam, Thase, 
Haas, Keshavan, & Sweeney, 1999; Puumala & Sirviö, 1998; Smith, Mattick, Jamadar, & 
Iredale, 2014; Wise, Murray, & Gerfen, 1996). Although the pain-modulation component 
appears related to cortical connections to the PAG, these latter functions are likely 
mediated through cortical projections to the hypothalamus and nucleus accumbens 
(Baldo, 2016). 
Taken together, the anterior cingulate, orbitofrontal and mPFC of rodents express 
ORs, opioid neurotransmitters, and are interconnected with other neuroanatomical 
regions that mediate the notable functions of opioids. These cortical regions interact with 
a vast network of subcortical regions to compose the endogenous opioid system. 
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1.4 Subcortical neuroanatomy of the endogenous opioid system 
Although the primary focus of these experiments is the ORs of the neocortex, both the 
cortical and subcortical opioidergic systems interact to exert their effects on animals. This 
is particularly true because opioids that are taken orally or injected intravenously can 
often bind to ORs in both areas. In addition, neuropsychiatric conditions that afflict the 
endogenous opioid neurotransmitter system may also include both cortical and 
subcortical regions, and extensive research on subcortical µORs has been performed for 
many years. These experiments can be used to make predictions about their mechanisms 
in the neocortex. I will therefore describe these subcortical components to explain how 
they collaborate with cortical regions. 
The periaqueductal gray (PAG) of the midbrain (in the brainstem) is perhaps the 
best-known pain-modulating center of the brain (Devinsky et al., 1995; Hardy & 
Leichnetz, 1981; Royce, 1983). The PAG manages descending pain inhibition mostly 
through its input on the rostroventral medulla (RVM). The RVM sends serotonergic 
fibers (interacting regions may send noradrenergic fibers) down the spinal cord and 
activate neurons in the dorsal horn of the spinal cord (Ossipov, Morimura, & Porreca, 
2014). The effect of serotonin on their spinal targets is predicted by the particular 
receptor subtype, but opioids administered to directly to the PAG results in recruitment of 
RVM neurons, which then leads to descending inhibition of pain (for review, see 
(Ossipov et al., 2014)). Many parts of the brain modulate activity of the PAG because, by 
extension, this allows many parts of the brain to modulate pain transmission. 
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The ventral tegmental area (VTA) is a part of the brainstem that has strong control 
over motivated/rewarding behaviors (Fields & Margolis, 2015). The VTA is rich the 
dopamine-secreting efferent fibers (fibers from principal cells of the VTA) which project 
to several parts of the brain, including the prefrontal cortex. Application of opioids into 
the VTA increases firing rates of the principal neurons there, and leads to greater 
dopamine secretion (Carr & Sesack, 2000). It serves as a critical link between opioids and 
reward/addictive behaviors; ORs in the VTA can modulate the secretion of dopamine to 
the nucleus accumbens to reinforce drug-seeking, while also projecting to cortical regions 
to influence decisions being made there (Langlois & Nugent, 2017). For instance, the 
VTA’s bidirectional connections with the anterior cingulate cortex facilitates the 
consideration of cost/benefit decisions in animals (rats, in this experiment) (Elston et al., 
2019). The prefrontal cortex also provides excitatory input back to the VTA and is 
therefore able to influence activity there as well by synapsing on the neurons of the VTA 
(Carr & Sesack, 2000). 
The amygdala is involved in fear and anxiety responses of animals, but it also 
plays a role in decision-making which will be discussed in greater detail later. But its 
function extends beyond its typical role of the “fear sensor” of the brain, and this region 
likewise contributes to reward-valuation in animals (Wassum, Ostlund, Maidment, & 
Balleine, 2009). Sensory cortices and the sensory portion of the thalamus project here to 
provide this region with their input (Janak & Tye, 2015). The central nucleus of the 
amygdala (CeA) projects to the PAG to modulate pain sensation. Meanwhile, the 
basolateral amygdala (BLA) projects to the prefrontal cortex to contribute to decision-
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making with rewards or aversive consequences (Barbas, 2000; Bechara, Damasio, Tranel, 
& Damasio, 1997; Morrison & Salzman, 2010). Opioids in this region can modulate 
excitability in the central nucleus and basal lateral amygdala (Winters et al., 2017). 
The data I have cited here mostly come from data about focal or application of 
opioids to a confined neuroanatomical region through microinfusions. This procedure 
allows researchers to determine the exact contribution of µORs in a given region of 
interest, but systemically-administered opioids tend to cause many effects (e.g., euphoria 
and pain-relief) to come hand-in-hand because they act on virtually all the components of 
the opioidergic system. For instance, by causing pain relief and euphoria to coincide by 
acting on opioid receptors in the cortex, PAG, amygdala, and VTA all simultaneously. 
Therefore, while the µORs in precise regions may fulfill narrow roles, all these effects 
tend to happen simultaneously when someone takes an opioidergic drug. 
1.5 Opioids: decisions and rewards 
One of the most well-known features of the opioid system is its relationship with reward 
valuation, addiction, and drug abuse. The relationship between opioids and rewards is 
partially due to the high levels of opioid receptors expressed in the VTA – a region rich 
in dopamine-expressing principal neurons which, in turn, then lead to 
rewarding/pleasurable feelings and could encourage certain behaviors in the future (for 
review, see (Fields & Margolis, 2015)). Decisions and reward-seeking behaviors is a 
closely related feature based on valuations, which is a function of the VTA and cortical 
areas. Binge-eating, for instance, is an aberration in the valuation process that leads an 
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animal to overconsume food even when they are presently satiated (Giuliano & Cottone, 
2015; Mena et al., 2011; Mena et al., 2013; Selleck et al., 2015).  
To explore the link between brain regions and the activity of endogenous opioids, 
researchers use radio-labeled µOR-agonists and brain scans to monitor the activity of 
those receptors when a subject is participating in a designated task. Drug use is correlated 
with the release of endogenous opioids in the human orbitofrontal and ACC (Colasanti et 
al., 2012; Mick et al., 2014; Mitchell et al., 2012). These scans also allowed researchers 
to explore the relationship between expected outcomes and activity in the neocortex as 
well; placebo effects enhance dopamine and opioid release in the cortex and VTA, while 
nocebo effects correlate with reduced dopaminergic and opioidergic activity there (Scott 
et al., 2008).  
Beyond the brain scans and correlative data, a great deal of information about the 
cortical contribution to reward-valuation and decision-making is also derived from 
microinfusions of opioids into discrete regions of the brain. Infusion of the opioid 
agonists (specifically, the µOR agonist DAMGO) into rat mPFC drives feeding, 
carbohydrate intake, and locomotive behaviors in satiated rats and is accompanied by 
enhanced activity in the hypothalamus and nucleus accumbens shell (Mena et al., 2011; 
Mena et al., 2013; Selleck et al., 2015). Blockade of the µOR from endogenous opioid 
neurotransmitter with naltrexone in the mPFC inhibits binge-eating in rats, which 
suggests a causal link between engaging in compulsive actions and release of endogenous 
opioids in the mPFC (Bartus et al., 2003; Blasio et al., 2014). Opioid antagonists (namely 
naltrexone) are also FDA-approved for treating poor impulse-control, presumably due to 
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their ability to unlink opioidergic and dopaminergic activity in the brain (Pettinati et al., 
2006; Soyka & Rosner, 2008). 
The VTA’s efferent connections to other parts of the brain allow it to stimulate 
reward-seeking behaviors where effort is invested (Narita et al., 2010; Ramsey, Gerrits, 
& Van Ree, 1999; Schweimer et al., 2005). In the VTA, like other areas of the brain, 
opioid receptors suppress local inhibitory neurons, which then produces an acute increase 
in activity of efferent principal neurons (Billy Chieng, Azriel, Mohammadi, & Christie, 
2011; Johnson & North, 1992; Margolis, Toy, Himmels, Morales, & Fields, 2012). These 
dopaminergic connections then project to several locations, including the nucleus 
accumbens and hypothalamus (Narita et al., 2010; Pierce & Kumaresan, 2006; Zheng, 
Patterson, & Berthoud, 2007). The nucleus accumbens is important to reinforce 
addictions/rewards, while the hypothalamus can drive feeding behavior (Carr & Sesack, 
2000). Additionally, the VTA also projects to cortical regions, such as the mPFC, OFC, 
ACC to facilitate the decision-making processes (Narita et al., 2010; Pierce & 
Kumaresan, 2006; Zheng et al., 2007) 
Both the mPFC and OFC play important roles in decision-making, but they do not 
have exactly the same roles. The OFC’s contribution to the reward system is encoding the 
hedonic value of the reward. For example, this region is associated with the devaluation 
of the reward during satiety or illness (Rudebeck & Rich, 2018). Consistent with this, 
infusion of opioid agonists in this region enhances the valuation of rewards (Castro & 
Berridge, 2017). Meanwhile the mPFC mediates the execution and monitoring of the 
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selected action once the decision has been made (Phillips, MacPherson, & Della Sala, 
2002). 
1.6 Opioids: analgesia and pain-perception 
Pain perception is sometimes (and erroneously) seen as a simple and reflexive process 
from the painful stimulus to the perception of it. But pain perception is profoundly 
shaped by emotional and affective processes happening in the frontal cortex (for review 
of the PFC and pain, see (Devinsky et al., 1995; Hardy & Leichnetz, 1981; Lasagna, 
1964; Ong et al., 2019; Petrovic, Kalso, Petersson, & Ingvar, 2002; Royce, 1983; 
Westlund & Willis, 2015). Expectations, moods, and dispositions all affect the way we 
perceive and express pain. For instance, the analgesic effects of placebos are mediated by 
the ACC, PFC, insula (Choi et al., 2016; Qiu, Wu, Xu, & Sackett, 2009; Zubieta et al., 
2001), which shows that pain perception is shaped by complex processes in the 
neocortex. 
Much of pain modulation is carried out by the PAG, which has control over 
descending fibers that can interfere with the transmission of pain in the spinal cord. 
Exogenous/endogenous opioids, drugs, and other neurotransmitters can enhance PAG 
activity, which then modulates the RVM. The RVM projects serotonergic efferent fibers 
down the spinal cord, along with noradrenergic fibers from associated regions. Thus, 
opioids can have a tremendous effect on descending pain modulation and reducing the 
pain signal that enters the brain. But opioids can reduce the affective expression of pain 
but leave the actual pain perception component intact (Amir & Amit, 1978; Oertel et al., 
2008). Therefore, animals may feel the pain, but simply just care less about it. Several 
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regions of the brain can modify the activity of the RVM and PAG to influence pain 
perception, including the PFC (Bingel et al., 2011).  
The PAG receives most of its afferent input from the mPFC, with smaller input 
from the somatosensory, insular, and cingulate cortices (Hardy & Leichnetz, 1981; Ong 
et al., 2019; Y.-f. Xie et al., 2009). This pathway appears to be specifically activated 
when treatments are expected to lead to pain relief (including placebos) (Choi et al., 
2016). Placebo and nocebo effects appear to have opposite polarity in opioid and 
dopamine release in cortical areas and the PAG which demonstrates a relationship 
between these two regions, evidence for cortical processing of pain perception, and the 
relationship between opioids and dopamine (Scott et al., 2008).  
To investigate the correlational studies from brain imaging, scientists have done 
experiments with microinfusions in animal models. For instance, infusion of opioid 
agonists into the ACC of rats blocks pain-induced aversion during conditioned place 
preference tasks (Navratilova et al., 2015). Infusions of opioid agonists into the 
ventrolateral cortex of rats induces a naloxone-reversible inhibition of their tail-flick 
reflex in response to pain (X. Huang, Tang, Yuan, & Jia, 2001). Therefore, it appears that 
opioid receptors in neocortical (ACC) regions can modulate our reactions and aversion to 
pain. 
Reactivity and expression of pain is also a very important feature that neocortical 
regions and the endogenous opioid system contribute to. Fear-conditioned analgesia 
(where an animal has a weak reactivity to painful stimuli in a place that has been 
previously paired with painful stimuli) has been shown to be modulated by endogenous 
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opioids through microinfusions into the amygdala (Butler et al., 2011; Tershner & 
Helmstetter, 2000). This is most likely related to projections from the amygdala to the 
PAG (Helmstetter, Tershner, Poore, & Bellgowan, 1998). However, in addition to 
directly projecting to the PAG, the BLA neurons can also project to the mPFC, and PNs 
in Layer 5 can then project down to the PAG as well (Cheriyan, Kaushik, Ferreira, & 
Sheets, 2016). The amygdala has bilateral connections with the cortex that are believed to 
be involved in fear conditioning an anticipation of pain and strengthened in people with 
chronic pain (Butler et al., 2011; Cheriyan et al., 2016; Simons et al., 2014). These 
nociceptive neurons of the mPFC are likely to be related to affective demonstration of 
pain, or the expectation of pain rather than to detect and discriminate pain (Onozawa, 
Yagasaki, Izawa, Abe, & Kawakami, 2011). µORs in the mPFC can modulate reactivity 
to fear (relayed by input from the basolateral amygdala) (Tejeda et al., 2015). 
So then if all of these brain regions collaborate to affect nociception, what then is 
the unique role of the PFC in this network? It is believed that the PFC uses the mood or 
expectations of the subject to modify the perception of their pain. Many factors could 
contribute these moods and expectations - for example, expectations from 
pharmacotherapy, memories, psychotherapy, and conscious suppression of pain could all 
modify the perception and expression of pain (Ong et al., 2019). 
The mPFC, OFC and ACC are therefore involved in pain perception, pain 
expression, and decision-making. They also have opioid receptors that can be used to 
affect all these features. Having explained the gross neuroanatomy component of the 
endogenous opioid system, I will now refocus the attention on the neocortex by 
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introducing the neurons in that region. By doing this, we can then begin to understand 
how endogenous opioids exert their effects on neocortical networks and individual 
neocortical neurons. 
1.7 Introduction to neocortical neurons 
Neurons of the neocortex are composed of 2 main categories of neurons that interact and 
form a network to carry out the functions of the neocortex: the excitatory neurons and 
inhibitory neurons. These excitatory and inhibitory neocortical neurons form synapses on 
other neurons, which allows them to influence the firing on the neuron that they synapse 
onto. Any given neocortical neuron may receive input from both inhibitory and excitatory 
neurons, as well as afferent fibers from distant brain regions that I have previously 
discussed here. Since these neurons receive both excitatory and inhibitory input, their 
own firing tendency (excitability) depends on which of the two types of input are stronger 
in any given moment. 
The most common type of neocortical neuron (about 80%) are the excitatory 
(glutamatergic) neurons that can synapse on nearby neurons, as well as neurons that are 
far away (DeFelipe & Fariñas, 1992; Noback, Strominger, Demarest, & Ruggiero, 2005). 
The other 20% are inhibitory (GABAergic) which synapse only on nearby neurons. 
The inhibitory neurons will suppress the nearby excitatory neurons by secreting 
GABA (γ-aminobutyric acid). Meanwhile the excitatory neurons synapse onto both near 
and far neurons and secrete the excitatory neurotransmitter glutamate. Both neuronal 
types may also produce other neurotransmitters, including endogenous opioids, which 
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may also produce other effects on their targets. These two neuron types interact heavily 
to regulate each other’s excitability (tendency to fire).  
1.8 Excitatory cortical neurons 
Most cortical excitatory neocortical neurons have a pyramidal shape and therefore are 
called Pyramidal Neurons (PNs). A smaller group of excitatory neurons, called granule or 
stellate neurons, can be also found, but they are mostly found in sensory cortex (Johns, 
2014). 
Pyramidal Neurons (PNs) are glutamatergic neurons found in all cortical layers 
except Layer I (DeFelipe & Fariñas, 1992); Noback et al., 2005). However, they tend to 
stratify in Layers 2/3 and Layer 5. Their projections can be directed locally or directed to 
other parts of the cortex and subcortical areas. They form asymmetric synapses at their 
targets, which include interneurons and dendritic spines of other PNs. Although these 
cells are relatively homogenous when compared to interneurons, PNs can assume a 
variety of shapes (DeFelipe & Fariñas, 1992). Generally, though, they have a pyramidal-
shaped soma between 20-120 µM wide and have elaborate branches directly off their 
soma. Their apical dendrites project into Layer I of the neocortex and disperses into 
branches. All PNs bear ~10,000 spines along their apical dendrites which represent an 
excitatory postsynaptic density – which is where another excitatory neuron has synapses 
onto them. They may also have smaller, basal dendrites at the other 2 angles of their 
pyramidal soma. Their axon projects from the basal part of the neuron, opposite the 
apical dendrite (Johns, 2014). 
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Excitatory neurons develop from the dorsal telencephalon (the pallium) and 
migrate radially to the cortical plate from the germinal zone during embryonic 
development(Campbell, 2005). PNs in the deep layers develop first and then are bypassed 
by newer progenitors that create the superficial cortical layers (Campbell, 2005). 
Therefore, the Layer 5 PNs usually develop earlier than Layer 2/3 PNs. 
Some research in the neocortex using immunocytochemistry (ICC; an antibody-
based technique to identify the localization of specific proteins) have specifically looked 
for expression of the µOR in PNs. For the most part, PNs in neocortical regions do not 
express the µOR. For example, 96.9% of the µOR-expressing (µOR+) neurons in the 
neocortex have been found to produce GABA (Taki, Kaneko, & Mizuno, 2000). On the 
other hand, some research teams have reported µOR-immunoreactivities on neocortical 
PNs during their immunocytochemistry (ICC) experiments – so there is a possibility that 
some do express the µOR (Schmidt et al., 2003). 
1.9 Inhibitory cortical neurons 
Cortical interneurons make up the remaining 20% of neocortical neurons and they can 
belong to smaller subcategories of interneurons. All the inhibitory neurons secrete the 
neurotransmitter GABA, which binds to postsynaptic/extrasynaptic GABAA and 
(sometimes) GABAB receptors, causing inhibition in their targets. Although these 
inhibitory neurons can be targeted by other neurons in distant parts of the brain, but they 
only synapse on local neurons. Therefore, these inhibitory cortical neurons are also called 
interneurons or, more precisely, GABAergic interneurons which excludes the 
glutamatergic interneurons.  
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Cortical interneurons have a short axon that projects locally, and they often 
receive afferent fibers from cortical and noncortical areas. For example, the mediodorsal 
nucleus of the thalamus projects to the rat mPFC and synapses on mostly interneurons 
over PNs (Rotaru, Barrionuevo, & Sesack, 2005), These axons can arise from the soma or 
principal dendrites of the interneuron (The Petilla Interneuron Nomenclature Group, 
2008). Beyond that, their morphology can differ dramatically from fellow interneurons 
and is not an unambiguous indicator of cell type. Given their wide range of properties, 
scientists were driven to categorize different interneurons in order to understand their 
collective role in the brain. 
However GABAergic interneurons are notoriously difficult to subclassify, 
because of the combinations of morphology, expression markers, and physiological 
properties that they can possess. But these distinctions are important because different 
subsets of interneurons have different roles, and there are some general patterns and 
distinctions. The lack of a formal criteria for classification led to formation of a 
consortium of scientists, the Petilla Interneuron Nomenclature Group (PING), that was 
established to consolidate research and to provide a standard classification of 
interneurons for neuroscientists (Batista‐Brito & Fishell, 2009; The Petilla Interneuron 
Nomenclature Group, 2008). Although individual labs have their own internal preferred 
categorization systems, most classification schemes are similar to PING’s scheme. 
Pioneering studies in rodent cortical interneurons have initially grouped all 
cortical interneurons into 3 distinct and non-overlapping classes based on expression of 
protein markers (Kawaguchi & Kubota, 1997; McCormick, Connors, Lighthall, & Prince, 
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1985). These classes are parvalbumin-positive (PV+) interneurons, vasoactive intestinal 
peptide-positive (VIP+) interneurons, and somatostatin-positive (SST+ or SOM+) 
interneurons. However, in the years since then, a much more complicated portrait 
emerged; interneurons are difficult to group into discrete classes because they sometimes 
express more than one of those definitive markers, or apparently don’t express any of 
those markers (Markram et al., 2004; Parra, Gulyas, & Miles, 1998). The variability in 
interneuronal properties could obfuscate results of experimental error (Markram et al., 
2004). Nevertheless, the conventional categorization scheme provides useful (though 
flawed) heuristics for inferring properties based on distinct cell markers. 
The proportions of each group to the total interneuron population in the 
somatosensory cortex are roughly as follows: 40% for PV+ interneurons; 30% for SST+ 
interneurons; and 30% for the serotonin receptor 5HTa3R+. The latter group 
encompasses VIP+ interneurons and, some have argued, is a more parsimonious 
interneuronal marker than VIP (Bernardo Rudy, Fishell, Lee, & Hjerling-Leffler, 2011). 
The subdivisions of interneurons could be further divided into groups based on the 
presence or absence of other markers, and they can have alternative cell markers (Kubota 
& Kawaguchi, 1997; Bernardo Rudy et al., 2011; Taki et al., 2000; The Petilla 
Interneuron Nomenclature Group, 2008). Cortical interneurons are often described in 
very literal terms; a given neuron might be described as “fast-spiking” during 
electrophysiological studies or “parvalbumin-positive” (PV+) during ICC studies - even 
though the properties tend to be mutually inclusive (i.e., fast-spiking neurons are almost 
always PV+, and vice versa).  
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Cortical interneurons have numerous properties that distinguish them from PNs. 
Experiments in the hippocampus show that many of these differences maximize their 
speed and reliability. Some cortical interneurons, such as PV+ basket cells, also innervate 
other interneurons of the same type through both electrical and chemical synapses 
(Galarreta & Hestrin, 1999, 2002; Gibson, Beierlein, & Connors, 1999; Juszczak & 
Swiergiel, 2009). These adaptations are predicted to enable interneurons to synchronize 
reliably and orchestrate network activity that are important for executive function (for 
review, see Miles (2000)) (Miles, 2000). The importance of synchronization will be 
discussed later. 
The presence of the µOR and endogenous opioids within interneurons have been 
reported extensively with ICC in studies of the hippocampus and neocortex (Arvidsson et 
al., 1995; Suzanne B Bausch & Chavkin, 1995; S. B. Bausch et al., 1995; Drake & 
Milner, 1999, 2002, 2006; Taki et al., 2000). These experiments also allow us to predict 
which categories of neurons are most likely to express the µOR, and further allow us to 
predict how this relates to the effects of the µOR given the groups that the µOR is found 
in. 
1.10 µOR-expressing cortical interneurons 
The rate of expression of the µOR has usually been determined through ICC stains of 
neocortical or hippocampal slices. However, antibodies generated for the µOR have 
shortcomings for reasons that I will address later. Another confounding feature is that 
different methods of localizing the µOR produces slightly different rates of expression. 
Finally, the hippocampal formation and the neocortex appear to show some differences 
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distributions of the receptor. While obviously neocortical data is more applicable to 
experiments of the µOR in the neocortex, a great deal of data about cortical µORs is 
derived from studies done in the hippocampal formation. These points of disagreement 
will be commented on throughout this literature review. 
Yet despite the limitations of primary antibodies for the µOR, they can still 
provide a useful starting point for understanding how often (and where) the receptor may 
be found; in the neocortex, ICC data and an experiment with a fluorescent ligand 
suggests that it is expressed by only 5-20% of neocortical interneurons (or 3-5% of all 
neurons) (M. C. Lee, Cahill, Vincent, & Beaudet, 2002; Taki et al., 2000).  
Researchers have also delved further to identity of these µOR+ neurons (µOR+ 
are neurons “positive” for the µOR) based on their coexpression of different markers for 
interneurons. ICC data on rat neocortical slices show that about 97% of µOR+ produce 
GABA, showing that µOR are mostly GABAergic. The majority (92%) of µOR+ had 
also expressed VIP indicating that the VIP+ pool of interneurons is the biggest 
contributor to the µOR+ interneurons. Inversely, 70.2% of VIP+ neurons showed 
presence of the µOR. Meanwhile, 8.2% showed presence of PV; and 2.9% showed 
presence of SST. Inversely, only 1.1% of PV+ neurons and 0.6% of SST+ neurons 
showed the presence of µOR puncta suggesting that these neurons rarely express the 
µOR – or at least not in their somata; this technique may not be relied upon to identify 




But electrophysiology-based experiments (which probably also include sampling 
bias towards certain interneurons) show much higher estimates than ICC experiments in 
neocortical slices; one group found a DAMGO response in 2/3rds of the neocortical 
interneurons that they surveyed with electrophysiology (while none of 18 PNs showed a 
response) (Witkowski & Szulczyk, 2006). 
Another electrophysiology-based experiment that also utilized sc-PCR tested 
various neocortical neurons for µOR mRNA and probed for a response to DAMGO; they 
found a DAMGO response (indicated by hyperpolarization and a decrease in input 
resistance) in 86 interneurons out of 169 recorded neurons. However, they only detected 
presence of µOR mRNA in 62.5% of the neurons that had responded to DAMGO, 
indicating that the DAMGO exposure was the more sensitive technique for detecting the 
receptor. Most of their responders were regular or irregular-spiking and had a high 
incidence of expression of VIP. They did not appear to sample neurons randomly, for 
example, only 98 of 360 recordings were PN, despite constituting 80% of the neurons of 
the cortex. All DAMGO responders tested positive for GAD65 or GAD67 mRNA, and 
none of the PNs hyperpolarized to the DAMGO application or showed presence of µOR 
mRNA (Férézou et al., 2007).  
Interestingly the Ferezou et al. (2007)  noted an exceptionally high rate of 
DAMGO responders were found in the Layer 1 of the cortex and conformed to the 
NGFCs morphology. This indicates that these neurons likely express high rates of the 
µOR (Férézou et al., 2007). This receptor has been observed in the NGFCs of the 
hippocampus as well (Krook-Magnuson, Luu, Lee, Varga, & Soltesz, 2011; C. J. Price, 
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Scott, Rusakov, & Capogna, 2008). Taken together, these studies indicate that cortical 
neurogliaform neurons are likely to express this receptor. 
Although hippocampal studies can often be applied to neocortical studies (in that 
the neuron types are strongly similar), the electrophysiology and ICC experiments in both 
locations has raised some debate over the localization of the µOR in the PV+ neurons of 
the neocortex. As I’ll explain next, several groups have observed the µOR in the PV+ 
interneurons hippocampus, but other research groups have failed to find it in the PV+ 
interneurons of the neocortex. While this may be pedantic, PV+ interneurons are the 
largest group of neocortical interneurons and are important to the regulation of 
neocortical PNs. Thus, their susceptibility to opioidergic activity is not a trivial matter 
and could be very consequential to neocortical activity. 
Expression of the µOR has been reported extensively in the somata of PV+ 
interneurons of hippocampal cortex, as indicated by immunostaining (Bartos & Elgueta, 
2012; Suzanne B Bausch & Chavkin, 1995; Drake & Milner, 1999, 2002, 2006; Stumm 
et al., 2004; Torres-Reveron et al., 2009). Studies have also shown that some PV+ 
interneurons of the hippocampus have also found a stereotypical hyperpolarizing 
response to DAMGO (Glickfeld, Atallah, & Scanziani, 2008; K. R. Svoboda, Adams, & 
Lupica, 1999). These experiments have led some to infer that they are also expressed by 
PV+ interneurons in the neocortex as well (Volk et al., 2012). However, the best current 
information suggests that this is rare (Taki et al., 2000). Additionally, in the report I 
described earlier, there was a lack of reported DAMGO responses in fast-spiking 
interneurons, even though 38 were tested for it (Férézou et al., 2007). Yet recent work 
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using electrophysiology and optogenetics in the mPFC cortices of mice found that the 
µOR regulates the amplitude and duration of inhibitory postsynaptic potentials in PNs 
with PV+ presynaptic terminals (C. Jiang et al., 2019). An even more-recent study 
likewise reported similar results in some parts of the OFC (Lau et al., 2020). Taken 
together, it appears likely that the µOR+ is sometimes found in PV+ neurons in the 
neocortex - as it is in the hippocampus. However, there does not appear to be perisomatic 
expression of the µOR in PV+ neurons of the neocortex (as there is in the hippocampus, 
to a high degree), which makes the frequency of colocalization in PV+ neurons difficult 
to determine. With the lack of perisomatic expression of the µOR+, there may not be a 
characteristic hyperpolarizing DAMGO response from recordings made in the somata of 
fast-spiking (mostly PV+) interneurons of the neocortex. 
So, it appears that neocortical expression of the µOR may be found in many VIP+ 
neurons, neurogliaform neurons, and likely PV+ terminals as well, but ICC perhaps is not 
the best way to definitively determine its localization, due to nonsomatic expression and 
the general difficulties of producing antibodies for GPCRs (Jo & Jung, 2016). 
Furthermore, efforts using OPRM1-driven (the gene for the µOR) expression of 
fluorescent proteins may not be a reliable indicator for the same reason (Erbs et al., 2015; 
Gardon et al., 2014). To address this problem, efforts are underway to leverage the 
Cre/Lox recombinase system to reliably localize this receptor (Bailly et al., 2020). Until 




While the pattern of expression can be roughly deduced from the combination of 
ICC and electrophysiology data shown here, it does not explain what these neurons do in 
circuits or an intact brain. To understand the effects of the µOR in the neocortex, I must 
next explain the roles of the PV+, VIP+, and neurogliaform neurons. From that 
information, we can make more informed predictions on the net result of µOR 
application on neuronal networks. 
1.11 Roles and features of µOR+ interneurons: PV+ and VIP+ 
The PV+ interneurons of the neocortex are powerfully involved in the regulation of the 
excitation/inhibition (E/I) balance in this region. Their inhibitory control over PNs is 
illustrated by data that show nearly every PV+ interneuron synapses with every nearby 
PN (Packer & Yuste, 2011). PV+ have strong control over the firing of PNs, and their 
synchronized network carefully controls the timing of PN neuron spiking (Agmon & 
Connors, 1991). These neurons are implicated in executive function of the neocortex 
(David A   Lewis, 2014), and are hypoactive in psychiatric conditions, such as 
schizophrenia (Glausier, Fish, & Lewis, 2014; Volk et al., 2002) and autism (McNally & 
McCarley, 2016; Rojas & Wilson, 2014). Therefore, there is a strong link between the 
role of PV+ interneurons and overall cortical function due to their tight regulation of 
excitatory activity (B. R. Ferguson & Gao, 2018). For review on the role of PV+ 
interneurons on neuropsychiatric illnesses, see (B. R. Ferguson & Gao, 2018). 
VIP+ interneurons that express the µOR have been shown to express nicotinic 
receptors (Férézou et al., 2007) and often also express ChAT (Taki et al., 2000). This 
finding is consistent with other research showing that VIP+ interneurons respond to 
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acetylcholine (Fu et al., 2014). On a larger scale, there is a relationship between the 
nicotine and the endogenous opioid system, namely, that nicotine seems to stimulate 
release of these endogenous opioids (Mandillo & Kanarek, 2001; Mathieu-Kia, Kellogg, 
Butelman, & Kreek, 2002; Pomerleau, 1998).  
VIP+ interneurons have been shown to inhibit nearby interneurons(Fu et al., 
2014; Jackson, Ayzenshtat, Karnani, & Yuste, 2016; Pi et al., 2013). Yet this raises an 
interesting issue; how can opioids, which suppresses VIP+ neurons, lead to disinhibition 
of PNs while high activity of VIP+ interneurons also lead to disinhibition of the PNs? 
This question does not seem to be thoroughly addressed in the literature. One of the 
explanations may be that, despite the high degree overlap between the µOR and VIP 
expression, the influence of other cortical neurons, such as PV+ interneurons and 
neurogliaform cells, are more powerful. 
1.12 Roles and features of µOR+ interneurons: NGFCs 
The neurogliaform cells (NGFCs) are perhaps one of the more idiosyncratic groups of 
interneurons. Santiago Ramon y Cajal provided the earliest published description of these 
neurons by noting their small soma, short but radiating dendrites, and short axons 
(Ramon y Cajal, 1995). They are multipolar interneurons that do not express the classic 
interneuronal markers, but usually do express Reelin and Neuropeptide Y (Jasper, 2012; 
Niquille et al., 2018). They do also express the serotonin 5-hydroxytryptamine 3A 
(5HT3a) receptor. This receptor is not expressed by SST+ or PV+ neurons but is 
generally expressed by most all VIP+ neurons and therefore not a specific cell marker for 
neurogliaform neurons (S. Lee, Hjerling-Leffler, Zagha, Fishell, & Rudy, 2010). 
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NGFCs have unique electrophysiological characteristics. Classically, they are 
known for their “late-spiking” firing pattern, i.e., when a sustained depolarizing current is 
injected, there is a short delay before firing their first spike (Chu, Galarreta, & Hestrin, 
2003; Kawaguchi & Kubota, 1997). Their RMP is typically around -60mV and they have 
low input resistances (Tricoire et al., 2010). Although they can most easily be found in 
Layer 1 of the neocortex, they are not exclusively found in Layer 1, and nor are they the 
only interneurons found in Layer 1 (Férézou et al., 2007; S. Lee et al., 2010; Miyoshi et 
al., 2010; Olah et al., 2007).  
NGFCs are well-known for producing dense axon terminals in extrasynaptic 
spaces and inhibiting targets through tonic GABA secretion (Overstreet-Wadiche & 
McBain, 2015). The effects of NGFCs on their targets has unique consequences. 
Consistent with their axon terminals in extrasynaptic space, NGFCs secrete a 
considerable amount of GABA into the extracellular environment which results in tonic 
inhibition of nearby neurons through volume transmission, in addition to the faster 
inhibition mediated by synaptic GABAA receptors (Karayannis et al., 2010; Olah et al., 
2009; Tricoire et al., 2010). Conversely, the tonic secretion of GABA may also 
desensitize their targets; NGFCs have been observed to produce rapid desensitization 
(Karayannis et al., 2010). The lack of spatial and temporal specificity makes the role of 
NGFCs difficult to predict (for review, see (Overstreet-Wadiche & McBain, 2015)).  
The GABAA receptor is not the only target of NGFCs; NGFCs uniquely secrete 
GABA onto GABAB receptors on PNs and interneurons, which can be located both on 
somata and glutamatergic terminals (Karayannis et al., 2010; Olah et al., 2009; 
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Christopher J. Price et al., 2005; Tamás, Simon, & Szabadics, 2003). NGFCs are the only 
neocortical neurons that have been observed to stimulate GABAB receptors with a single 
AP - whereas other interneurons usually need trains of APs to activate GABAB receptors 
on their targets (Christopher J. Price et al., 2005; C. J. Price et al., 2008; Tamás et al., 
2003). Therefore, the recruitment of these neurons can create long-lasting inhibitory 
postsynaptic potentials in interneurons through the stimulation of GABAB receptors (Olah 
et al., 2007; Tamás et al., 2003). Consistent with the inhibitory role for µOR and its 
localization on neurogliaform neurons, DAMGO has been found to decrease activation of 
the GABAB receptor in neocortical neurons (Lafourcade & Alger, 2008; McQuiston, 
2008). This effect appears to be partially mediated by voltage-gated calcium channels – a 
known target of the µOR, particularly at axon terminals (M. Connor, Schuller, Pintar, & 
Christie, 1999; Law, Wong, & Loh, 2000; Rubovitch, Gafni, & Sarne, 2003). 
NGFCs frequently interlink with interneurons and PNs through chemical and 
electrical synapses (X. Jiang et al., 2015; Olah et al., 2009). While NGFCs are known to 
electrically couple with other NGFCs, there is conflicting evidence that they may couple 
with non-neurogliaform interneurons as well (Chu et al., 2003; Fukuda, Kosaka, Singer, 
& Galuske, 2006; Hestrin & Galarreta, 2005; Anna Simon, Oláh, Molnár, Szabadics, & 
Tamás, 2005; Zsiros & Maccaferri, 2005).  
NGFCs also show a type of slow integration (perhaps presumptuously) called 
retroaxonal barrage firing; in the 10s of seconds following a sustained depolarizing 
current, the neurons will fire many action potentials after the stimulus has already ended 
(Overstreet-Wadiche & McBain, 2015; Norimitsu Suzuki, Tang, & Bekkers, 2014). 
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Documented reports of this type of firing in the neocortex is presently restricted to 
NGFCs and PV+ interneurons in slices and in vivo (N. Suzuki & Bekkers, 2010). While a 
similar phenomenon has been reported in other neurons before, retroaxonal barrage firing 
in the cortex can be blocked with chemical gap junction inhibitors, but not GABAergic or 
glutamatergic inhibitors, and therefore implicates gap junctions as transducing this firing 
(Overstreet-Wadiche & McBain, 2015; M. E. J. Sheffield, Best, Mensh, Kath, & 
Spruston, 2011). To explain the mechanism inherent in its name, some have suggested 
that axon terminals of NGFCs can become tonically active during the depolarizing 
current injection and conduct APs through the electrically linked network (M. E. J. 
Sheffield et al., 2011; Norimitsu Suzuki et al., 2014). Regardless of the mechanism, some 
data has shown that DAMGO application reduces retroaxonal barrage firing and provides 
additional corroborating data that NGFCs express this receptor and reduces this barrage 
firing phenomenon (Krook-Magnuson et al., 2011; Norimitsu Suzuki et al., 2014).  
1.13 µOR disinhibition 
The ICC and autoradiography data I have discussed mostly indicate that interneurons 
express the µOR with some ambiguity about whether PNs do express it. To take a closer 
look at function of this receptor, researchers have taken electrophysiological recordings 
from neurons and applied µOR-agonists. 
In contrast to autoradiography and ICC which simply inform us of the location of 
the µOR, electrophysiology gives us a better idea of the effect of the µOR on individual 
neurons. The electrophysiology data mostly continue this theme and show that there is 
little doubt that some cortical interneurons react to µOR-agonism with inhibition 
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(Férézou et al., 2007; Glickfeld et al., 2008; K.-W. Kim et al., 2000; Madison & Nicoll, 
1988; Pang & Rose, 1989; K. R. Svoboda et al., 1999; Kurt R Svoboda & Lupica, 1998; 
Wimpey & Chavkin, 1991; Witkowski & Szulczyk, 2006; Zieglgansberger, French, 
Siggins, & Bloom, 1979). However, there is also some data that suggest that some PNs 
are directly excited by µOR-agonism (Przewlocki et al., 1999), while others have 
reported inhibition of PNs with µOR agonism (E. Tanaka & North, 1994). Naturally, one 
must be cautious about the bias towards reporting positive results, for instance, some 
groups have used electrophysiology and sc-PCR to examine the µOR’s effect on PNs and 
observed none (Férézou et al., 2007; Witkowski & Szulczyk, 2006). 
Researchers have also investigated whether µOR agonists enhance cortical 
excitation through disinhibition (that is, creating greater excitatory activity by inhibiting 
the suppressive effects of GABAergic interneurons). Several studies indicate that 
excitation in PNs is secondary only through inhibiting the nearby GABAergic neurons 
(Homayoun & Moghaddam, 2007; C. Jiang et al., 2019; H. K. Lee et al., 1980; Madison 
& Nicoll, 1988; Pang & Rose, 1989; Zieglgansberger et al., 1979). However, several 
other studies suggest that the µOR upregulates activity of PNs, thereby directly activating 
them (Przewlocki et al., 1999; Rola, Jarkiewicz, & Szulczyk, 2008; Schmidt et al., 2003; 
Witkowski & Szulczyk, 2006). This matter remains unresolved. 
1.14 Excitation/inhibition balance 
If the µOR inhibits interneurons and disinhibits PNs – why would that matter? A 
continuous loop of excitatory-only neurons could never organize and would likely be 
nearly impossible to properly regulate, especially given the afferent pathways that tend to 
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converge on any neuroanatomical structure and may compete for control. GABAergic 
interneurons fulfill an important purpose: properly regulating the output of brain 
structures and enabling flexibility (Isaacson & Scanziani, 2011; Klausberger et al., 2003). 
Therefore, persistent conditions that reduce the excitability of GABAergic interneurons 
can in turn result in neurological defects (B. R. Ferguson & Gao, 2018). 
The excitation of cortical networks is kept in careful balance by inhibition, and 
vice versa. This balance must be maintained for the coordinated activity to be sustained 
during cognitive tasks (Yizhar et al., 2011). Several psychiatric disorders, including; 
autism (Bozzi, Provenzano, & Casarosa, 2018; Nelson & Valakh, 2015; Orekhova et al., 
2007; Rubenstein & Merzenich, 2003), Rett syndrome (V. S. Dani et al., 2005), 
schizophrenia (Fazzari et al., 2010; D. A. Lewis, Hashimoto, & Volk, 2005; Yizhar et al., 
2011) and epilepsy (Bozzi et al., 2018; Engel, 1996) are believed to result from an 
improper excitation/inhibition E/I balance. These syndromes may appear from 
abnormalities during interneuronal migration, dysregulated postnatal apoptosis (Wong et 
al., 2018), synaptogenesis (Fazzari et al., 2010; J.-M. Yang et al., 2013), neurotransmitter 
release (Bozzi et al., 2018; McNally & McCarley, 2016), or temporary states from drug 
use (Berke, 2009; Premoli et al., 2017). 
1.15 Cognitive function and band oscillations 
The invention of the electroencephalogram allowed researchers to record the mass 
activity of neurons firing synchronously due to their effect on the electrical field around 
the subject’s head. These band oscillations (BOs) (Berger, 1929; Steriade, 2001). 
Eventually, researchers were able to induce large-scale neuronal activity with transcranial 
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magnetic stimulation (Barker, Jalinous, & Freeston, 1985). These inventions allow us to 
measure brain activity and a limited means to affect that activity. They were also some of 
the earliest methods to understand how neurons in specific regions collaborate to fulfill a 
collective function. 
The activity of neurons produces a measurable electric field that, when graphed 
against time, creates a pattern of high-frequency oscillations. Known mammalian 
oscillatory frequency can occur between 0.5 MHz and 500 MHz. While a given structure 
can have a prevailing frequency depending on their brain state, task and neuroanatomical 
structure, a given structure usually has a composite of multiple BOs contributing to the 
net oscillation (Steriade, 2001). Slower frequencies of oscillations (which are usually 
more widespread) have a strong modulatory role, whereas faster band oscillations are 
more confined in space and relatively easily disrupted/modulated (Buzsáki & Draguhn, 
2004; Buzsáki, Geisler, Henze, & Wang, 2004; Csicsvari, Jamieson, Wise, & Buzsáki, 
2003; Sirota, Csicsvari, Buhl, & Buzsáki, 2003). 
The Gamma Band Oscillations (GBOs) are a particularly relevant band oscillation 
to the study of cortex. These GBOs are believed to contribute to proper memory, 
attention, and sensory binding (which links senses together) (Bragin et al., 1995; 
Csicsvari et al., 2003; Fell et al., 2001; Fries, Reynolds, Rorie, & Desimone, 2001; Gray, 
1994; Llinás, Ribary, Contreras, & Pedroarena, 1998; Singer, 1993; Varela, Lachaux, 
Rodriguez, & Martinerie, 2001). Although the features of these bands may vary by region 
and frequency, the GBOs of the hippocampus and neocortex appear to involve both the 
PNs and the cortical interneurons interacting to produce BOs as detected through an EEG 
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(Blatow et al., 2003; Csicsvari, Hirase, Czurkó, Mamiya, & Buzsáki, 1999; Csicsvari et 
al., 2003; Suffczynski, Crone, & Franaszczuk, 2014; Traub, Jefferys, & Whittington, 
1997; M. A. Whittington, Traub, & Jefferys, 1995).  
A primary role for cortical interneurons is to provide synchronization inhibition 
for the PNs, and permit PNs to then synchronize their activity in the transient gaps of 
inhibition (Blatow et al., 2003; Cobb, Buhl, Halasy, Paulsen, & Somogyi, 1995; 
Hartwich, Pollak, & Klausberger, 2009; Lytton & Sejnowski, 1991; M. A. Whittington et 
al., 1995). Perturbations that disrupt the balance of excitation and inhibition can lead to 
deleterious consequences to the cognitive ability of mammals. Disorganized BOs is one 
of the features of numerous mental illnesses, such as schizophrenia (Cho, Konecky, & 
Carter, 2006; Hirano et al., 2015; David A. Lewis et al., 2012; Minzenberg et al., 2010), 
which also coincides with abnormalities that downregulate activity of their inhibitory 
neurons (Lodge, Behrens, & Grace, 2009). The relationship between BOs and their 
symptoms is not presently clear but may be related to their disrupted sensory perception 
and reduced cognitive ability (Green & Nuechterlein, 1999). However strong and 
persistent GBOs are not always beneficial, for instance these GBOs are particularly 
strong in people with chronic pain and tend to be weaker after therapy (Ebrahimian et al., 
2018). The use of opioid drugs disrupts cortical BOs (Gulyás et al., 2010; M. Whittington 
et al., 1998; Y. Zhang et al., 2019). 
These band oscillations are decent correlates of the task the subject is handling, 
but they do not lend a mechanistic understanding of how the µOR is affecting cortical 
processes. For instance, while the µOR is shown to increase net cortical excitation, EEGs 
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cannot immediately relate that to glutamatergic activity. To accomplish that, I will refer 
to a different kind of oscillation: calcium oscillations. Whereas band BOs are phenomena 
produced by synchronous depolarizations of massive amounts of neurons in an intact 
brain, calcium oscillations are smaller-scale events to visualize glutamatergic activity that 
can be seen in neuronal cultures. 
1.16 Calcium transients and excitability 
Data from microelectrode array experiments in dissociated neurons demonstrate that 
interventions that increase excitability of the neurons leads to global coupling and 
uniform activity (Nakanishi & Kukita, 1998; Penn, Segal, & Moses, 2016). But to more 
easily monitor network activity in many culture neurons at once, calcium-imaging has 
been used to visualize excitation as synchronous calcium oscillations (calcium transients) 
(Bacci, Verderio, Pravettoni, & Matteoli, 1999; Inglefield & Shafer, 2000; Robinson et 
al., 1993). This produces a sporadic “flickering” effect in cultured neurons from the 
transient binding of calcium the calcium-indicator dye loaded into neurons. These 
flickering events are often synchronized in multiple neurons at once, but this is not 
always the case. Several groups have done experiments to determine the cause of these 
calcium oscillations, and these oscillations relate to neuronal activity. 
To investigate the cause of these calcium oscillations, various groups have 
simultaneously recorded electrophysiology and calcium-dye fluorescence to correlate the 
two. They found that these oscillations correspond to bursts APs on top of a feature that 
resembled an EPSPs (Bacci et al., 1999; Muramoto, Ichikawa, Kawahara, Kobayashi, & 
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Kuroda, 1993; T. H. Murphy, Blatter, Wier, & Baraban, 1992; Przewlocki et al., 1999; 
Shen, Piser, Seybold, & Thayer, 1996; Sombati & Delorenzo, 1995). 
The oscillations can be prevented by blocking depolarizations with TTX, or by 
blocking all glutamate receptors (Dravid & Murray, 2004; Lo, Fallert, Piser, & Thayer, 
1992; T. H. Murphy et al., 1992; Nuñez, Sanchez, Fonteriz, & Garcia‐Sancho, 1996; 
Przewlocki et al., 1999). Blocking voltage-gated calcium channels generally does little to 
weaken the oscillations, which indicates that these channels are not a major route for 
calcium entry in this phenomenon (Cao et al., 2014; Dravid & Murray, 2004). In some 
instances, inhibition of Phospholipase C abolished the waves indicating that calcium-
induced calcium release was a large component of this effect (Dravid & Murray, 2004). 
However, groups are split on whether the major source of calcium to activate PLC is 
through NMDA receptors that conduct extracellular Ca2+ into the cells, or from the 
internal stores by an mGluR coupled to a Gq protein (Dravid & Murray, 2004; Przewlocki 
et al., 1999). 
The identity of the glutamate receptor responsible for the calcium oscillations, and 
the contribution of calcium-induced calcium release has become a point of disagreement 
for researchers. This disagreement at least partially stems from the [Mg] used in the 
ACSF, with some groups preferring physiological concentrations while others use no-Mg 
ACSF to amplify and synchronize the oscillations; some researchers have tested these 
oscillations in presence of low [Mg2+] and have proposed that these calcium oscillations 
are due to the calcium-conducting properties of the NMDA receptors (Canepari, Bove, 
Maeda, Cappello, & Kawana, 1997; Hemstapat, Smith, & Monteith, 2004; Inglefield & 
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Shafer, 2000; Lawrie, Graham, Thorn, Gallacher, & Burgoyne, 1993; Nuñez et al., 1996; 
Penn et al., 2016; Shen et al., 1996; T. Tanaka, Saito, & Matsuki, 1996; X.-s. Wang & 
Gruenstein, 1997), but others have tested these oscillations at physiological [Mg2+] and 
argued that calcium oscillations are mostly caused by calcium-conducting AMPA 
receptors and Group I metabotropic Glutamate receptors (mGluRs) coupled to calcium-
induced calcium release (Bacci et al., 1999; Cao et al., 2014; Dravid & Murray, 2004; 
Flint, Dammerman, & Kriegstein, 1999).  
Somewhat confusingly, “calcium oscillation” and “calcium wave” are frequently 
used interchangeably through the literature I have cited here; a distinction should first be 
made regarding the durations of these events and the cell types that they occur in. One 
well-known calcium-imaging phenomena are the slow calcium waves which are usually 
observed in non-excitable cells (e.g., glia, HEK293 cells), though they can be relayed to 
neurons as well (Berridge, 1993; Kawabata et al., 1996). These slow calcium waves 
typically have long rise and decline phases; they can take 10s of seconds to rise and can 
last for several minutes (J. W. Dani, Chernjavsky, & Smith, 1992). Calcium waves are 
believed to be a phenomenon that results from gap junctions and the slow spread of IP3 
(which can stimulate the release of Ca2+ from internal stores) through them (Balaji et al., 
2017; Leybaert & Sanderson, 2012). However, calcium waves can be instigated by 
glutamatergic activity, thus there may be a causal relationship between the 2 phenomena 
(Zur Nieden & Deitmer, 2005). Calcium oscillations are on the shorter scale; they consist 
of calcium spikes that can rise in less than a second, and then taper off back to baseline 
over the course of a few seconds. These shorter oscillations have been found previously 
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in cultured neocortical neurons and correspond to activation of postsynaptic glutamate 
receptors through glutamate release. Though IP3 may very well be involved in these 
oscillations, there was no evidence that it was spreading through gap junctions in neurons 
(Dravid & Murray, 2004; T. H. Murphy et al., 1992).  
These calcium oscillations are linked to development and gene expression in 
neurons (Dolmetsch, Xu, & Lewis, 1998; Spitzer, Olson, & Gu, 1995). Oscillations may 
also have a neuroprotective effect against rising [Ca2+]in that follow neurological trauma 
(possibly by dismounting NMDA receptors from the actin cytoskeleton) (Geddes-Klein, 
Serbest, Mesfin, Cohen, & Meaney, 2006). 
This model has been used previously to study activation of luteinizing hormone-
releasing neurons (Terasawa, Schanhofer, Keen, & Luchansky, 1999), and their response 
to estrogen (Abe, Keen, & Terasawa, 2008); the effects of the kappa opioid receptor on 
glutamate release in spinal cord cultures (Kelamangalath, Dravid, George, Aldrich, & 
Murray, 2011); the excitatory effects of nicotine on neocortical neuron cultures (J. Wang 
et al., 2016); cannabinoid regulation of glutamate release in the hippocampus (Shen et al., 
1996); HIV-1 envelope protein and cytotoxicity (Lo et al., 1992); environmental toxins 
on neurons (Inglefield & Shafer, 2000); and dopamine receptor 4 on hippocampal 
cultures (Y.-L. Wang et al., 2017). Efforts are also underway to develop this model to 
study seizure-related drugs; the hypersynchrony observed under certain conditions 
(including low Mg2+) resemble that of epileptiform patterns (Cao et al., 2015; Pacico & 
Mingorance-Le Meur, 2014). 
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While the effects of the µOR on network activity is one thing, the receptor’s 
mechanism inside the neuron is another. Due to the boom in interest in the µOR, there is 
much known about this receptor’s intracellular cascade and target ion channels. However, 
there is a great deal that is not known because of the µOR’s vast complexity. In order to 
explain the unknown features of this receptor, I will provide more details about the 
receptor, its ligands, and its intracellular signaling pathway. 
1.17 Opioid receptors 
There are 3 known types of opioid receptors the Δ Opioid Receptor (DOR), the µ 
Opioid Receptor (µOR), the Κ Opioid Receptor (KOR) (Al-Hasani & Bruchas, 2011). All 
these ORs are Gi-coupled Protein Receptors. Several other receptors were initially 
proposed as ORs (e.g., sigma and opioid-like receptor 1) but were subsequently ruled out 
as classical opioid receptors due to their wide binding profile to non-opioid 
neurotransmitters (Sauriyal, Jaggi, & Singh, 2011; Stein, 2016). But these receptors may 
still play a modulatory role in the effects of the 3 classical opioid receptors (F. J. Kim et 
al., 2010; Kobayashi, Ikeda, Ichikawa, Togashi, & Kumanishi, 1996). 
Opioid receptors can be found in both peripheral and central locations; besides the 
brain, they can also be found on immune cells, neuroendocrine organs and some 
ectodermal cells. Opioid receptors are subjected to alternative splicing posttranslational 
modifications to introduce variety in receptor properties. Generally, both the DOR and 
µOR can be found throughout most of the neocortex. The KOR can also be found in the 
deep layers of the neocortex but is less concentrated than the other ORs (Hiller & Fan, 
1996; Merrer, Becker, Befort, & Kieffer, 2009). 
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Opioid receptors are also believed to form homodimers or heterodimers with 
other ORs in vitro and in vivo, though this view is not universally accepted (Cvejic & 
Devi, 1997; Y.-X. Pan, Bolan, & Pasternak, 2002; Prinster, Hague, & Hall, 2005; Rios, 
Jordan, Gomes, & Devi, 2001; D. Wang, Sun, Bohn, & Sadée, 2005). While all the 
implications of heterodimerization of ORs is not immediately clear, this possibility 
introduces more variability into the response of these receptors to agonist binding and the 
receptors may therefore mix their signaling pathways.  
The KOR earned a lot of attention as a potential target for therapy since it was an 
opioid receptor that is not associated with addiction. Unfortunately, the KOR agonists are 
not clinically useful for pain relief, though their antagonists might be. The KOR tends to 
have the opposite effects of the µOR and DOR. While µOR-acting drugs are euphoric, 
hedonic, and addictive; KOR agonists are usually just unpleasant (dysphoric), 
hallucinogenic, and dissociative - and therefore not drugs of abuse (Chavkin, 2011; 
Shippenberg, 2009). But this aversion and dysphoric is not always seen in KOR-acting 
drugs (Butelman & Kreek, 2015). These receptors can be found in the PFC, where they 
inhibit dopamine release from VTA afferents there (Tejeda et al., 2013). However, there 
is still interest in developing KOR agonists to treat itchiness and opioid abuse (Chavkin, 
2011), or KOR antagonists to treat chronic stress and anxiety (Chavkin, 2011; Knoll & 
Carlezon, 2010).  
The DOR has attracted interest as a potential target for therapy and specific 
peptidergic drugs have developed to study this receptor (Gavériaux-Ruff & Kieffer, 
2011). However, this receptor has not benefitted from the boom in interest that µOR-
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acting drugs have brought to that receptor. DOR knockout mice show relatively subtle 
changes in pain response (Martin, Matifas, Maldonado, & Kieffer, 2003). Interestingly, 
whereas the µOR is useful for acute pain and acute mood problems, the DOR may be 
more useful for chronic pain and depression (Filliol et al., 2000; Gavériaux-Ruff & 
Kieffer, 2011; Nadal, Baños, Kieffer, & Maldonado, 2006; Scherrer et al., 2006; 
Valentino & Volkow, 2018). However, they tend to also have convulsive effects and 
research has progressed only slowly and cautiously (Pradhan, Befort, Nozaki, Gavériaux-
Ruff, & Kieffer, 2011; Saitoh & Yamada, 2012). 
1.18 µ opioid receptor 
The µOR is the principal site of exogenous opioidergic drugs (Valentino & Volkow, 
2018). The µOR has benefitted greatly from the surge in interest of opioid receptors. 
To discover the role of the µOR in adults, scientists performed gene knockouts in 
mice of the µOR and tested their analgesia, addictive tendencies, motivation, and 
maternal attachment. Mice that lack the µOR are resistant to morphine addiction and 
analgesia (Matthes et al., 1996; Merrer et al., 2009). µOR knockout mice also suffer from 
reduced motivation to eat and reduced maternal attachment (Kas et al., 2004; Papaleo, 
Kieffer, Tabarin, & Contarino, 2007). Therefore, this specific receptor appears to be the 
primary OR in mediating the effects of exogenous opioidergic drugs, as well as the 
endogenous means for motivation and pain suppression. 
The µOR can be found throughout much of the neocortex, except in visual 
regions at the posterior side of the brain. It can be found in a roughly caudal-to-rostral 
gradient and, consequently, is more concentrated in frontal regions of the brain. Its 
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staining is relatively dense in Layer 3, followed by Layers 1 and 2 (Hiller & Fan, 1996). 
The µOR is expressed at birth, but expression gradually increases for the first several 
postnatal weeks (Clendeninn, Petraitis, & Simon, 1976; Coyle & Pert, 1976; Garcin & 
Coyle, 1977). I have previously alluded to the difficulty of developing antibodies to 
GPCRs and the µOR, which I will now explain in more detail.  
One of the most remarkably-paradoxical features of the µOR, is that this 
expression of this receptor is driven by only one gene – the OPRM1 (oprm1 in rodents, 
according to IUPHAR nomenclature) gene – and yet its effects and regulation introduce a 
spectrum of features that make it difficult to study (Classification, 2020). This receptor is 
extremely variable due to splice variants, RNA editing, post-translational modifications, 
presumed multiple agonist binding sites, functional selectivity, and other characteristics 
that introduce variability into their structure and binding profile (Groer et al., 2007; 
Gavril W. Pasternak & Pan, 2013). Its property of functional selectivity (also called 
biased agonism) is a particularly problematic aspect to understand, because this receptor 
can respond differently to different agonists. 
This variability is on full display with opioid-acting drugs causing vastly different 
opioid effects on different patients (Cherny et al., 2001) and rodent strains (Mogil, 1999; 
Reith, Sershen, Vadasz, & Lajtha, 1981). In other instances, µOR antagonists are unable 
to reverse all µOR agonist effects in patients when they are taken concurrently (Andoh et 
al., 2008). The variable states of the receptor may be the factor that allows patients to 
cycle drugs to mitigate the effects of opioid tolerance to specific µOR-acting drugs 
(Cherny et al., 2001; Moulin, Ling, & Pasternak, 1988). 
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Localization of this receptor has primarily been driven by autoradiography and 
ICC, but both techniques have shortcomings and points of disagreement due to the nature 
of this receptor. The µOR is one of the few receptors known to have distinguishable 
agonist and antagonist conformations; radiolabeled antagonists tend to label the receptor 
more widely than agonists, and therefore antagonist conformation usually assumed to be 
the more stable conformation (Bruno Cauli et al., 1997). These conformations may be 
strongly influenced by presence by ions, including Na+ and Mg2+ (G. W. Pasternak, 
Snowman, & Snyder, 1975). 
Antibodies for the µOR have primarily been limited to C-terminus epitopes for 
the µOR because of the receptor’s susceptibility to glycosylation on the external side 
(Gavril W. Pasternak & Pan, 2013). However, the C-terminus of the µOR is also the 
primary source of variation between splice forms, which prevents primary antibodies 
from recognizing all forms of the µOR (Abbadie, Pan, Drake, & Pasternak, 2000; Gavril 
W. Pasternak & Pan, 2011). For a review of these characteristics, see (Gavril W. 
Pasternak & Pan, 2013). 
There are several known splice variants of the OPRM1/oprm1 gene, which have 
unique regional distributions through the brains of rodents (Abbadie et al., 2000; Y. X. 
Pan et al., 1999), Studies have found OPRM1/oprm1 to be well-conserved in rodents and 
humans, which at least lends itself to study in rodent models (J. Xu, Xu, Rossi, Pasternak, 
& Pan, 2011). 
The µOR shows the properties of ‘biased agonism’ or ‘functional selectivity’ and 
makes the µOR’s potential effects more variable. This property allows the receptor to 
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respond differently to different agonists. This has implications for trafficking, 
desensitization, and intracellular mechanisms of the receptor which will be discussed 
later (von Zastrow, 2010). While precise terms (e.g. “full agonist”) has traditionally been 
applied to particular ligands, the influence of functional selectivity enables receptors to 
have much more varied responses than this general terminology permits (Raehal, Schmid, 
Groer, & Bohn, 2011).  
1.19 Endogenous opioid ligands 
Endogenous opioids are all peptide neurotransmitters that are derived from pre-
propeptides. These pre-propeptides are processed through posttranslational modifications, 
splicing, and proteolytic cleavage to yield several different peptide neurotransmitters 
from the same family (McLaughlin, 2013). Although there may be dozens of individual 
endogenous opioids, they can be grouped into just a few categories based on a common 
epitope. Enkephalins (µOR and DOR) are mostly derived from preproenkephalin-A gene, 
dynorphins (KOR) are derived from the Dynorphin-A gene, and β-endorphins (µOR and 
DOR) are derived from the prohormone proopiomelanocortin (POMC) (McLaughlin, 
2013; McLaughlin & Zagon, 2013; Spampinato, Bedini, & Baiula, 2013; Taki et al., 
2000). However, POMC is not transcribed in the neocortex and therefore will not be 
discussed here further (Gee, Chen, Roberts, Thompson, & Watson, 1983). There is also a 
fourth group of opioid peptides – the endomorphins which are products of a presently-
unidentified pre-propeptide. Endomorphins 1 and 2 (µOR) are especially powerful and 
specific agonists for the µOR. These peptides are a product of an unknown precursor 
(Terskiy et al., 2007). 
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The Pre-proenkephalin A gene produces 6 peptides from the 2 major varieties of 
enkephalin (Enk); Met-enkephalin (Met-Enk) and Leu-Enkephalin (Leu-Enk). This gene 
produces multiple forms of Met-Enk, including an octapeptide and heptapeptide, but only 
one form of Leu-Enk (McLaughlin, 2013). Meanwhile Pre-prodynorphin A transcripts, 
which mostly produces KOR-acting peptides, also contains a sequence for Leu-Enk on a 
decapeptide. Although this Leu-Enk can stimulate the µOR, other dynorphins products do 
not (Spampinato et al., 2013). Pre-prodynorphin and Pre-proenkephalin proteins have 
been observed extensively in both interneurons and some PNs, but mostly interneurons 
(Alvarez‐Bolado, Fairén, Douglass, & Naranjo, 1990; Fallon & Leslie, 1986; Olenik & 
Meyer, 1997). Interestingly, these pre-propeptides are often produced by the same 
neurons that express the µOR, suggesting that these are autocrine and paracrine 
regulators as well (Férézou et al., 2007; Taki et al., 2000). 
Enkephalins are highly expressed in the neocortex by several types of neurons, 
though localizing it to specific neurons has been a problem despite its high expression 
there. As pointed out by Férézou et al. (2007), the concentration of enkephalins in the 
neocortex is 4 times more than the concentration of VIP – which is considered to be a 
major marker for many interneurons (Crawley, 1985; Lindberg, Smythe, & Dahl, 1979; 
Rossier et al., 1977). Yet experiments generally show relatively restricted expression of 
the precursor to µOR+ neurons; ICC experiments in the neocortex show a very high 
degree (80-90%) of overlap between expression of the µOR and pre-proenkephalin 
within the same interneurons (Taki et al., 2000). On the other hand, experiments that used 
colchicine treatment – as well as Ferezou et al.’s own sc-PCR data – show that PNs do 
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often have low levels of the neurotransmitter which may not be detectable with the ICC 
experiments used extensively (F, van der Kooy, & Bloom, 1984; Férézou et al., 2007).  
Genetic deletion of pre-proenkephalin A in mice produces offspring that are 
surprisingly healthy and seemingly normal – they even have normal stress-induced 
analgesia. However, they are also hyper-aggressive and anxious (König et al., 1996). 
These knockout mice, interestingly, are also resistant to the effects of chronic stress and 
depression (Bilkei-Gorzo, Michel, Noble, Roques, & Zimmer, 2007; Melo, Drews, 
Zimmer, & Bilkei-Gorzo, 2014). 
Endomorphins 1 and 2 (EM-1 and EM-2) are very highly selective and have high 
affinity for the µOR, but less is known about those neurotransmitters (Hackler, Zadina, 
Ge, & Kastin, 1997; Martin-Schild, Gerall, Kastin, & Zadina, 1999; Mizoguchi, 
Sakurada, & Sakurada, 2013; Terskiy et al., 2007; J. Zadina, Kastin, Ge, & Hackler, 
1994; J. E. Zadina, Hackler, Ge, & Kastin, 1997). They are products of an unidentified 
precursor protein which unfortunately has made it difficult to localize to particular 
neurons (Terskiy et al., 2007). EM-1 can be found abundantly in the cerebral cortex, 
while EM-2 is reportedly rarer in the cortex according to ICC data (Gu et al., 2017; 
Martin-Schild et al., 1999; Schreff, Schulz, Wiborny, & Höllt, 1998). However, both 
endomorphins have been reported in human cortical brain lysates in reportedly high 
concentrations, though a direct comparison with other neurotransmitters is difficult to 
make with these limited data (Hackler et al., 1997).  
Therefore endomorphins 1&2 and enkephalins are the endogenous 
neurotransmitters for the (neocortical) µOR. While they have a spectrum of selectivity 
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and affinity, and given this wide variety of µOR agonists, efforts were devoted to 
selecting a highly selective and high-affinity agonist for the µOR. 
1.20 DAMGO 
To study the physiological effects of the µOR, obviously, an agonist is needed. While 
there are many opioid peptides, they have varying levels of specificity and affinity for the 
µOR. The endogenous forms of enkephalins have off-target binding to other ORs (mostly 
to the DOR) (Merrer et al., 2009; Takahashi, 2016). Considering that endogenous opioids 
already consist as many different peptides, efforts were made to produce a specific, 
stable, high-affinity µOR agonist that was structurally derived from the endogenous 
peptide and therefore had similar receptor effects as endogenous forms of enkephalins 
(Handa et al., 1981). 
The synthetic peptide [D-Ala2,N-MePhe4,Gly-ol5]enkephalin (DAMGO) was 
discovered to be a selective agonist for the µOR and is used extensively for µOR-related 
research ranging from brain slices (Bushell et al., 2002; Chiou & Huang, 1999; Faber & 
Sah, 2004; Férézou et al., 2007; Finnegan, Chen, & Pan, 2006; McQuiston, 2008; Qu et 
al., 2015; K. R. Svoboda et al., 1999; Witkowski & Szulczyk, 2006), to in vivo testing 
(Castro & Berridge, 2014; Helmstetter et al., 1998; Kekesi et al., 2011; Ma et al., 2020; 
Newman, Pascal, Sadeghian, & Baldo, 2013; Selleck et al., 2015), to cell culture (Patel et 
al., 2006; Piros, Prather, Law, Evans, & Hales, 1996; Piros et al., 1995; Przewlocki et al., 
1999; Rubovitch et al., 2003; E. Tanaka & North, 1994). The currently favored 
pharmacological antagonist for the µOR is CTAP D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-
Thr-NH2 (CTAP) for its specificity and low promiscuity (Carrero, Kaigler, Hartshorn, 
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Fadel, & Wilson, 2019; B. Chieng, Connor, & Christie, 1996; Falk et al., 2020; Ma et al., 
2020). 
1.21 Opioid receptor intracellular cascades 
The µOR has a complex intracellular cascade that can terminate with regulation ion 
channel proteins, as well as transcription factors. Unfortunately, due to the complexity of 
this receptor, the details for its mechanism in regulating potassium channels are not 
completely well-understood. However, experiments done in heterologous systems and 
neurons show some key components that will be discussed here. I will outline its basic 
intracellular cascade in this section. But later, I explain its interaction with specific ion 
channels. 
The superfamily of opioid receptors is composed of seven transmembrane 
spanning (7TM) segments and signal through Gi/Gs signaling pathways. They are 
categorized as class A (Rhodopsin) Gi/Go G-protein coupled receptors with an 
extracellular N-terminal and an intracellular C-terminal end (Katritch, Cherezov, & 
Stevens, 2013). They are usually coupled to pertussis toxin-sensitive heterotrimeric Gi/Go 
proteins (Law et al., 2000). Binding of agonists results in activation of both α and βγ 
subunits of the G-protein complex, which can interact with separate signaling pathways 
and can itself deactivate some ion channels through a direct interaction. The Gβγ subunits 
interacts with calcium channels directly (more about ion channels later), while the Gαi 
subunit typically inhibits adenylyl cyclase and suppresses cAMP formation (Zamponi & 
Snutch, 2002). Diminished levels of cAMP can downregulate PKA and lead to decreased 
levels of phospho-CREB, which then causes upregulation or downregulation of different 
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genes (Nonnemacher et al., 2017; Purves, 2008). While this may cause acute effects, the 
most consequential gene regulation changes may occur when cellular tolerance creates 
chronic hyperactivation of PKA and cAMP, which then causes gene expression changes 
(Bilecki & Przewlocki, 2000; Noble & Cox, 1996; Terwilliger, Beitner-Johnson, 
Sevarino, Crain, & Nestler, 1991). However, the route to ion channel regulation is more 
convoluted. 
The downregulated PKA releases Phospholipase AA (PLA2) from inhibition (Zor 
& Reiss, 1991). Activated PLA2 metabolizes the esterified form of arachidonic acid, 
found in cell membranes, and the metabolized product can participate in at least 3 
pathways; the cyclooxygenase, lipoxygenase and expoxygenase (cytochrome p450 
pathway) (Piomelli & Greengard, 1990; Vaughan, Ingram, Connor, & Christie, 1997). 
The cyclooxygenase pathway leads to formation of prostaglandins, prostacyclin, and 
thromboxane A2. The lipoxygenase pathway results in formation of 12-lipoxygenase 
products. Inhibition of the cyclooxygenase and 5-lipoxygenase pathways potentiated the 
µOR’s neurophysiological inhibition of hippocampal neurons, while inhibition of 12-
lipoxygenase blocked much of it (Vaughan et al., 1997). These data suggest that the 12-
lipoxygenase pathway likely mediates some of the µOR’s inhibitory effect in 
hippocampal interneurons. The authors also found that inhibition of PLA2 likewise 
blocked the effect of DAMGO and it appears that PLA2 was the enzyme that was 
cleaving arachidonic acid (Vaughan et al., 1997). This pathway likely also contributes to 
the synergistic effects of NSAIDs (which block the cyclooxygenase pathway) and opioid 
drugs by directing AA metabolites towards the 12-oxygenase pathway (MacDonald J 
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Christie, Connor, Vaughan, Ingram, & Bagley, 2000; M. J. Christie, Vaughan, & Ingram, 
1999).  
There is also strong evidence that Gβγ subunits from Gi receptors can activate 
phospholipase C (PLCβ). This mobilizes intracellular calcium release and increase 
Protein Kinase C activity and IP3 levels, even though this mechanism is typically 
associated with Gq receptors rather than Gi receptors (C. L. Huang, Feng, & Hilgemann, 
1998; Law et al., 2000; Rubovitch et al., 2003; Smart & Lambert, 1996; Smart, Smith, & 
Lambert, 1994; Tsu, Chan, & Wong, 1995; Zimprich, Simon, & Höllt, 1995). While this 
finding may be somewhat controversial, a group did find that PKC (and PKA) may 
mediate some of the µOR’s inhibitory effects in neocortical interneurons (Witkowski & 
Szulczyk, 2006). Other research has shown that DAMGO can upregulate the activity of 
PLCβ, and that PLCβ is necessary to mediate the antinociceptive effects of morphine in 
mice (W. Xie et al., 1999). Consistent with this, PLCβ I implicated in increasing the 
activity of PLA2, which I previously mentioned cleaved arachidonic acid to mediate the 
µOR’s regulation of voltage-sensitive K channels in hippocampal neurons (Zor & Reiss, 
1991). Additionally, µOR activation of Gαq proteins has also been reported as mediating 
some of the supraspinal analgesic effects of opioids as well (Sánchez-Blázquez, Gómez-
Serranillos, & Garzón, 2001). 
The µOR may have more direct and indirect interactions with many receptors and 
ion channels; it co-immunoprecipitates with the NR1 subunit of NMDA receptors 
(Rodríguez-Muñoz, Sánchez-Blázquez, Vicente-Sánchez, Berrocoso, & Garzón, 2012); 
the µOR, intracellular calcium, and NMDA receptors may work collaboratively to alter 
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gene transcription (Chartoff & Connery, 2014; Hyman, Malenka, & Nestler, 2006; 
Konradi, Cole, Heckers, & Hyman, 1994). NMDA receptor antagonism has also been 
shown to reverse the effects of morphine tolerance, suggesting some upregulation of 
NMDARs occurs, though it may not be clearly demonstrated to occur as a direct 
regulation – as opposed to a disinhibitory effect and increase in glutamatergic outflow 
(Trujillo & Akil, 1991). 
On the topic of biased agonism and functional selectivity, researchers have 
observed that different agonists can differentially regulate intracellular signaling 
pathways. Application of the label-free integrative pharmacology on-target (iPOT) 
approach demonstrated that dozens of µOR agonists could bias the receptor towards 
different pathways (Morse, Sun, Tran, Levenson, & Fang, 2013). This has also been 
demonstrated on a smaller scale and appears to result from biased activation of different 
Gαi/o proteins associated with the receptor (S. Allouche, Polastron, Hasbi, Homburger, & 
Jauzac, 1999; Massotte, Brillet, Kieffer, & Milligan, 2002; Raehal et al., 2011). There are 
also many studies that have found that different agonists can induce phosphorylation of 
the µOR at several different sites (Grecksch et al., 2011; McPherson et al., 2010; Rivero 
et al., 2012; Y. Yu et al., 1997). 
Naturally, this raises the issue of how these different effects relate to the 
intracellular signaling cascade, and eventually, to different neurophysiological effects of 
different ligands. Unfortunately, limitations to understanding this phenomenon are 
imposed by current technology, different cell types that express the µOR, and the dozens 
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of exogenous and endogenous ligands available to screen. Some of these repercussions 
are discussed later. 
1.22 Opioid desensitization  
In addition to the addictive potential of opioids, the µOR is known to desensitize and 
accumulate tolerance to follow-up exposure to agonists. This reduces the effect of opioid 
agonists over the course of sequential doses and can ultimately require higher doses to 
achieve the same effect. Adaptations that occur over longer-term exposure are usually 
classified as tolerance, while shorter term adaptive responses to acute effects are 
classified as desensitization. Desensitization can happen within minutes (Stéphane 
Allouche, Noble, & Marie, 2014). Tolerance can develop against all actions of opioids, 
but it accumulates at different rates for different aspects (Blanchet & Lüscher, 2002; 
Gavril W. Pasternak & Pan, 2013). Similarly, different biochemical effects of ORs can 
desensitize at different times (Stéphane Allouche et al., 2014). 
Studies using in vitro models to research the µOR report a wide variety of 
desensitization properties. With DAMGO, desensitization is sometimes visible by 5 
minutes of exposure with observable reductions in DAMGO effects, but usually takes 10-
20 minutes – or even longer than that (Koch et al., 2005; Law et al., 2000; Raehal et al., 
2011). This varies system-to-system, and agonist-to-agonist. Morphine is highly 
desensitizing, while DAMGO is less desensitizing; co-applying DAMGO with morphine 
can reduce morphine-alone desensitization, suggesting that this principle may have 
clinical applications (Finn & Whistler, 2001; Ma et al., 2020). Different pathways can 
also desensitize along different timelines, for instance; the presynaptic effects 
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(interactions with voltage-sensitize calcium channels) is stable for at least 15 minutes 
after exposure to DAMGO, but the postsynaptic effects are significantly reduced at that 
timepoint (Blanchet & Lüscher, 2002). 
Many explanations and mechanisms for the development of desensitization (and 
ultimately tolerance) revolve around the trafficking and regulation of the µOR after it has 
bound a ligand, therefore the endocytic cycling process will be discussed next. 
1.23 µOR endocytic cycling 
Opioid receptors, like many GPCRs, can be rapidly endocytosed by clathrin-coated pits. 
β-arrestin, which binds to activated ORs, facilitates this process (S. S. Ferguson et al., 
1996; Goodman et al., 1996). Endocytosis can also be facilitated by phosphorylation by 
GRKs (Kovoor, Celver, Abdryashitov, Chavkin, & Gurevich, 1999). Consistent with the 
functional selectivity of the µOR, this process is remarkably influenced by the ligand; 
morphine usually does not lead to internalization of the receptor, but DAMGO (including 
in cultured rat neocortical neurons), etorphine, methadone, and fentanyl all do rapidly 
(Finn & Whistler, 2001; L. He, Fong, Von Zastrow, & Whistler, 2002; Keith et al., 1998; 
Keith et al., 1996; Schulz et al., 2004; Trafton & Basbaum, 2004). DAMGO can also 
recruit β-arrestins more consistently than morphine is able to (Bohn, Dykstra, Lefkowitz, 
Caron, & Barak, 2004; Whistler & Von Zastrow, 1998, 1999; Jie Zhang et al., 1998). 
Recruitment of β-arrestins does not halt all of the intracellular signaling pathway, though 
some branches of the pathway may stop (Williams et al., 2013). Failing to induce rapid 
internalization of the µOR may lead to quick desensitization of the receptor (Williams et 
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al., 2013). For a review of the µOR, functional selectivity and desensitization, see 
(Raehal et al., 2011) or (Williams et al., 2013). 
Once endocytosed, the ligand dissociation can occur and the receptor can be 
sorted to its new destination; the µOR can potentially be shuttled back to the cell 
membrane, or to a lysosome for destruction (von Zastrow, 2010). Trafficking it back into 
the membrane can promote resensitization by enabling it to activate again, while the 
lysosome will lead to its proteolytic destruction (Ma et al., 2020; von Zastrow, 2010). 
Numerous factors can influence this fate, for instance ubiquitylation has been shown to 
exert an influence on the fate of endocytosed ORs (J.-G. Li, Haines, & Liu-Chen, 2008), 
or the splice variant of the µOR (Tanowitz, Hislop, & von Zastrow, 2008; Tanowitz & 
von Zastrow, 2003). Coactivation of other receptors can influence recycling of the 
receptor, for instance, the NK1 neurokinin receptor (activated by substance P) can reduce 
arrestin activity and receptor endocytosis (Y. J. Yu, Arttamangkul, Evans, Williams, & 
Von Zastrow, 2009). 
Some have proposed that agonist-induced endocytosis enhances sensitivity and 
allows drugs like DAMGO (which promotes endocytosis) to be less desensitizing than 
drugs like morphine, which typically does not promote endocytosis (Finn & Whistler, 
2001; Ma et al., 2020). Others have argued against this view by claiming endocytosis is 
not the causal factor, though this may be a heuristic to relate endocytosis to 
desensitization (Finn & Whistler, 2001; Gavril W. Pasternak & Pan, 2013). 
Although the existence of µOR/DOR dimers has not been proven, there is 
evidence that these dimers may promote the development of tolerance. Heterodimers of 
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the mu/delta opioid receptors are suspected to play a role in development of tolerance (S. 
Q. He et al., 2011). DOR agonism promotes µOR desensitization (S. Q. He et al., 2011), 
while disrupting µOR domains suspected of linking µOR/DOR dimers also disrupts 
tolerance (S. Q. He et al., 2011). Some have pointed out that the DOR appears to have the 
opposite tolerance/trafficking pattern of the µOR; endocytosing the DOR correlates with 
greater tolerance (Scherrer et al., 2006; von Zastrow, 2010). For a review of opioid 
heterodimers and tolerance, see (Gavril W. Pasternak & Pan, 2011). 
1.24 Basics of neurophysiology 
Ohm’s Law states that V=IR and therefore generation of a voltage requires a current to 
move through a resistor. Neurons use their plasma membrane (PM) is a natural resistor 
and conduct ionic currents through the plasma membrane, which then produces its 
membrane voltage (Vm). Different ion currents can create different voltage magnitudes 
and polarities; therefore, a neuron can modulate its Vm by controlling which (and when) 
ions can cross the PM. When a neuron sends its signal, it does so by rapidly changing its 
polarity, and then rapidly repolarizing to its initial starting point. It does this by rapidly 
changing the identity of the dominant ion that can pass through the PM. This 
depolarization is called an Action Potential (AP). Neurons normally start off with a 
negative polarity compared to their extracellular environment. During an AP (also called 
a spike), their polarity rapidly shifts from negative to positive. They can do this by 
rapidly altering the permeability of their PM to different ions and therefore change the 
rapidly ionic current through their PM. 
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Differential distributions of ions on the inside and outside of cells creates an ion 
gradient. Given the opportunity (permeability through the PM), the ions will diffuse 
down their concentration gradient. Sodium and calcium ions are highly concentrated on 
the outside of the cells and therefore will diffuse into the inside of cells through sodium 
ion channels and calcium ion channels. This creates a depolarizing effect on the neuron 
and a transiently-positive Vm during an AP. Importantly, these depolarizations also allow 
calcium ions to enter and interact with various biochemical pathways – for instance, by 
enhancing neurotransmitter release at synaptic terminals or activating gene transcription 
and synaptogenesis. Potassium is highly concentrated on the inside of the cells. The 
outward potassium current has a hyperpolarizing effect on cells. Neurons at rest (not 
during an action potential) have a relatively high permeability to potassium and therefore 
restricts their excitability. Neurons have very high resistance and therefore can maintain 
and alter their polarity with very little current (very little ion flow). 
Each cell has a resting membrane potential (RMP) produced to the slow outward 
K current and a little inward sodium current. GPCRs, such as the µOR, can add or 
subtract leak channels from the membrane. In the µOR’s case, it can make the RMP more 
negative (more hyperpolarized) by opening more leak channels. The details and identities 
of these channels will be given later, but the µOR is also implicated in trafficking 
voltage-sensitive channels, which are more complex. 
GPCRs can move voltage-sensitive ion channels (VSICs) that are mostly not open 
at rest. These VSICs but can open/close in response to a change in Vm. After opening, 
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they may rapidly inactivate. But others do not inactivate and simply stay open until the 
Vm moves out of their preferred range.  
These voltage-sensitive ion channels, which affect Vm, can themselves also be 
triggered by changes in Vm, and this sets up a potential positive feedback loop. Voltage-
sensitive sodium channels, for instance, are activated by depolarized Vm, but themselves 
also create a more-depolarizing Vm before they inactivate and close. These Voltage-
sensitive sodium channels create sharp APs (spikes) as they open and then inactivate. 
Voltage-sensitive calcium channels act similarly but are even more depolarizing, and the 
calcium ions they conduct can interact with biochemical pathways. Voltage-sensitive 
potassium channels, meanwhile, can dampen this chain reaction (dampen APs or smaller 
depolarizations that don’t rise to the level of an AP) by activating at depolarized Vm but 
conduct an outward potassium current to repolarize the membrane and, thus, they 
counteract the sodium and calcium channels by maintaining a strongly negative Vm and 
preventing the sodium and calcium channels from opening. 
There are also receptors, such as the NMDA and AMPA receptors that bind the 
excitatory neurotransmitter glutamate and allow sodium (and sometimes calcium) to enter 
and produce a transient depolarization. The NMDA receptor, though, is occluded by a 
Mg2+ ion and frequently requires the AMPA receptors to depolarize the cell and dislodge 
that ion. Therefore, they are channels that can initiate the process of an AP by binding 
glutamate and causing a transient depolarization. The NMDA receptor (and some AMPA 
receptors) can conduct calcium, and therefore also can cause gene transcriptional and 
biochemical changes in the neuron. 
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On the other side of the spectrum are the GABAA and GABAB receptors, which 
are usually inhibitory and bind the inhibitory neurotransmitter GABA. GABAergic 
interneurons activate these. These receptors, respectively, conduct an inward chloride 
current, or an outward potassium current which both hyperpolarize the neuron and 
counteract glutamatergic excitation. GABAA receptors are faster to open than GABAB 
receptors, because GABAB receptors are GPCRs, that act indirectly – like the µOR does. 
To put this together as an example, a typical resting neuron may receive 
numerous, transient excitatory postsynaptic potentials (EPSPs) a result of their NMDA 
and AMPA receptors and inhibitory postsynaptic potentials (IPSPs) from activation of 
their GABAA and GABAB receptors. The outcome of those 2 forces depends on the 
activity of the neuronal network as the. But eventually that Vm may become so positive 
that it triggers a critical amount of voltage-dependent sodium channels to open causing a 
spike (an AP). Voltage-sensitive potassium channels, which are slower to open, then 
bring the Vm back down to a hyperpolarized Vm value, ending the AP. Neurons have 
axons that these APs can be conducted along, and at the terminal ends of axons are 
neurotransmitter vesicles which could contain glutamate, GABA, or other 
neurotransmitters depending on the identity of the neuron. At the axon terminals, voltage-
dependent calcium channels can open during APs and allow calcium stimulate release of 
neurotransmitter onto the next neuron. They will then release their glutamate, GABA, 
enkephalins, and the cycle continues into the next neuron. 
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1.25 Hyperpolarization by the µOR 
The µOR has been observed to be strongly inhibiting on neurons with the receptor by 
hyperpolarizing the neuron and diminishing its capability to fire APs, including with the 
synthetic agonist DAMGO (Brunton & Charpak, 1998; B Chieng & Christie, 1994; 
Childers, 1991; Ikeda, Kobayashi, Kumanishi, Niki, & Yano, 2000; Kovoor, Henry, & 
Chavkin, 1995; Stein & Machelska, 2011; Stein & Zöllner, 2009). This is also observed 
in cortical neurons as well with DAMGO (Férézou et al., 2007; Glickfeld et al., 2008; 
Krook-Magnuson et al., 2011; K. R. Svoboda et al., 1999; Wimpey & Chavkin, 1991; 
Witkowski & Szulczyk, 2006). This is normally one of the µOR’s faster responses (Law 
et al., 2000). For a review of OR coupling with GIRK channels, see (Ikeda, Yoshii, Sora, 
& Kobayashi, 2003). 
Much of this hyperpolarizing effect has been attributed to G-protein coupled 
inwardly-rectifying channels (GIRK or Kir3 channels), which are open at rest and 
provide the cell membranes with a constant hyperpolarization and decreased input 
resistance (A. M. Brown & Birnbaumer, 1990; Harris & Williams, 1991; Ikeda et al., 
2000; Kobayashi et al., 1996; Lüscher & Slesinger, 2010; Nockemann et al., 2013; R 
Alan North, 1989; Signorini, Liao, Duncan, Jan, & Stoffel, 1997). Activation of these 
channels is believed to be mediated by the Gβγ subunits of the G-protein complex (Raveh, 
Cooper, Guy-David, & Reuveny, 2010). The µOR-mediated upregulation of GIRK 
channels is the first interaction to desensitize, with significantly reduced upregulation of 
GIRK channels occurring around 15 minutes (Blanchet & Lüscher, 2002). Tis subunit’s 
regulation of GIRK channels is believed to be a direct interaction and can be terminated 
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when the Gβγ subunit re-associates with the Gαi/o-GDP protein (Schreibmayer et al., 
1996). 
There are 4 GIRK channels (GIRK1-GIRK4) but only GIRK1-GIRK3 are highly 
expressed in the neocortex; GIRK4 is restricted to deeper layers and only found in small 
amounts (Karschin, Dißmann, Stühmer, & Karschin, 1996; Murer et al., 1997). GIRK 
channels form tetramers, and typically heterotetramers (Lüscher & Slesinger, 2010). 
To understand the colocalization of the µOR and GIRK channels (GIRK1 
specifically) researchers have used ICC with antibodies to both proteins in various parts 
of the brain, including the neocortex. They found a high degree of overlap between these 
2 proteins there in the soma and proximal dendrites of cortical neurons. However, the 
overlap was not complete; distal puncta (presumed to be axon terminals) occasionally 
stained for the µOR, but not GIRK1, indicating that the µOR’s inhibitory effect in distal 
processes are not associated with hyperpolarization there (Suzanne B Bausch & Chavkin, 
1995). Unfortunately, it appears that similar studies have not been attempted with GIRK1 
or GIRK3. 
Another important issue to address is whether µOR+ interneurons always 
hyperpolarize when they are exposed to the µOR agonist, DAMGO. This is difficult to 
answer since electrophysiology seems to be the most sensitive technique, for instance 
Férézou et al. (2007) (Férézou et al., 2007) found µOR mRNA in only 20 out of 32 
neurons (with sc-PCR) that hyperpolarized with DAMGO (Férézou et al., 2007). 
According to Wimpey & Chavkin (1991) (Wimpey & Chavkin, 1991), most of their 
DAMGO responders in the CA1/subiculum region of the hippocampal formation did not 
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hyperpolarize, but instead activated unidentified voltage-sensitive K channels (VSKCs) 
(Wimpey & Chavkin, 1991). It appears that while electrophysiology is still the most 
sensitive technique, but hyperpolarization may not be the only indicator of a DAMGO 
response (Férézou et al., 2007). It should also be noted that the GIRK1/µOR 
colocalization study discussed earlier analyzed at least 20 different brain regions and 
found the greatest degree of discordance of coexpression in the hippocampal formation 
and therefore the neocortical µORs may be more likely to induce somatic 
hyperpolarization than hippocampal µORs (Suzanne B Bausch & Chavkin, 1995). 
In summary, it appears that a strong hyperpolarization may not be the only 
indicator of a response to DAMGO and neurons. In addition to Wimpey & Chavkin 
(Wimpey & Chavkin, 1991), there are numerous reports that cortical and noncortical 
µORs can upregulate VSKCs in response to DAMGO (Faber & Sah, 2004; Finnegan et 
al., 2006; Vaughan et al., 1997; Wimpey & Chavkin, 1991) and Met-Enk (Vaughan et al., 
1997) which is the next topic. 
1.26 Voltage-sensitive K channels 
Voltage-sensitive K channels (VSKCs) can be divided into several different groups based 
on their shared properties. VSKCs can mediate either A-type current, which activates and 
deactivates rapidly, or delayed rectifier current that activate slowly and deactivate slowly 
or do not inactivate at all. They are also grouped into families based on their genetic 
similarity; channels within the family typically generate the same type of current, but 
sometimes they do not. These channels are expressed widely throughout the brain, 
including the neocortex. 
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The Shaker (Kv1) family of Kv channels comprise the largest group of voltage-
sensitive K channels. They are constituted of 4 α-subunits and sometimes auxiliary β 
subunits. There are 6 known members expressed in the brain and are numbered Kv1.1-
Kv1.6. These peptides may homotetramerize with identical subunits, or they more form 
heterotetramers with each other which can lead to various combinations of properties. 
They are typically slower to inactivate, and they deactivate slowly, or not at all. They 
tend to be triggered at more negative potentials when compared to other VSKCs (B Rudy 
et al., 2009). These channels can be blocked with 4-aminopyridine (4-AP). The protein 
αDendrotoxin (αDTX) selectively blocks Kv1.1, Kv1.2 and Kv1.6 subunits; possession 
of even a single Kv1.1, Kv1.2 or Kv1.6 subunit in heterotetramers will result in channel 
blockade. Their current is called D-type (ID) current due to their susceptibility to 
dendrotoxin (B Rudy et al., 2009). The tendency of these channels to heterotetramerize, 
complex with auxiliary subunits, and capability to undergo post-translation modifications 
in their α and auxiliary subunits makes the function and properties of ID current extremely 
variable. While the Kv1 channels are usually delayed rectifiers, Kv1.4 channels and other 
Shaker modified Kv1 channels may mediate A-type current (Carrasquillo, Burkhalter, & 
Nerbonne, 2012). The αDTX-sensitive current in has been reported to modulate threshold 
voltage for action potentials, afterhyperpolarization, spike frequency, and small effects on 
the AP repolarization kinetics rat visceral sensory neurons (Glazebrook et al., 2002). 
This Shaker class of channels is believed to exert a strong influence over the 
excitability of neocortical PVBCs (X. Li, Surguchev, Bian, Navaratnam, & Santos-
Sacchi, 2012). The high sensitivity to voltage of these channels allows them to control 
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repeated firing (J. Connor & Stevens, 1971). These channels can be found in neocortical 
PNs to restrict firing rates, however expression of Kv1 channels tends to be strongly 
influenced by layer and region (Bekkers & Delaney, 2001; Martina, Schultz, Ehmke, 
Monyer, & Jonas, 1998). The αDTX-sensitive subset of Shaker channels is also 
implicated in duration of afterhyperpolarizations in hippocampal PNs (Golding, Jung, 
Mickus, & Spruston, 1999). 
The Shab (Kv2) family of Kv channels has two known members: Kv2.1 and 
Kv2.2, and they typically function as delayed rectifiers, but in some instances, they can 
influence the repolarization phases of APs (A-type) (Liu & Bean, 2014). These channels 
can likewise heterotetramerize and undergo posttranslational modifications to alter their 
kinetics (B Rudy et al., 2009). These channels can be found at axon initial segments of 
hippocampal PNs (Sarmiere, Weigle, & Tamkun, 2008) and is generally a common 
feature of both interneurons and PNs (Murakoshi & Trimmer, 1999). 
The Shaw family (Kv3) are a group of A-type channels that typically activate and 
deactivate quickly. They also tend to be activated ay more depolarized voltages than the 
previously mentioned channels. It’s believed that this channel manages the duration and 
repolarization phases of action potentials due to these fast kinetics, but unfortunately this 
family is difficult to investigate due to the lack of specific blockers for Kv3 channels 
(Labro, Priest, Lacroix, Snyders, & Bezanilla, 2015; B Rudy et al., 2009). RT-PCR 
results from hippocampal experiments show that these channels are expressed in at least 
some types of interneurons and a minority of PNs (Martina et al., 1998). Blocking these 
channels with the non-specific channel blocker 4-aminopyridine reduces their firing rates 
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(Martina et al., 1998). These channels can be found in Layer 1 interneurons (Weiser et 
al., 1994) They can enable cortical neurons to repolarize more quickly, and fire more APs 
(Cao et al., 2014). 
The Shal (Kv4) family of K channels are another group of A-type channels that 
are similar to the Shaw family, but are generally capable of activating at more 
hyperpolarized voltages. They are believed to modulate repolarization phases of action 
potentials and possibly interspike intervals. Although Shal Kv channels do tend to 
inactivate quickly, they are believed to recover from inactivation relatively rapidly. 
Immunofluorescence of rat visual cortex shows that Kv4 channels can be found in both 
cortical interneurons and PNs. This includes GABAergic post-synaptic sites, somata, 
dendrites and dendritic spines (Burkhalter, Gonchar, Mellor, & Nerbonne, 2006). These 
channels are believed to modulate the duration and frequency of APs in neocortical PNs 
(Carrasquillo et al., 2012). 
Finally, the Kv7 (KCNQ) channels are a group of channels that mediate the IM 
current, which is targeted by many neuropeptides. This current is active between RMP 
and threshold for APs. While it is somewhat slow to activate, it either does not deactivate 
or deactivates very slowly. Therefore, these channels are unlikely to influence individual 
APs, but may suppress spike frequency adaptation and interspike interval (D. Brown, 
1988; Storm, 1987). This IM current is believed to be modulated specifically by Gq 
Coupled Protein Receptors, like the eponymous muscarinic receptor that the current is 
named after. The likely mechanism is through mobilization of PLCβ and regulation of 
PIP2 (B Rudy et al., 2009). These channels are found in hippocampal PNs and 
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interneurons and regulate interspike interval (Hu, Vervaeke, & Storm, 2007; Lawrence et 
al., 2006). These channels have been demonstrated to show powerful effects on cortical 
excitability and performance (Leão, Tan, & Fisahn, 2009; Peters, Hu, Pongs, Storm, & 
Isbrandt, 2005). 
To summarize, there are many families of potassium channels that can mediate K 
currents with slightly different properties. Delayed rectifiers tend to be associated with 
ability to fire APs, while the faster A-type current is more likely to modulate the duration 
of the spikes. To fully assay the potassium channels in current clamp mode (which 
enables APs to happen as they would in neurons) there are several important measures. 
Specifically, the firing frequency or interspike interval, the resting membrane potential, 
input resistance, repolarization rate or duration of an AP, and the magnitude of 
afterhyperpolarization. 
1.27 µOR regulation of voltage-sensitive channels 
The µOR is a pertussis toxin sensitive Gi coupled receptor that generally acts through two 
divergent mechanisms (Al-Hasani & Bruchas, 2011; Ingram & Williams, 1994). Upon 
binding of an agonist to an opioid receptor the Gαi and Gβγ subunits dissociate from each 
other. The Gαi activates local inhibits adenylyl cyclase, meanwhile the Gβγ inhibits Ca
2+ 
conductance by binding to, and inactivating, local voltage-gated calcium channels 
(Capogna, Gähwiler, & Thompson, 1993; M. Connor et al., 1999; Glickfeld et al., 2008; 
Rusin, Giovannucci, Stuenkel, & Moises, 1997; Zamponi & Snutch, 2002). Upregulation 
of potassium channels appears to be cAMP-dependent in at least some cases (Chen & Yu, 
1994), but not in others (Sánchez-Blázquez et al., 2001; Witkowski & Szulczyk, 2006). 
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The µOR is also believed to negatively regulate calcium (and some sodium) 
currents as well. This includes: suppression of N-type Ca2+ channels (Law et al., 2000; 
Rubovitch et al., 2003); suppression of L-type Ca2+ channels (Piros et al., 1996; Piros et 
al., 1995); P/Q-type Ca2+ channels and G protein-activated inwardly-rectifying K 
channels (M. Connor et al., 1999; Henry, Grandy, Lester, Davidson, & Chavkin, 1995; 
Jeong & Ikeda, 1998). µORs are also believed to downregulate activity of NMDARs (C. 
W. Xie & Lewis, 1997). µORs have also been reported to regulate a variety of other 
channels in DRG neurons, including inhibiting TRPV1 channels (Endres-Becker et al., 
2007; Spahn et al., 2013), inhibiting acid-sensing ion channels (Cai et al., 2014). 
Yet not all channels that the µOR modulates in cortical neurons have been 
identified. In dorsal striatal neurons, researchers found that multiple K currents were 
being modulated by DAMGO (Ponterio et al., 2013). Researchers found that an 
unknown, voltage-dependent K current was activated with DAMGO as well in 
hippocampal neurons (Wimpey & Chavkin, 1991). Follow-up research with both the 
endogenous ligand Met-Enk and DAMGO indicated these agonists were upregulating a K 
current that was 4-AP sensitive and likely belong to the Shaker family of K channels 
(Vaughan et al., 1997). Limited knowledge of voltage-sensitive K currents at the time 
may have prevented further inquiry about the identity of these channels in cortical 
neurons, but more recent research from other parts of the brain provides more insight 
about the identity these channels. 
Findings from the lateral amygdala by Faber et al. (2004)(Faber & Sah, 2004) 
indicated that the µOR was upregulating a voltage-sensitive K current to increase spike 
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frequency adaptation – a feature that suppresses the number of evoked action potentials 
and increases the time between spikes (interspike interval). They likewise found that this 
effect was blocked by inhibiting phospholipase A2 with AACOCF3. Most interestingly 
they identified this current as sensitive to both αDTX and Tityustoxin-Kα (TsTx-Kα), 
which is a feature of the Shaker-family channel Kv1.2. In a similar study on basolateral 
amygdala neurons that project to the central nucleus of the amygdala, Finnegan et al 
(2006) (Finnegan et al., 2006) found that DAMGO reduces the amplitude of evoked 
IPSCs and reduced the frequency of mIPSCs. They found that 4-AP, αDTX, TsTx-Kα, 
and Dendrotoxin-K (blocker of Kv1.1, another Shaker channel). These findings in 
amygdalar structures suggest that the µOR upregulates the Shaker channels Kv1.1 and 
Kv1.2 to inhibit neurons in a PLA2-dependent manner. These results closely mirrored 
findings in cortical neurons that suggested that unidentified VSKCs were being 
upregulated by the µOR (Wimpey & Chavkin, 1991).  
Therefore, these mechanisms and data collected from the amygdala implicate 
αDTX-sensitive current as a target of modulation, which can then modulate the number 
of APs that are evoked from µOR+ neurons. The relationship between these αDTX-
sensitive channels and the µOR has not presently been explored in neocortical neurons 
but could be one of the mechanisms that the µOR uses to suppress neocortical them. 
1.28 Measures of excitability in individual neurons 
Cortical neurons have a variety of mechanisms that they can leverage to modulate their 
output. These mechanisms are used to adjust their firing rates, probability of an action 
potential (AP), and their neurotransmitter release at synaptic terminals. 
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Perhaps the simplest way is for neurons to increase their permeability to 
potassium, which moves their Vm closer to EK and hyperpolarizing the cell – moving it 
away from its threshold for an action potential. This can be accomplished by opening K 
leak channels which provide their PM with a constant hyperpolarization. Therefore, their 
RMP will become more negative. Opening more channels also decreases their input 
resistance, as measured by a recording electrode. This is potentially more challenging 
than measuring RMP, since measuring input resistance necessarily requires inputting a 
current. A depolarizing current may cause the neuron to fire, and a hyperpolarizing 
current may not fully capture the breadth of voltage-gated channels that would be 
activated by a depolarizing current. The µOR is consistently shown the hyperpolarize 
neurons. 
Neurons may also modulate their threshold for an AP – a voltage range at which 
voltage-sensitive Na channels are likely to begin to open and create the positive-feedback 
loop that creates an AP. This could be done by utilizing posttranslational modifications or 
trafficking of voltage-sensitive K channels to the cell membrane and make them more 
likely to open upon a depolarizing stimulus. On the other hand, cells may also 
downregulate their voltage-sensitive Na channels to make them less able (by trafficking 
or posttranslational modifications) to open upon a depolarizing stimulus. The µOR is not 
necessarily known to modulate AP threshold (Faber & Sah, 2004), though it is relatively 
easy to measure since the spikes evoked at threshold is normally minimal and can 
produced a stable change in Vm. 
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Cortical neurons rarely fire only one AP in response to a depolarizing stimulus – 
they often fire several. The pattern, frequency, and number of APs is subject to 
modulation to alter their excitability. Interspike interval (ISI) – the length in time between 
APs – is a property that is inversely related to the frequency of APs. The µOR has been 
shown to increase the ISI in amygdalar neurons, which is reversible with αDTX (Faber & 
Sah, 2004). Therefore, this is an important aspect to measure. Similarly, the number of 
evoked APs is closely related to the ISI.  
The duration of an action potential that neurons can modulate too and may lead to 
variable physiological effects. For instance, neurons may reduce the activity of their A-
type K currents to make APs longer in duration. This may slow down the rate of APs – 
because the Vm will take longer to reset down to RMP and allow the VSNCs channels to 
shift into the closed conformation. However, at a presynaptic terminal, the longer-
duration AP may make it more likely that Ca channels will open and cause release of 
neurotransmitter. 
1.29 Cortical neurodevelopment and Dlx genes 
Discriminating PNs from GABAergic interneurons is a common issue with any testing 
preparation of neocortical neurons. This distinction may be important to understanding 
how PNs are affected by DAMGO exposure or targeting a specific population for 
electrophysiology. Luckily, this obstacle can be overcome with the help of transgenics. 
Excitatory and inhibitory neocortical neurons have different embryonic origins. 
They therefore are hallmarked by expression of different genes, which can be used to 
identify them. Utilizing unique homeobox genes expressed by either excitatory or 
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inhibitory neurons allows researchers to identify them in virtually any experimental 
system.  
All cortical neurons, whether inhibitory or excitatory, are produced from 
temporary proliferative zones (the ventricular zone and subventricular zone) and migrate 
into the prenatal cortex. The deeper layers of the cortex migrate the earliest and Layer 2 
developing the latest – Layer 1 is an exception; the most superficial cortical layer appears 
to develop first and develop persistently through the postnatal period (Rakic, 2009) 
While PNs migrate radially into the cortex from the pallium, the cortical 
interneurons are generated in the prenatal, basal telencephalon (the sub pallium) and 
migrate tangentially into the cortex. The subpallium consists of several domains, 
including the medial ganglionic eminence (MGE), the lateral ganglionic eminence 
(LGE), the preoptic area (POA). The caudal ganglionic eminence (CGE), meanwhile, is 
located at a caudal fused area of the MGE and LGE. Fate-mapping experiments show that 
interneurons are born in the ventricular zone of these ganglionic eminences, while PNs 
are born in the VZ of the cortex (Stewart A Anderson, Marín, Horn, Jennings, & 
Rubenstein, 2001). Mouse interneurons begin this migration on about day E12 and the 
neurons populate all cortical areas (including hippocampal cortex and neocortex) (Flames 
& Marin, 2005). Migration of progenitors from the subcortical telencephalon appears to 
be complete by around E17 in rodents – including in rat models (S. A. Anderson, 
Eisenstat, Shi, & Rubenstein, 1997; Metin, Baudoin, Rakic, & Parnavelas, 2006; Q. Xu, 
Cobos, De La Cruz, Rubenstein, & Anderson, 2004).  
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While some researchers have proposed that interneurons are granted their unique 
identity based on where they happen to stratify, fate-mapping data suggest that their 
identities are determined prior to migration (Stewart A Anderson et al., 2001; Batista-
Brito, Machold, Klein, & Fishell, 2008; Butt et al., 2005). The MGE interneuronal pool 
gives rise to most PV+ and SST+ interneurons, while the CGE gives rise to other classes 
(Butt et al., 2005). 
Interneuron migration and development is supported by unique expression of the 
homeodomain transcription factors Dlx of the family which can be used to identify 
interneurons from PNs (Flames & Marin, 2005; Pla et al., 2017). Six known Dlx 
orthologs are known, numbered 1 through 6 are expressed by prenatal cortical 
interneurons but data derived from a Dlx 5/6 BAC suggests that expression of Dlx5/6 
persists in mature cortical interneurons (Y. Wang et al., 2010). Using transgenic 
expression of β-galactosidase, researchers have shown that Dlx5 or Dlx6 are expressed 
by only, and all, cortical interneurons. Sc-PCR analyses revealed that these neurons 
represent all the major expression categories of neurons (SST+, 5HTr3a+, and PV+) (de 
Lombares et al., 2019). Furthermore, experiments using Dlx5/6-Cre mice show that these 
neurons differentiate into GABAergic interneurons, while the excitatory neurons are 
instead predicted by expression of Emx1 (Batista-Brito et al., 2008; Gorski et al., 2002). 
A Dlx5/6-Cre construct has also been used to disrupt the excitatory drive into mouse 
interneurons in vivo and thereby create behavioral defects that resemble a schizophrenic 
endophenotype (Fazzari et al., 2010). 
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Unfortunately, the embryonic lethality of Dlx gene knockout makes it difficult to 
determine the exact roles of these genes, but in mature interneurons Dlx5/6 appears to 
promote expression of the GABA-synthesizing enzymes GAD65 and GAD67; ectopic 
expression of these genes can induce production of GABA (de Lombares et al., 2019). 
1.30 Primary neuron culture 
The need to conduct experiments on neurons in an accessible environment led to 
development of several models to investigate neurons that are grown in vitro. Some 
models of neurons are derived from tumors (Biedler, Helson, & Spengler, 1973), but the 
primary neuron culture model enables researchers to extract otherwise-normal neurons 
from the brains of rodents and culture them in a controlled environment for experiments 
(Gordon, Amini, & White, 2013). The present-day neuron culture protocol has evolved 
for 100 years (Harrison, 1910) to enhance their validity and study the phenomena 
referenced in this literature review. Modern iterations of this technique have developed to 
maximize their similarity with neurons in situ. 
Primary Neuron Cultures are popular models for use with electrophysiology due 
to the ease-of-access and separation from tonic factors secreted by neocortical neurons 
(Brewer, Torricelli, Evege, & Price, 1993; Dichter, 1978; Mains & Patterson, 1973). This 
simplifies many of interactions between neurons. 
Primary neuron cultures, as described above, have been used extensively to study 
calcium oscillations for the ease of imaging a network of neurons in a single plane 
(Dravid & Murray, 2004; T. H. Murphy et al., 1992; Przewlocki et al., 1999; J. Wang et 
al., 2016). These cultures are highly amenable for these studies for their ease of use and 
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the ability to resolve single neurons without obfuscation from additional tissue layers. 
They can enable the collection of a large volume of data that may be required to sample a 
heterogenous population, such as neocortical interneurons. 
Primary cultures of rat neocortical neurons have been used extensively to 
investigating µOR’s intracellular signaling pathway, mechanisms (Arttamangkul, 
Torrecilla, Kobayashi, Okano, & Williams, 2006; M. C. Lee et al., 2002; Junhui Zhang, 
Qian, Zhao, Hong, & Xia, 2006), and electrophysiology (E. Tanaka & North, 1994) - 
including the µOR’s disinhibitory effect in non-cortical primary cultures (Crain, Shen, & 
Chalazonitis, 1988). Therefore, primary neuron cultures are a powerful tool to investigate 
the phenomena outlined in this literature review. 
 
CHAPTER 2: NEOCORTICAL µ OPIOD RECEPTORS ENHANCE 
SPONTANEOUS CALCIUM OSCILLATIONS THROUGH 
DOWNREGULATION OF GABAA AND GABAB RECEPTORS 
 
2.1 Introduction 
The endogenous opioid system of the cerebral cortex mediates antinociception, reward 
valuation and reward-seeking behaviors. Dysregulation of this system is believed to 
contribute to pathological and compulsive behaviors, such as behaviors eating disorders, 
pathological gambling, and drug-seeking (B. Bencherif et al., 2005; Badreddine 
Bencherif et al., 2005; Joutsa et al., 2018; Mick et al., 2016; Mitchell et al., 2012; Qu et 
al., 2015; Zubieta et al., 1996). Experimentally, impulsive behaviors and binge-eating can 
be induced through infusion of the µ opioid receptor specific (µOR) agonist [D-Ala2, N-
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Me-Phe4, Gly5-ol]-Enkephalin (DAMGO) into the frontal cortex of animal models 
(Mena et al., 2011; Selleck et al., 2015). Blockade of the µOR with naltrexone inhibits 
these compulsive behaviors (Bartus et al., 2003; Blasio et al., 2014). These aberrancies 
are believed to result from disruption of the activity of cortical networks (Haider, Duque, 
Hasenstaub, & McCormick, 2006; M. Whittington et al., 1998; Y. Zhang et al., 2019).  
The µOR is believed to suppress GABAergic release through its expression 
primarily on cortical GABAergic interneurons, and therefore lead to overactivity of the 
targets of their inhibition, the glutamatergic Pyramidal Neurons (PNs) (Drake & Milner, 
1999, 2002, 2006; Férézou et al., 2007; Huo et al., 2005; Madison & Nicoll, 1988; 
Stumm et al., 2004; Taki et al., 2000; Witkowski & Szulczyk, 2006; Zieglgansberger et 
al., 1979). But some research suggests that the µOR µOR may localize to PNs and 
directly activate them as well (Przewlocki et al., 1999; Rola et al., 2008; Schmidt et al., 
2003; Witkowski & Szulczyk, 2006). Therefore, it is unclear whether excitatory effects 
of µOR agonism is due to disinhibition or excitation of Pyramidal Neurons, or whether 
the µOR can perform both functions. These conflicting results have presented a challenge 
to understanding how the µOR exerts its effects on cortical circuits. Furthermore, several 
lines of evidence suggest that the µOR suppresses the neurogliaform class of neurons, 
which uniquely activate GABAB receptors on excitatory Pyramidal Neurons (Krook-
Magnuson et al., 2011; Olah et al., 2007; Tamás et al., 2003) – whereas other cortical 
interneurons generally activate only GABAA receptors. This positions µOR+ 
interneurons to play an important role on slower-acting and longer-lasting inhibition on 
cortical networks by regulating postsynaptic activity of GABAB receptors.  
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The dynamics of excitatory and inhibitory network activity have been explored in 
cultured neurons, where neurons engage in frequent spontaneous activity and 
synchronized depolarizations due to synaptic interlinkage (Canepari et al., 1997; 
Chiappalone, Bove, Vato, Tedesco, & Martinoia, 2006; Nakanishi & Kukita, 1998). To 
easily monitor network activity in many culture neurons at once, calcium-imaging has 
been used to visualize large-scale network events in cultured neurons; excitation in 
cultured neurons can be visualized as spontaneous synchronized calcium oscillations 
(SCOs) resulting from synchronized activation of glutamatergic receptors (Bacci et al., 
1999; Muramoto et al., 1993; Nakanishi & Kukita, 1998; Robinson et al., 1993). These 
oscillations can be prevented by blocking depolarizations with TTX, or by blocking 
glutamate receptors (Dravid & Murray, 2004; Kelamangalath et al., 2011; T. H. Murphy 
et al., 1992; Nuñez et al., 1996; Przewlocki et al., 1999). Within individual neurons, these 
calcium transients correspond with excitatory postsynaptic potentials as well as bursts of 
action potentials (Muramoto et al., 1993; T. H. Murphy et al., 1992). Some researchers 
have used this model in low concentrations of Mg2+ and found that these calcium 
oscillations and bursts of action potentials are due to the calcium-conducting properties of 
the NMDA receptors (Canepari et al., 1997; Penn et al., 2016; Przewlocki et al., 1999; T. 
Tanaka et al., 1996), but others argue that calcium oscillations in physiological [Mg2+] 
are actually caused by calcium-conducting AMPA receptors and mGluRs coupled to 
calcium-induced calcium release (CICR) (Dravid & Murray, 2004; Flint et al., 1999). Yet 
other authors have suggested that voltage-sensitive calcium channels play a large or 
predominant role in generating SCOs (Bacci et al., 1999; Dravid & Murray, 2004; 
Inglefield & Shafer, 2000). Although there is disagreement over the identity of the 
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glutamatergic receptor or ion channel based on the type of neuronal culture and 
experimental condition, these calcium oscillations appear to be related to activity in 
excitable cells. 
The effect of DAMGO on SCOs was explored in previous experiments by another 
lab, and it was suggested that the µOR directly stimulates NMDA receptors on 
hippocampal Pyramidal Neurons (Przewlocki et al., 1999), which may throw doubt on 
the view that the µOR excites cortical networks by suppressing interneurons. On the 
other hand, electrophysiological experiments done by our lab (Dutkiewicz & Morielli, 
2020), and another lab (Férézou et al., 2007), suggest that neocortical interneurons are 
suppressed by DAMGO stimulation. Although these mechanisms are not mutually 
exclusive, these lines of evidence have presented a challenging research issue, whether 
the µOR’s role in exciting cortical networks is mainly driven by suppressing cortical 
interneurons, or by directly activating the Pyramidal Neurons. Furthermore, the evidence 
that the µOR localizes to neurogliaform neurons also raises the possibility that DAMGO 
stimulation may reduce GABA release onto both GABAA and GABAB receptors, and 
thus DAMGO-induced disinhibition may be more consequential to network activity than 
previously considered. 
We hypothesized that the µOR’s excitatory effect on cultured neurons was 
primarily by suppressing subsets of GABAergic interneurons (i.e., disinhibition) rather 
than by directly exciting the PNs themselves. We further predicted that DAMGO would 
suppress GABA release onto both GABAA and GABAB receptors due to the research 
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suggesting that neurogliaform neurons express the µOR. We therefore tested DAMGO in 
the presence of GABAR-blockers to prevent the DAMGO-induced SCO changes. 
2.2 Materials and methods 
2.2.1 Cell cultures 
All procedures were authorized by the Institutional Animal Care and Use Committee 
(IACUC) at University of Vermont. We dissected CD® IGS Sprague-Dawley (Charles 
River) pregnant rat dams to harvest neocortical neurons from the frontal cortices of E21 
rat embryos. Brain cortices were rinsed in Hibernate A (Gibco, Grand Island, NY), 
dissociated with papain (Worthington, Columbus, OH) and mechanically separated 
through gentle trituration with a pipette. Dissociated cortical neurons were and cultured 
on round 12mm glass, PEI-coated (Sigma-Aldrich, St. Louis, MO) coverslips at an 
approximate density of 3x104 cells/cm2. We maintained the neurons in Neurobasal A, 
B27, Penicillin-Streptomycin and Glutamax (All from Gibco), in a humidified 37° C 
incubator with 5% CO2. For experiments where we utilized the interneuron marker, we 
transformed those cultures on DIV0 with AAV-mDlx-NLS-mRuby2, which was a gift 
from Viviana Gradinaru (Addgene viral prep # 99130-AAV1); 
http://n2t.net/addgene:99130; RRID:Addgene_99130). 
2.2.2 Calcium imaging 
We removed coverslips for their growth media and incubated them in the dark, at 
ambient temperature in a combination of a 1:50 dilution of B27 and Hibernate A. We 
prepped the fluo-4 AM dye (Molecular Probes, Eugene OR) by combining 2uLs of a 1 
µg/µL (in DMSO) stock solution with 2µLs of 20% Pluronic F-127 (Molecular Probes). 
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After ensuring the dye was dissolved in the Pluronic F-127, we combined this with the 
neuron’s Hibernate A (Gibco) buffer at a final concentration of 1 µg fluo-4, AM/1 mL of 
Hibernate A+B27. The neurons were incubated in this solution for 1 hour before imaging. 
The drugs were purchased from two main sources: [d-Ala2,N-Me-Phe4,Gly5-ol]-
Enkephalin] (DAMGO), D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP), 
picrotoxin, and CGP55845 were purchased from Sigma (St. Louis, MO); 6-Cyano-7-
nitroquinoxaline-2,3-dione disodium (CNQX) and D-(-)-2-Amino-5-phosphonopentanoic 
acid (dAP5) were from Tocris (Bristol, United Kingdom). 
After dye loading, we transferred them into a recording chamber and perfused 
them with ACSF (in mM): NaCl, 126; KCl, 5; NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1; 
NaHCO3, 26; Glucose, 20; and pyruvate, 5(Férézou et al., 2007). The ACSF was warmed 
to 30oC and constantly bubbled with a mixture of 95% O2 and 5% CO2. Neurons were 
visualized and recorded on a Nikon Eclipse E600 fluorescence microscope. We used a 
40x objective dipping lens and acquired an imaging area with at least 15 neurons. During 
image capture, we illuminated the neurons with an X-Cite 120 fluorescence illuminator to 
activate green fluorescence (Excelitas, Waltham, MA). In instances where we used red-
fluorescent interneurons, we captured red fluorescence (mRuby2) with one image prior to 
recording the green (fluo-4) channel. Fluorescence was captured with a Photometrics 
CoolSnapES Monochrome Camera (Roper Scientific, Sarasota Florida) and imaged with 
an exposure time of 250ms with either Metavue 6.1 (Molecular Devices, San Jose, CA) 
software or µManager (Edelstein et al., 2014). 
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Our preliminary experiments indicated that we could capture at least 125s of 
images at 4 frames/second before significant bleaching occurred. Therefore, we recorded 
two 62.5s stacks; one before the drug (slot 1) and one after the drug (slot 2).  
Although previously published studies by other labs have sometimes opted to use 
low or no [Mg2+] ACSF, which enhances spontaneous synchronized calcium oscillations 
(SCOs), we observed spontaneous calcium oscillations in the presence of physiological 
levels (1 mM Mg2+), which has also has been reported previously in rodent cortical 
cultures (Dravid & Murray, 2004; T. H. Murphy et al., 1992). We therefore continued to 
use 1mM Mg2+ ACSF. 
For the first dataset (Figure 7), we recorded .tiff image timestacks under a pre-
drug condition, and then applied the drug buffer for 62.5s and subsequently recorded an 
image time stack for the post-drug condition while continuously applying the drug 
(Figure 5). However, the drug sequence varied depending on which data set it was 
collected from; in the first dataset, slot1 always corresponded with vehicle ACSF (saline), 
and timeslot 2 always corresponded to a combined drug bolus. This drug combination is 
indicated on the graphs.  
In the second dataset (Figure 11), picrotoxin and CGP55845 were preincubated 
for 15-25 minutes before exposure to DAMGO, such that DAMGO was applied in a 
background of those drugs. In the case of Figure 12, CGP55845 was similarly applied in 
a background of picrotoxin. 
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2.2.3 Calcium-imaging analyses 
Data initially were contained in the form a brightfield image and a stack of 250 green-
channel images. Cell counting and image analyses were done on ImageJ 1.52p 
(Schindelin et al., 2012) prior to running the Python script. We used ImageJ to draw ROIs 
separately around nonred or red (where applicable in the second data set) with the Timer 
Series Analyzer V3 plugin, which produced a table of calcium-indicator fluorescence 
over the 250 images. That table was copied over onto separate Microsoft Excel 
Spreadsheets into labelled data folders. Those labelled folders and the spreadsheets 
therein served as the data input for the calcium-imaging Python scripts. These Excel 
spreadsheets were analyzed directly by the ca_transient_peak_finder_14.5.py script. in 
the first dataset (for Figure 6 and Figure 7) which was programmed to generate xy plots 
for the peaks (Figure 1 and Figure 2).  
 
Figure 1. Representative example of calcium peaks in one neuron.Spontaneous calcium oscillations were 
captured in each neuron over 62.5s (4 frames / second) and graphed on xy plots. The y axis represents 
relative proportional units of calcium indicator fluorescence ((F-F0)/F0), where the highest peak in the 
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timestack (including all of the neurons/ROIs not shown here) is set to an amplitude of 1.00, and these peaks 
are scaled against the tallest peak. X axis represents frames at (4 frames/sec). On the calcium peaks: yellow 
lines denote the base of each recognized peak, green horizontal lines are the measures of halfwidth for the 
peaks, and the red dot at the tips of the peaks are noting that the peak has been successfully culled for 
analysis by the Python script. 
 
The data for the second dataset (for Figure 11) utilized the 
auto_mask_red_cell_v2.5.py script to automatically generate ROIs in neurons. It created 
two spreadsheets, one for red neurons and one for nonred neurons. These spreadsheets 
were then analyzed separately in the same manner as described above. 
We observed that groups of neighboring neurons captured within imaging frames 
tended to experience apparently synchronous SCOs, and therefore opted not to use 
individual neurons as members of the sample (Figure 2). Instead, we measured all SCOs 
occurring in all neurons within the imaging frame and derived median values of the SCOs 
in each neuron within the frame. We then further determined the mean value of these 
median values, to calculate the average SCO from each imaging stack. Through these 
calculations, we compared the SCOs before and after various drug treatments to 
determine how the drugs impacted the average SCO occurring within the imaging frame. 
Thus, each member of our sample represented the average (mean of median) SCO 








Figure 2. Neurons in image field have synchronous spontaneous calcium oscillations. A temporal 
alignment of all neurons in an imaging field (Left) before DAMGO, and the same neurons (Right) after 
DAMGO. Y axis shows calcium indicator fluorescence with each separate neuron arranged in a separate 
row. Each neuron’s highest peak is set to a value of 1.00 to standardize the scale across neurons. X axis 
represents a period of 80s in each of the two conditions. We observed that neurons in the imaging field had 
synchronized spontaneous calcium oscillations (SCOs). Therefore, we derived median peak values for each 
neuron, and then derived the mean of the median values across all the neurons in the field for each of the 2 
conditions, in order to derive the average peak value before and after the drug. DAMGO’s enhancement of 
calcium peak halfwidth is also evident from these graphs. 
 
 2.2.4 Validation for auto_mask 
To validate the auto_mask script that automatically drew ROIs in the second dataset, we 
hand-drew ROIs in 214 spreadsheets that were also analyzed using the auto_mask script. 
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We performed a bivariate correlation in IBM SPSS 27.0.0.0. to correlate the mean SCO 
amplitude, halfwidth, and number between the script-drawn and manually drawn ROIs. 
Measure Bivariate Correlation 
Amplitude R = 0.790, p < 0.001 
Halfwidth R = 0.909, p < 0.001 
Number R = 0.856, p < 0.001 
Table 1. Validation for auto_mask ROI generator. To determine whether the automatic generator could 
derive values positively correlated with hand-drawn ROIs (in ImageJ), we utilized the script and hand-
generated ROIs on 214 image stacks across all drug conditions. We determined that all measures featured 
here were positively and significantly correlated with each other, indicating that the auto_mask script ROIs 
were consistent with the manually drawn ROIs. 
2.2.5 Whole-cell recordings  
Patch pipettes with resistances of 5-10MΩ were fabricated from borosilicate glass 
capillaries and filled with intracellular saline containing (in mM) K-gluconate, 144; 
MgCl2, 3; ethyleneglycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, 0.5; 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, 10 (Férézou et al., 2007). The pH was 
adjusted to 7.2 with potassium hydroxide and confirmed for an osmolarity of 285/295 
mosm. Whole-cell recordings were made with an Axopatch 200B (Axon Instruments) 
amplifier and Clampex 9.2.1.9 (Molecular Devices) software. Signals were sampled at 
10kHz with a Digidata 1322a (Axon Instruments) DA converter. Calcium-imaging was 
aligned with electrophysiology through a green light emitting diode that was linked to the 
Digidata 1322a converter and controlled by the Clampex software; the LED emitted a 
start sequence of light flashes which were visible in the first 16 seconds of recording and 
removed prior to analysis. 
2.2.6 Sample sizes and statistics 
Sample sizes were initially calculated based on preliminary data on DAMGO’s effect in a 
large test group of 21 saline and 21 DAMGO recordings. This test group was used to 
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determine future sample sizes and the polarity of DAMGO effects for statistical testing 
(one-tailed versus two-tailed). Although we measured several properties of SCOs, we 
focused on DAMGO’s effect on SCO halfwidth, since preliminary data indicated that it 
was the most frequent DAMGO effect, and also the only persisting effect in the presence 
of picrotoxin. In this large pool of preliminary recordings, we found that fold changes of 
halfwidth in the DAMGO recordings (N = 21, M = 1.80, SD = 0.78) were significantly 
greater (t(40) = 4.68, p < 0.001) than the fold changes in saline controls (N = 21, M = 
0.97, SD = 0.78). A posthoc analysis of that preliminary data pool revealed that the effect 
size d was a value of 1.44. We used G*Power software (Faul, Erdfelder, Buchner, & 
Lang, 2009; Faul, Erdfelder, Lang, & Buchner, 2007) to determine that the required 
sample size was an n = 12 for a one-tailed t test. For the first dataset, we therefore used 
groups of n = 12 for each group. In the second dataset, we used an n = 13 to provide a +1 
sample number in case of technical difficulties, which did not occur, and we thus used all 
13 recordings. 
The mean scores for calcium peak halfwidth, number of peaks, and amplitude in 
all drug conditions were graphed and analyzed in GraphPad Prism version 8.4.3 for 
Windows, GraphPad Software, San Diego CA, USA www.graphpad.com. Statistical 
testing on the first dataset commenced by testing for a normal distribution with a 
D’Agostino-Pearson’s omnibus test. When data within a group were significantly 
different from a normal distribution (p < 0.05), then that group was compared with a 
Mann-Whitney U test. Data that were not significantly different from normal 
distributions were instead tested with a one-tailed unpaired t-test. Statistical testing on 
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(Figure 11), where 4 groups were included, we instead tested with ordinary one-way 
ANOVAs and Sidak’s test for multiple comparisons in GraphPad Prism. 
 
2.3 Results 
2.3.1 Measuring synchronized spontaneous calcium oscillations 
To measure spontaneous calcium oscillations, we directed our analyses on 3 basic 
properties of the calcium spikes to comprehensively analyze SCOs: peak height, duration, 
and the number of calcium peaks. Respectively, these represent the y dimension of the 
calcium peak, the x dimension, and the quantity of SCO peaks (Figure 1).  
2.3.2 SCOs require neuronal activity and glutamatergic signaling 
Other labs have reported SCOs similar to our observations (Figure 1) and found that these 
oscillations correspond to excitatory postsynaptic potentials and bursts of action 
potentials in the neurons (Bacci et al., 1999; T. H. Murphy et al., 1992; Przewlocki et al., 
1999; Robinson et al., 1993). To investigate whether SCOs in our preparation correlated 
with neuronal activity, we counted SCOs in a variety of conditions designed to prevent 
glutamatergic drive and action potentials,  
Other labs have found that SCOs are produced by activation of postsynaptic 
glutamate receptors (Bacci et al., 1999; Dravid & Murray, 2004; T. H. Murphy et al., 
1992; Przewlocki et al., 1999). To test this in our preparation, we counted calcium 
oscillations occurring during pharmacological blockade of glutamatergic receptors. We 
therefore applied the combination of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
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acid receptor (AMPA) and kainate blocker 6-Cyano-7-nitroquinoxaline-2,3-dione 
(CNQX; 20 µM) and the N-methyl-D-aspartate (NMDAR) inhibitor D-(-)-2-Amino-5-
phosphonopentanoic acid (AP5; 50 µM), which eliminated all SCO activity (Figure 3). 
The finding that, SCOs depend on intact glutamatergic signaling is in agreement with 
previous reports of SCOs in primary cortical cultures (Cao et al., 2015; Dravid & Murray, 
2004; Inglefield & Shafer, 2000; T. H. Murphy et al., 1992; Nuñez et al., 1996; 
Przewlocki et al., 1999; Shen et al., 1996).  
To test whether SCOs were dependent on spontaneous action potentials, we 
applied 1 mM of the sodium channel inhibitor tetrodotoxin (TTX) to block them. We 
found that this drug also prevented SCOs from occurring (Figure 3). These findings were 
again consistent with previous research from other labs which have found TTX 
suppresses SCOs (Dravid & Murray, 2004; T. H. Murphy et al., 1992; Przewlocki et al., 
1999; Shen et al., 1996) (Inglefield & Shafer, 2000). 
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Figure 3. Neuronal activity and glutamatergic signaling required for SCOs. We counted calcium peaks 
occurring in a 160s period in 3 groups: saline controls; voltage-sensitive sodium channel inhibitor 
tetrodotoxin (TTX; 1 µM); and the combination of (20 µM) AMPA/kainate blocker 6-Cyano-7-
nitroquinoxaline-2,3-dione (CNQX) and the NMDAR inhibitor (50 µM) D-(-)-2-Amino-5-
phosphonopentanoic acid (AP5). In the saline condition, neurons exhibited a median of 6.93 oscillations 
(range 0.25 to 12.66) per neuron, per minute. In the TTX condition, neurons exhibited a median of 0.00 
(range 0.00 to 0.10). In the CNQX+AP5 condition, neurons exhibited a median of 0.03 oscillations (range 
0.00 to 0.24) per neuron, per minute. We found that the number of calcium oscillations in the TTX (t(11) = 
1.45, p = 0.17) and CNQX+AP5 (t(11) = 2.19, p = 0.05) condition were not significantly different from a 
test value of 0 (one-sample t tests), while the saline group was significantly different from a test value of 0 
(t(11) = 10.01, p < 0.0001). Therefore, spontaneous calcium oscillations are virtually undetectable in TTX 
and the combination of CNQX+AP5. 
 
We next performed simultaneous electrophysiology and calcium imaging to 
determine whether the SCOs corresponded to neuronal activity, and thus determine 
whether SCOs could be used to indicate bursts of activity (Figure 4). Previous studies on 
SCOs have found that they correlate with large depolarizations, which appear to be 
excitatory postsynaptic potentials, and bursts of action potentials - but not single, isolated 
action potentials (Bacci et al., 1999; T. H. Murphy et al., 1992; Przewlocki et al., 1999; 
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Robinson et al., 1993). We similarly found that the SCOs correlated with large 
depolarizations that resembled excitatory postsynaptic potentials. Importantly, we also 
found that these SCOs do not correspond to isolated action potentials, but instead bursts. 
 We found that depolarizing current injections (Figure 4) were capable of causing 
calcium peaks, spontaneous bursts of activity were sometimes greater. Thus, bursts of 
action potentials were correlated with SCOs. 
 
Figure 4. SCOs correspond to bursts of activity. We simultaneously performed electrophysiology and 
recorded calcium indicator fluorescence, in order to correlate the SCOs with bursts of activity. Every 3 
seconds, we applied a 1s suprathreshold current to induce action potentials, to determine whether the bursts 
of activity were causal or correlation. (Red Line) Vm over time, showing action potentials and RMP. (Gray 
line) Applied current over time. (Blue line) Calcium indicator fluorescence. This image indicates that 
calcium peaks are generally produced through spontaneous activity in this neuron. 
 
Taken together, SCOs were dependent on intact spontaneous glutamatergic 
signaling and action potentials, and thus necessarily dependent on excitatory drive and 
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spontaneous neuronal activity. Our observations of the simultaneous electrophysiology 
and pharmacological experiments were consistent with previous experiments of other 
labs; we similarly saw large depolarizations and bursts of action potentials that 
corresponded to synchronized SCOs. These large depolarizations appeared consistent to 
previous descriptions that suggested that they were excitatory postsynaptic potentials. 
Having found that the SCOs in our preparation were correlated with bursts of activity, 
and that they are dependent on spontaneous APs and availability of glutamatergic 
receptors, we next conducted a series of pharmacological experiments to elucidate the 
nature and mechanism of DAMGO’s effects on SCOs. 
2.3.3 First dataset experimental design 
To assay the effects of drugs on the SCOs, we designed an experiment to measure SCOs 
before and after drug combinations to determine how drugs altered SCOs (Figure 5). 
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Figure 5. Timecourse of experiment. We recorded calcium transients during an 80s period before exposure 
to the drug (slot 1) and after exposure to the drug or drug combination (slot 2) to study the effects of these 
drugs on SCOs. To measure the change in the properties of these calcium oscillations, we divided the 
postdrug value by the predrug value to calculate the fold-change in that property due to the drug. 
 
2.3.4 µOR agonism enhances spontaneous Ca2+ oscillations Given our result that SCOs 
correlate with neuronal activity, we next applied DAMGO and measured SCOs before 
and after this drug to find whether µOR-agonism enhanced their SCO amplitude, duration 
(halfwidth), and/or frequency. This finding would support the µOR’s known role in 
exciting cortical circuits and could provide a basis for determining whether the effect of 
DAMGO was disinhibitory or providing direct excitation to cortical cultures. 
We found that DAMGO (3 µM, 80s) induced a significant increase (t(22) = 2.74, 
p = 0.006) in SCO amplitude (M = 1.80, SD = 0.94) when they were compared to 
negative controls (M = 0.93, SD = 0.58). We also found a significant (t(22) = 2.69, p = 
0.007) increase the halfwidths of DAMGO-exposed neurons (M = 1.71, SD = 0.69) when 
compared to saline controls (M = 1.09, SD = 0.42). However, we did not find significant 
changes (U = 43, p = 0.050) in the number of calcium transients in the DAMGO (Mdn = 
1.17) condition versus the control (Mdn = 0.71). In summary, we found that DAMGO 
enhances the duration and magnitude of these calcium oscillations, but not their number. 
Although these findings substantiated the µOR’s known role in enhancing the activity of 
neuronal circuits, it was unclear whether DAMGO was directly activating excitatory 
neurons or inhibiting GABAergic neurons. For instance, our finding that DAMGO 
enhanced the duration (halfwidth) of SCOs could suggest that µORs directly (on 
Pyramidal Neurons) were inducing release of glutamate over a longer period, or it could 
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also suggest that µOR+ inhibitory neurons were slower in being recruited to suppress 
excitatory neurons, which in turns allows the PNs to release glutamate over longer 
periods before being sufficiently inhibited to cease secretion of glutamate. However, in 
the latter (disinhibitory) scenario, GABA antagonists could prevent inhibitory 
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Figure 6. DAMGO enhances calcium oscillation duration and amplitude. We measured the average 
amplitude, halfwidth, and number of calcium transients after incubation with (n = 12) vehicle saline or (3 
µM; n = 12) DAMGO. (Top Row) Amplitude numerical values are taken as a proportion of the tallest peak 
in the predrug recording of the timestack. (First column) Real values of saline controls for a) amplitude, e) 
halfwidth, and i) average number of peaks before and after vehicle saline. (Second column) Real values of 
DAMGO-exposed neurons in (b) amplitude, (f) halfwidth, and (j) average number of peaks before and after 
DAMGO. (e,f) Frames measured in 4 frames/second. To visualize the change in these properties in 
individual neurons, we graphed the fold change from baseline in these same properties. We found 
significant DAMGO-induced increases (p < 0.05) in (c) amplitude and (g) halfwidth of calcium transients 
relative to the change in the saline group. However, we did not find a significant DAMGO-induced change 
(p > 0.05) in (k) number of peaks relative to the saline controls. (d,h,l) Validation for the specific effect of 
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DAMGO by combining it with the µOR-specific antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 
(CTAP) successfully blocked the effect of DAMGO relative to fold changes in saline controls (p > 0.05) 
Table 2. DAMGO enhances amplitude and halfwidth of SCOs. We found that DAMGO enhanced the 
amplitude and halfwidth of SCOs in cultured neurons. However, the number of SCOs occurring within 
imaging frames were not significantly impacted by DAMGO. Statistical testing was performed with 
unpaired t-tests that compared fold changes in the DAMGO group with fold changes in the saline control 
group, after first being tested for normality with D’Agostino-Pearson’s test. Peak Number was significantly 
different from a normal distribution, and therefore tested with a Mann-Whitney U test. 
 
2.3.5 The effect of DAMGO is mediated through both GABA receptors 
Prior investigations by other groups (Drake & Milner, 1999, 2002, 2006; Férézou et al., 
2007; Huo et al., 2005; Madison & Nicoll, 1988; Stumm et al., 2004; Taki et al., 2000; 
Witkowski & Szulczyk, 2006; Zieglgansberger et al., 1979) and our own lab (Dutkiewicz 
& Morielli, 2020) into the mechanism of the µOR have suggested that the µOR acts 
primarily by inhibiting activity of inhibitory interneurons. However, other groups have 
indicated that the µOR is found on excitatory neurons as well (Rola et al., 2008; Schmidt 
et al., 2003; Witkowski & Szulczyk, 2006), including a series of experiments that used 
the SCO model in cultured hippocampal neurons (Przewlocki et al., 1999). Therefore, it 
was unclear whether DAMGO was suppressing inhibitory neurons and enhancing SCOs 
through disinhibition, or whether DAMGO was directly promoting the activity of 
excitatory neurons and enhancing SCOs through a more direct mechanism. 
Our previous study showed that µOR inhibits primary culture neocortical 
interneurons (Dutkiewicz & Morielli, 2020). We therefore predicted that DAMGO 
augmented spontaneous calcium oscillations by through its effects on GABAergic 
   PARAMETER Mean Difference 
(DAMGO-Saline) 
P value 95% Confidence Interval for Difference 
 
Lower        Upper               
Amplitude 0.88 0.006 0.21 1.54 
Halfwidth 0.63 0.007 0.14 1.11 
Number 0.33 0.050 -0.20 0.86 
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interneurons. In this disinhibitory model, we anticipated that blocking GABA receptors 
would prevent DAMGO from exerting its effects on SCOs. In contrast, if DAMGO acts 
by directly enhancing the activity of PNs, GABA receptor inhibitors should fail to 
prevent DAMGO from enhancing the calcium oscillations. 
We tested this first by applying the GABAA antagonist, picrotoxin; if DAMGO 
was inhibiting release of GABA onto GABAA receptors, this drug should mimic 
DAMGO in polarity. Picrotoxin alone (M = 2.31, SD = 1.64) significantly enhanced SCO 
amplitude (t(22) = 2.76, p = 0.006) when compared to the saline controls (M = 0.93, SD = 
0.58). Picrotoxin also significantly enhanced calcium oscillation halfwidth compared to 
the change in control. However, picrotoxin (Mdn = 0.69) did not significantly (U = 62, p 
= 0.295) enhance SCO number compared the change in control (Mdn = 0.71). Therefore, 
the effects of picrotoxin were similar in polarity to the effects of DAMGO and could 
suggest that the µOR downregulated GABAA receptors. To test this, we coapplied 
DAMGO and picrotoxin together to determine whether DAMGO had an additive effect 
(Figure 6). Effects of DAMGO with picrotoxin would suggest that DAMGO’s effects 
were not solely mediated by downregulated GABAA receptors. 
We found that the combination of picrotoxin and DAMGO (M = 1.81, SD = 1.08) 
did not result in a significantly different (t(22) = 0.89, p = 0.192) change in SCO 
amplitude versus picrotoxin alone (M = 2.31, SD = 1.64). However, the combination of 
picrotoxin and DAMGO (M = 4.51, SD = 2.10) did significantly (t(22) = 1.86, p = 0.039) 
enhance SCO halfwidth compared to the fold change in picrotoxin alone (M = 3.10, SD = 
1.61). This result suggested that other factors may be involved than reduced GABA 
97 
 
release onto GABAA receptors, which picrotoxin should have blocked. The combination 
of picrotoxin and DAMGO (M = 0.55, SD = 0.26) did not significantly (t(22) = 0.89, p = 
0.191) change SCO number when compared to picrotoxin alone (M = 0.68, SD = 0.42). 
Therefore, neither the µOR nor GABAA receptors do not to appear to alter the number of 
SCOs (Figure 6k and Figure 7e). 
Picrotoxin with DAMGO failed to completely block the DAMGO effect; this 
could mean that the µOR directly excites PNs, or that the effect of DAMGO is mediated 
through both GABAA and GABAB receptors. We hypothesized that blocking both 
GABAA and GABAB receptors would block the DAMGO effect based on studies by 
other labs that suggest that the µOR is expressed by GABAB-stimulating neurogliaform 
neurons (Lafourcade & Alger, 2008; Olah et al., 2007).  
To determine whether DAMGO was mediating its excitatory effect through 
downregulation of GABAA + GABAB receptors or direct excitation of PNs, we tested 
DAMGO in combination of picrotoxin and the GABAB antagonist CGP55845. We found 
that this combination of GABAA receptor blockade and GABAB receptor blockade 
DAMGO (M = 2.65, SD = 1.04) did not result in significantly different (t(22) = 1.71, p = 
0.51) fold change in halfwidth versus CGP55845 and picrotoxin themselves (M = 2.04, 
SD = 0.65), which indicated that this drug combination could block the DAMGO effect 
where picrotoxin alone did not (Figure 7c,d). This finding was consistent with our 
hypothesis, that DAMGO was mediating its SCO-enhancing effect by suppressing 
interneuronal release of GABA onto both GABAA and GABAB receptors, and not 
GABAA receptors alone. 
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The combination of CGP55845 + picrotoxin + DAMGO (M = 1.76, SD = 0.65) 
also did not result in a significantly different change (t(22) = 1.28, p = 0.106) in SCO 
amplitude versus CGP55845 + picrotoxin (M = 2.25, SD = 1.14; Figure 7b). This was 
consistent with Figure 7a, because picrotoxin (without CGP55845) itself could prevent 
this DAMGO effect that we observed. Unexpectedly, we also found that CGP55845 + 
picrotoxin + DAMGO (M = 0.40, SD = 0.24) resulted in a significantly fewer (t(22) = 
2.03, p = 0.027) SCOs versus CGP55845 and picrotoxin alone (M = 0.82, SD = 0.68).  
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Figure 7. Blockading both GABARs prevents DAMGO-enhancement of SCOs. We tested for the effect of 
DAMGO when GABA receptors were blockaded. (Left column) We co-administered (100 µM) picrotoxin 
with DAMGO. We found that picrotoxin alone produced significant increases in (a) peak amplitude and (c) 
halfwidths of calcium peaks. Co-administering DAMGO with picrotoxin blocked the effect of DAMGO in 
(a) amplitude not in (c) halfwidth. (Right column) We therefore coapplied DAMGO with both picrotoxin 
and the GABAB antagonist CGP55845 and found that this drug combination blocked the DAMGO effect (p 
in both (b) amplitude as well as (d) halfwidth. (e,f) Meanwhile, we found no significant effects in number 
of calcium peaks in either condition. (First and Second column) Lines connect the same neuron’s pre and 
postdrug value for each individual replicate. (Third and Fourth column) Edges of the boxes are drawn at the 
1st and 3rd quartiles while the “whiskers” connect the largest and smallest values for that group. We tested 
the data with D’Agostino-Pearson omnibus K2 test (p > 0.05) to ensure a normal distribution. Figure (d) 
was analyzed with Mann-Whitney U test (one-tailed) due to a nonnormal distribution, while the rest of the 
















Figure 8. Representative calcium peaks for various drug conditions. (Top Row) Before and after DAMGO. 
(Bottom Row) Before and after picrotoxin. Y axes are calcium indicator fluorescence, when the highest-
intensity calcium peak in the pre-drug timestack (not pictured) is set to a value of 1.00, and all other peaks 
are a proportion of the tallest peak. X axes represent imaging frames (4 frames/sec). On the calcium peaks, 
yellow lines denote the base of each recognized peak, green horizontal lines are the measures of halfwidth 
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for the peaks, and the red dot at the tips of the peaks are indicating that the peak has been successfully 
culled for analyses by the Python script.  
 
2.3.6 Interneurons and Pyramidal Neurons 
Our results suggested that interneurons were being downregulated by DAMGO, which 
caused the PNs to become hyperactive in response to reduced activity of GABA 
receptors. If this is true, we might expect activity of interneurons to decrease, as activity 
of excitatory neurons to increase. However, the data described so far did not discriminate 
between inhibitory and excitatory types of neurons, and we could not determine if 
activity of interneurons in this preparation was decreasing despite the net enhancement of 
SCOs. We therefore separately labelled interneurons to determine whether their SCOs 





Figure 9. Cultured neurons transformed with AAV-mDlx-NLS-mRuby2. Brightfield image of cultured rat 
neurons. (Top Right) Fluorescence of mRuby2 in red. (Bottom) Overlay of both images to show the 
neocortical interneurons in the field. Neurons at DIV (40x magnification). 
 
Neocortical interneurons only constitute 10-25% of all neocortical interneurons, 
while excitatory neurons constitute the remaining proportion (Beaulieu, 1993; Jones, 
1993; Meyer et al., 2011; Ren, Aika, Heizmann, & Kosaka, 1992). We therefore expected 
that interneurons in these cultures would comprise a similar proportion. To identify 
interneurons in our model, we exposed the cultured neurons to an AAV that induces 
expression of a red fluorescent protein in interneurons by using the interneuron-specific 
enhancer Dlx5/6. We manually counted neurons in 110 images across 3 independent 
cultures and found that interneurons constituted 432 neurons out of a total of 2428 
neurons (17.8%). We also used a separate approach with a Python script that 
automatically enumerated neurons and found that interneurons constituted 1037 out of 
6461 neurons (16.1). Collectively, these data show that interneurons in our culture system 
comprised the expected 10-25% range (Beaulieu, 1993; Jones, 1993; Meyer et al., 2011; 
Ren et al., 1992). 
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2.3.7 Second dataset experimental design 
In our first dataset, we observed that picrotoxin alone could significantly enhance SCO 
halfwidth and amplitude (Figure 7) and its effect outweighed the effects of DAMGO. 
While this was expected, the magnitude of picrotoxin’s effect in that model made the 
effect of DAMGO difficult to separate from the larger effect of picrotoxin. To address 
this, we instituted a change in the drug exposure protocol by applying picrotoxin for 15-
25 minutes before applying DAMGO (i.e., a “background” of picrotoxin). While this 
drug application procedure did depart from our earlier method, it also conferred the 
benefit of testing these effects in a slightly different way to reinforce their validity.  
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Figure 10. Second dataset experimental design. For our next dataset, we administered a preincubated 
background of (100 µM) GABAA-specific inhibitor picrotoxin or picrotoxin +  the GABAB specific 
inhibitor CGP55845 (10 µM), and then applied (3 µM) DAMGO. This mitigated the more drastic effects of 
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combining DAMGO with the GABAR blockers, in order to further isolate the effect of DAMGO from the 
effects of picrotoxin and CGP55845. 
 
2.3.8 Changes similar in interneurons and excitatory neurons 
Based on our data, we believed that interneurons were specifically being suppressed, 
which allowed excitatory PNs to enhance their activity. We therefore hypothesized that 
interneurons would have diminished SCOs when compared to enhanced SCOs in PNs. To 
determine whether DAMGO was differentially affecting inhibitory versus excitatory 
neurons, we tested for DAMGO effects we previously found in here separately in the 
populations of neurons (Figure 11). 
Post-hoc comparisons using Tukey’s multiple comparisons test revealed that 
significant effects of DAMGO on SCO halfwidth could be found in both interneurons (M 
= 1.98, SD = 0.58) and noninterneurons (M = 1.72, SD = 0.64) relative to inhibitory and 
excitatory controls exposed to vehicle saline (M = 1.09. SD = 0.25; M = 1.20, SD = 0.35). 
Therefore, the effect of DAMGO was not significantly different between excitatory and 
inhibitory neurons. Unexpectedly, the SCOs in interneurons and PNs were similarly 
upregulated, and augmentation of SCO halfwidth could be found in both neuronal types. 
We next investigated whether this DAMGO enhancement of SCO halfwidth was 
again distinguishable in picrotoxin, and absent in the presence of picrotoxin and 
CGP55845. These findings would replicate our conclusion that DAMGO suppressed 
GABA release onto GABAA and GABAB receptor. Consistent with this, administering 
DAMGO in a background of picrotoxin resulted in significantly larger halfwidths in both 
interneurons (M = 1.33, SD = 0.39) and noninterneurons (M = 1.49, SD = 0.41) relative to 
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their no-DAMGO vehicle controls (M = 0.99, SD = 0.16; M = 1.13, SD = 0.14). This 
showed again that the effect of DAMGO was not solely mediated by downregulation of 
GABAA receptors. We therefore tested whether DAMGO-enhancement of SCO 
halfwidth was blocked in a background of picrotoxin and CGP55845. 
The effect of DAMGO was blocked only in the presence of both picrotoxin and 
CGP55845 in both interneurons (M = 1.01, SD = 0.29) and excitatory neurons (M = 1.15, 
SD = 0.27) in comparison to their respective controls (M = 1.25, SD = 0.56; M = 1.28, SD 
= 0.56). 
In summary, found that interneurons and excitatory neuronal SCO durations were 
similarly enhanced in response to DAMGO. However, we also found here that DAMGO 
enhancement of SCO halfwidth was still present in a background of picrotoxin, but not a 
background of picrotoxin + CGP55845. Therefore, we were able to replicate our main 
finding from the first dataset – that DAMGO’s effects were mediated through cortical 
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Figure 11. DAMGO enhancement of SCOs observed in both neuron types. To test whether DAMGO-
induced changes in SCOs were similar in both neuronal types, we tested DAMGO in the presence of 
GABAergic blockade. (Left column) Changes in a background of saline. (Middle column) Changes due to 
DAMGO in a 10-minute preincubation with the GABAA-antagonist picrotoxin. (Right column) Changes 
due to DAMGO after a 10-minute preincubation with picrotoxin and the GABAB-antagonist CGP5845. We 
found DAMGO enhanced (d) SCO halfwidth, and not (g) number of SCOs. Unlike the previous dataset, 
however, there were not significant differences in SCO amplitude in this dataset. (e) In the presence of 
picrotoxin, DAMGO again enhanced SCO halfwidth, and failed to enhance their (b) amplitude and (h) 
number which recapitulated our earlier dataset. In the presence of picrotoxin and CGP55845, DAMGO 
once again failed to change (c) amplitude (g) halfwidth, and (j) number, which also recapitulated our earlier 
findings. All groups include the same number (n = 13) trials. Mean fold changes were tested by comparing 
mean fold changes in properties relative to other cell types and the same cell type in the vehicle condition. 




2.3.9 Effect of DAMGO in picrotoxin similar to GABAB blockade 
Our data had indicated that DAMGO still enhances SCO halfwidth in the presence of 
picrotoxin in both datasets, and that the DAMGO enhancement was found in both 
excitatory and inhibitory neurons. We next investigated whether CGP55845 in a 
background of picrotoxin resemble the effect of DAMGO in the same background, which 
would be consistent with our hypothesis that DAMGO reduces activity at both GABAA 
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Figure 12. Effect of GABAB inhibition. We found that application of the GABAB antagonist CGP55845 in 
a background of picrotoxin resulted in no significant changes in (a) SCO amplitude. However, we found 
significant increases in (b) SCO halfwidth after CGP55845 in both interneurons and excitatory neurons. We 
also found significant reductions in (c) SCO number after CGP55845 in both neuronal types. Mean fold 
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changes were tested by comparing mean fold changes in properties relative to other cell types and the same 
cell type in the vehicle condition. Statistics were analyzed using Sidak’s test for multiple comparisons. 
 
In a background of picrotoxin, CGP55845 produced no significant change in SCO 
amplitude in interneurons (M = 0.57, SD = 0.24) or excitatory neurons (M = 0.82, SD = 
0.23) relative to their vehicle controls (M = 0.50, SD = 0.25; M = 0.81, SD = 0.39). We 
found that addition of CGP55845 produced a significant increase in SCO halfwidth 
relative in both interneurons (M = 1.80, SD = 0.65) and excitatory neurons (M = 1.91, SD 
= 0.81) relative to controls (M = 0.98, SD = 0.17; M = 1.04, SD = 0.14). These effects 
were consistent with our DAMGO findings in a background of picrotoxin (Figure 7c), 
which showed that DAMGO produces an increase in SCO halfwidth.  
We observed a consistent and significant trend towards fewer SCOs upon 
application of CGP55845 (Figure 11c). While SCO number did not generally change 
throughout our previous experiments, the number of SCOs was significantly reduced in 
both interneurons (M = 0.60, SD = 0.28) and excitatory neurons (M = 0.58, SD = 0.21) 
versus their respective controls (M = 0.96, SD = 0.21; M = 0.96, SD = 0.21) under this 
condition.  
Taken together, these results (Figure 11) do show similar effects of DAMGO in a 
background of picrotoxin; enhancement of SCO halfwidth but not amplitude, which is 
further evidence that DAMGO reduces GABA release onto both GABAA and GABAB 




We report here that µOR agonism upregulates spontaneous activity in primary 
neocortical cultures; on average, we observed that DAMGO enhanced SCO duration by 
63% (Table 2). These results therefore strongly suggest that the µOR excites neocortical 
circuits, in part by enhancing durations of bursts of activity being indicated by SCOs. In 
addition, our results also implicate the µOR in a disinhibitory role by suppressing the 
activity of interneurons, as shown by our findings that the µOR’s enhancement of SCO 
can be blocked by coapplication with GABA inhibiters (Figure 7), or in a background of 
GABA inhibitors (Figure 11). Given the ambiguity in the field about whether DAMGO 
provides disinhibition, or direct excitation to PNs, these experiments provide additional 
evidence that the main network effect of µOR stimulation is due to inhibition of 
interneurons. 
We speculate that this enhancement may indicate that cortical interneurons were 
slower in counteracting bursts of action potentials (being indicated by the SCO), which 
allowed pulses of excitatory activity to continue for longer before being suppressed by 
interneurons. This finding could suggest that the µOR may make the cultured networks of 
interneurons less responsive and able to provide feedback inhibition to local excitatory 
neurons. Therefore, these results may suggest that this receptor dysregulates networks of 
interneurons by reducing their ability to respond quickly to bursts of glutamatergic 
activity. 
A previous study by another lab has found that DAMGO enhances SCOs in 
hippocampal cultures, but our findings contract it in 2 major ways (Przewlocki et al., 
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1999). We performed simultaneous GABAA and GABAB receptor blockade to show that 
effects of DAMGO are ameliorated only when both receptors are blocked, and GABAA 
blockade fails to do that. Therefore, our main conclusions that DAMGO disinhibits 
neocortical networks appears to be well-supported in both datasets (Figure 7 and Figure 
11). Our results also departed from those earlier findings in another way – we obtained 
fairly inconsistent results on DAMGO enhancement of SCO amplitude, but instead we 
observed that DAMGO consistently enhanced the duration (halfwidths) of the SCOs.  
Our electrophysiological recordings indicate that SCOs generally are not caused 
by isolated APs, which appear to correspond to no detectable SCO activity (Figure 4). 
Instead SCOs generally correspond to longer-lasting depolarizations that appear to be 
excitatory postsynaptic potentials. Our results therefore are similar to previous reports 
that used simultaneous electrophysiological recordings to show that SCOs correspond to 
excitatory postsynaptic potentials (Bacci et al., 1999; T. H. Murphy et al., 1992; 
Przewlocki et al., 1999). In addition to that, we also found that depolarizing current 
applications are capable of causing calcium peaks, though spontaneous activity could 
trump those induced calcium peaks (Figure 4). This suggests that the causal arrow could 
point both ways; bursts of action potentials can cause SCOs, while our data discussed to 
this point also suggest that EPSPs themselves can induce both bursts of action potentials 
and SCOs that correlate with them. We also observed a possible refractory period (Figure 
4) towards the end of the calcium indicator fluorescence traces, which could suggest that 
CICR phenomena may be involved with the calcium peaks being induced by the current 
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application. In summary, SCOs correspond to bursts of activity, but SCOs can be 
proximally caused by different phenomena.  
We investigated whether this model can be used to show inhibition of 
interneurons and overactivity of PNs upon application of DAMGO. Yet, our results 
showed uniformly that the SCOs were not significantly different between the two types in 
various drug conditions. How do we reconcile this with disinhibition? On one hand, some 
authors show that SCOs are constituted of a voltage-sensitive calcium channel 
component (Bacci et al., 1999; Dravid & Murray, 2004; Inglefield & Shafer, 2000). 
However other authors show that SCOs are mostly a result of glutamatergic input (Cao et 
al., 2015; Dravid & Murray, 2004; Inglefield & Shafer, 2000; T. H. Murphy et al., 1992; 
Nuñez et al., 1996; Przewlocki et al., 1999; Shen et al., 1996). Our own results support 
the latter model – that the SCO is a result of excitatory drive being input into each 
neuron, which would explain why SCOs are similar in interneurons and excitatory 
neurons, because nearby neurons receive the same input. This explanation would further 
suggest that interneurons are unable to provide adequate inhibition despite the increase in 
excitation going into both neuronal types; electrophysiological experiments from 
neocortical interneurons show that DAMGO reduces frequency and duration of action 
potentials elicited by same-magnitude depolarizations from an electrode(Dutkiewicz & 
Morielli, 2020; Férézou et al., 2007). Therefore, these electrophysiological data are 
consistent with the notion that interneurons are downregulated, despite experiencing 
greater glutamatergic input being indicated by the SCOs. Although GABAA receptors are 
the main cortical GABA receptor, our results indicated that the DAMGO-enhancement of 
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duration calcium oscillations was successfully blocked only by combined GABAA and 
GABAB receptor inhibitors and failed to be blocked by only GABAA blockade in both of 
our datasets (Figure 7 and Figure 11). While cortical GABAA receptors are plentiful, 
GABAB receptors are confined to synaptic and extrasynaptic spaces in neurons that are 
most strongly activated by neurogliaform neurons (Olah et al., 2007; Tamás et al., 2003). 
These neurogliaform neurons are shown to express high rates of the µOR in the cortex 
(Férézou et al., 2007) and hippocampus (Krook-Magnuson et al., 2011). Therefore, our 
data that µOR+ neurons release GABA onto GABAA and GABAB receptors are 
consistent with previous experiments by other labs (Olah et al., 2007; Tamás et al., 2003) 
and consistent with studies that suggest that neurogliaform neurons are µOR+ (Férézou et 
al., 2007; Krook-Magnuson et al., 2011). These experiments suggest that this 
phenomenon can be reproduced in the SCO model. 
We found that picrotoxin blocked the DAMGO-enhancement of calcium 
oscillation amplitude, even though the DAMGO effect of picrotoxin on duration 
(halfwidth) persisted. One possible reason is that picrotoxin had so profoundly amplified 
the intensity of calcium oscillations, that DAMGO did little to add to the height of the 
calcium peaks. This may happen, for instance, if the picrotoxin condition fully recruited 
the NMDA receptors by sufficiently releasing glutamatergic neurons from enough 
inhibition to promote glutamate release, which itself may in turn further activate other 
glutamatergic neurons. Previous experiments by other labs have related SCO amplitude 
to the activity of NMDA receptors, which is expected to promote greater Ca2+ entry 
during postsynaptic potentials (Bacci et al., 1999; Inglefield & Shafer, 2000; T. H. 
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Murphy et al., 1992; Nuñez et al., 1996; Przewlocki et al., 1999; Shen et al., 1996). This 
can potentially pose a limitation to this study, because any potential positive regulation of 
NMDA receptors may be overlooked by the overwhelming enhancing effect of picrotoxin 
on SCO amplitude (Figure 7a), though this does not appear to mask the effect of 
DAMGO on SCO halfwidth (Figure 7c and 11e). 
There were several effects that we found in our first data set (Figure 6 and Figure 
7) but were not found when a similar experiment was repeated in the second dataset 
(Figure 11). Firstly, we initially found an effect on SCO amplitude due to DAMGO 
(Figure 6c), however this effect was not present in the second data set (Figure 11a). 
DAMGO’s effect on SCO amplitude appeared to be weaker and less frequent than its 
effect on SCO halfwidth, which may have led to the inconsistent results. Secondly, we 
initially found a statistically significant reduction in SCO number in the first dataset 
(Figure 7f). We initially believed that DAMGO’s effect under the combination may be 
limited to cortical interneurons and suppressed SCO number in interneurons, however the 
effect was not found in interneurons (nor in noninterneurons) in the second dataset 
(Figure 11i). Therefore, it seems more likely that this was a statistical anomaly. While the 
failure to replicate these findings present a more complicated picture of DAMGO’s 
effects, the repetition of these experiments at least may provide more validity and insight 
for follow-up studies. For example, the effect of DAMGO on SCO amplitude may be less 
consistent. However, both datasets show clearly that DAMGO shows a picrotoxin-
resistant enhancement of SCO duration (Figure 7c and Figure 11e), and that all effects of 
DAMGO are blocked by coapplication (Figure 7d) or preincubation (Figure 11f) with a 
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combination of picrotoxin and CGP55845. Therefore, our conclusions that DAMGO 
promotes excitation secondary to inhibition of interneurons appears to be well-supported 
by our data, and by data from other labs in different models that suggests µORs localize 
to GABAergic interneurons (Drake & Milner, 1999, 2002, 2006; Férézou et al., 2007; 
Huo et al., 2005; Madison & Nicoll, 1988; Stumm et al., 2004; Taki et al., 2000; 
Witkowski & Szulczyk, 2006; Zieglgansberger et al., 1979). 
One lingering issue is the neurophysiological mediators of SCO amplitude and 
duration (halfwidth). Previous experiments on SCOs, which generally use low ACSF 
[Mg2+], have consistently linked SCO amplitude with activity of various postsynaptic 
glutamate receptors (Bacci et al., 1999; Nuñez et al., 1996; Przewlocki et al., 1999; Shen 
et al., 1996). SCO duration (halfwidth, in our experiment) has only occasionally been 
quantitatively analyzed but, it too, may be modulated by NMDAR activation because 
[Mg2+] manipulations can modify it (T. H. Murphy et al., 1992). Our data show that 
GABAB receptors modulate SCO duration, though the mechanism requires some 
speculation. One conceivable explanation is that the prolonged glutamatergic stimulation 
indicated by the SCO activates cortical interneurons which provide an immediate GABA 
release. However, the background of picrotoxin prevented GABAA receptors prevented a 
quick counterbalance, and the eventual termination of the SCO was brought about 
through the slower action of GABAB receptors. This explanation is corroborated by our 
data that show that DAMGO or CGP55845 in a background of picrotoxin both 
significantly enhance the SCO halfwidths (Figure 11 and Figure 12), and support our 
main conclusion that DAMGO is downregulating GABA release onto both GABAA and 
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GABAB receptors, which is consistent with their known role in suppressing the GABAB-
stimulating neurogliaform neurons of the neocortex (Craig & McBain, 2014; Olah et al., 
2007; C. J. Price et al., 2008). 
The downstream physiological origin of these Ca2+ oscillations is presently 
unknown, and the various mechanisms proposed to contribute to the calcium transients 
may be responsible for this uncertainty. Calcium transients have previously been linked 
the development and gene expression in neurons (Dolmetsch et al., 1998; Spitzer et al., 
1995). They are also believed to confer a neuroprotective role against trauma (Geddes-
Klein et al., 2006). 
 
CHAPTER 3: µ OPIOID RECEPTORS MODULATE ACTION POTENTIAL 
KINETICS AND FIRING FREQUENCY IN NEOCORTICAL INTERNEURONS 
 
3.1 Introduction 
The endogenous opioid system of the cerebral cortex mediates antinociception and 
reward valuation (Choi et al., 2016; Ong et al., 2019; Qiu et al., 2009; Zubieta et al., 
2001). Dysregulation of this system is believed to contribute to pathological and 
compulsive behaviors such as eating disorders, pathological gambling, and drug-seeking 
(Ashok et al., 2019; B. Bencherif et al., 2005; Giuliano & Cottone, 2015; Joutsa et al., 
2018; Mick et al., 2016; Mitchell et al., 2012; Qu et al., 2015; Zubieta et al., 1996). 
Experimentally, impulsive behaviors and binge-eating can be induced through infusion of 
the µ opioid receptor (µOR) specific agonist [D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin 
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(DAMGO) into the frontal cortex of animal models (Mena et al., 2011; Selleck et al., 
2015). Blockade of µORs with naltrexone inhibits compulsive behaviors (Bartus et al., 
2003; Blasio et al., 2014). These aberrancies are believed to result from the disruption of 
activity within cortical networks by µORs (Haider et al., 2006; M. Whittington et al., 
1998; Y. Zhang et al., 2019). More specifically, µORs appear to dysregulate cortical 
networks by suppressing GABAergic activity and thereby altering the balance of 
excitation and inhibition in the cortex (David A. Lewis et al., 2012; Shi et al., 2020; Volk 
et al., 2012). The µOR is believed to suppress GABAergic signaling through its 
expression primarily on cortical interneurons. This leads to overactivity of the targets of 
their inhibition, the glutamatergic Pyramidal Neurons (PNs) (Drake & Milner, 1999, 
2002, 2006; Férézou et al., 2007; Huo et al., 2005; Madison & Nicoll, 1988; Stumm et 
al., 2004; Taki et al., 2000; Witkowski & Szulczyk, 2006; Zieglgansberger et al., 1979). 
However, some research suggests that µOR may activate PNs directly as well (Rola et al., 
2008; Schmidt et al., 2003; Witkowski & Szulczyk, 2006). Immunohistochemical 
experiments have found high rates of expression of µOR in interneurons that express 
vasoactive-intestinal peptide (VIP+) (Taki et al., 2000). Electrophysiological and sc-PCR 
data in neocortical neurons have supported this finding (Férézou et al., 2007) and have 
also implicated neurogliaform neurons as expressing this receptor (Férézou et al., 2007; 
Lafourcade & Alger, 2008; McQuiston, 2008). Evidence for µOR expression in somata 
of parvalbumin-positive (PV+) interneurons of the hippocampal formation is fairly clear 
(Bartos & Elgueta, 2012; S. B. Bausch et al., 1995; Drake & Milner, 1999, 2002, 2006; 
Stumm et al., 2004; Torres-Reveron et al., 2009), however perisomatic expression of this 
receptor in neocortical PV+ neurons has been investigated but, to our knowledge, has not 
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been reported (Férézou et al., 2007; Taki et al., 2000), though recent evidence shows that 
µORs are sometimes found in PV+ axon terminals of the frontal cortex (C. Jiang et al., 
2019; Lau et al., 2020) and insular cortex (Yokota et al., 2016). Therefore, neocortical 
VIPergic, neurogliaform, and some PV+ interneurons are generally believed to express 
µORs – though not necessarily in their somata. 
In addition to the uncertainty surrounding the µOR’s localization, there is also 
some mystery surrounding its mechanism by which µORs affect interneuron activity. The 
µOR is a G-protein coupled receptor and has been shown to activate potassium-
conducting inwardly rectifying K (GIRK) channels (Henry et al., 1995; Ikeda et al., 2000; 
Loose & Kelly, 1990; Marker, Lujan, Loh, & Wickman, 2005). Regulation of GIRK 
channels and hyperpolarization are characteristic features of various ORs (Ikeda et al., 
2003). Agonist-induced hyperpolarization has been found in cortical µOR+ neurons 
(Férézou et al., 2007; Glickfeld et al., 2008; Madison & Nicoll, 1988; E. Tanaka & North, 
1994) non-cortical µOR+ neurons (Grudt & Williams, 1993; Harris & Williams, 1991; 
Johnson & North, 1992; Kelly, Loose, & Ronnekleiv, 1990; Lagrange, Ronnekleiv, & 
Kelly, 1994; Lagrange, Rønnekleiv, & Kelly, 1995; Loose & Kelly, 1990; R. A. North, 
Williams, Surprenant, & Christie, 1987; Sugita & North, 1993), and is also a feature of 
other opioid receptors as well (B Chieng & Christie, 1994; Chiou & Huang, 1999; Grudt 
& Williams, 1993; Johnson & North, 1992; Loose & Kelly, 1990; Loose, Ronnekleiv, & 
Kelly, 1990; Madison & Nicoll, 1988; R. A. North et al., 1987; Sugita & North, 1993). 
However, hyperpolarization does not always occur in response to DAMGO (Faber & 
Sah, 2004; Wimpey & Chavkin, 1991), possibly due to an incomplete overlap between 
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GIRK channel expression and µORs, which may be the case in the cortex (S. B. Bausch 
et al., 1995). Additionally, reductions in spontaneous APs with µOR-agonism is also 
found in various parts of the brain, though not all µOR+ neurons fire spontaneously 
(Loose & Kelly, 1990; Mitrovic & Celeste Napier, 1998; Ponterio et al., 2013). 
Hyperpolarization and decreased spontaneous activity are both commonly found in 
response to the activation of µOR and other opioid receptors, and the two effects often 
coincide (Chiou & Huang, 1999; Elghaba & Bracci, 2017; Kelly et al., 1990; Loose & 
Kelly, 1990; R. A. North et al., 1987). While it is possible that hyperpolarization could 
induce a decrease in spontaneous APs by increasing the distance to Vm threshold for 
action potentials, some studies in cortical neurons have found reductions in spontaneous 
APs with only small accompanying hyperpolarization (Krook-Magnuson et al., 2011; M. 
E. Sheffield et al., 2013; M. E. J. Sheffield et al., 2011; Norimitsu Suzuki et al., 2014). 
Therefore, the µOR may induce hyperpolarization of varying magnitude along with 
reductions in tonic APs, and one effect could occur independently of the other.  
In addition to hyperpolarization and reductions in spontaneous APs, research from 
other parts of the brain suggests that µORs modulate αDendrotoxin-sensitive channels; 
αDTX inhibits Kv1.1, Kv1.2, and Kv1.6 channels (Ponterio et al., 2013). Experiments 
have found that µORs modulates αDTX-sensitive channels in the basolateral amygdala 
(Finnegan et al., 2006), periaqueductal gray (Vaughan et al., 1997), as well as 
thalamocortical terminals within the frontal cortex (Lambe & Aghajanian, 2001). 
Although these channels are known to be expressed by several families of neocortical 
interneurons (Casale, Foust, Bal, & McCormick, 2015; Goldberg et al., 2008; Golding et 
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al., 1999; T. Li et al., 2014; Porter et al., 1998), they have not been directly investigated 
for mediating the µOR’s inhibitory effect in the neocortical interneurons. We therefore 
predicted that µORs activate αDTX-sensitive channels to inhibit neocortical interneurons. 
Several studies have investigated the role of the αDTX-sensitive channels by 
analyzing its effects on action potentials. While Kv1.1, Kv1.2, and Kv1.6 channels have 
been shown to modulate spike frequency and AP threshold, (Bekkers & Delaney, 2001; 
Faber & Sah, 2004; Finnegan et al., 2006), and some studies have suggested that they 
contribute to AP shape as well. Specifically, researchers have found that αDTX-sensitive 
channels hasten repolarizations and shorten durations of APs (Geiger & Jonas, 2000; 
Pathak, Guan, & Foehring, 2016), including in neocortical interneurons (Casale et al., 
2015). We therefore predicted that part of the mechanisms by which the µOR act in 
neocortical interneurons is through one or a combination of these αDTX channel-
mediated electrophysiological effects. To investigate this, we cultured neocortical 
neurons and performed patch-clamp electrophysiology on interneurons in current-clamp 
mode to stimulate and measure their APs. To measure the kinetics of APs, we created 
Python scripts to measure 54 membrane properties, AP kinetic properties, and ratios. We 
were primarily interested in 7 properties that have previously been implicated in 
mediating DAMGO or αDTX effects in neurons. We predicted that DAMGO and αDTX 
would modulate (in opposite polarity) resting membrane potential, AP threshold, number 
of evoked APs, interspike interval, AP halfwidth, maximum repolarization rates, 
amplitude of afterhyperpolarizations.  
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3.2 Materials and methods 
All procedures were authorized by the Institutional Animal Care and Use Committee 
(IACUC) at University of Vermont. We dissected CD® IGS Sprague-Dawley (Charles 
River) pregnant rat dams to harvest neocortical neurons from the frontal cortices of E21 
rat embryos. Brain cortices were rinsed in Hibernate A (Gibco, Grand Island, NY), 
dissociated with papain (Worthington, Columbus, OH) and mechanically separated 
through gentle trituration with a pipette. Dissociated cortical neurons were and cultured 
on round 12mm glass, PEI-coated (Sigma-Aldrich, St. Louis, MO) coverslips at an 
approximate density of 3x104 cells/cm2. We maintained the neurons in Neurobasal A, 
B27, Penicillin-Streptomycin and Glutamax (All from Gibco), in a humidified 37° C 
incubator with 5% CO2. Cultures were transformed on day in vitro 1 with an AAV-mDlx-
NLS-mRuby2 to induce expression of a red fluorescent protein in cortical interneurons. 
Culture media was half-replaced every 3 days. Experiments commenced between day in 
vitro 16-37. AAV-mDlx-NLS-mRuby2 was a gift from Viviana Gradinaru (Addgene 
viral prep # 99130-AAV1); http://n2t.net/addgene:99130; RRID:Addgene_99130).  
3.2.2 Whole-Cell Recordings 
Cultured neurons were transferred from their growth media into a chamber perfused with 
ACSF (in mM: NaCl, 126; KCl, 5; NaH2PO4, 1.25; CaCl2, 2; MgCl2, 1; NaHCO3, 26; 
Glucose, 20; and pyruvate,5 (Férézou et al., 2007). The ACSF was warmed to 30oC and 
constantly bubbled with a mixture of 95% Oxygen and 5% CO2. When indicated, both 
CNQX (20 µM; Sigma-Aldrich) and dAP5 (50 µM; Sigma-Aldrich) were included in the 
ACSF, which was then constantly perfused through the recording chamber. Saline 
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controls were done alternately with drug condition recordings throughout the course of 
the experiments. α-Dendrotoxin (αDTX) was purchased from Alomone Labs (Jerusalem, 
Israel). 
Patch pipettes with resistances of 5-10MΩ were fabricated from borosilicate glass 
capillaries and filled with intracellular saline containing (in mM) K-gluconate, 144; 
MgCl2, 3; ethyleneglycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, 0.5; 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, 10 (Férézou et al., 2007). The pH was 
adjusted to 7.2 with potassium hydroxide and confirmed for an osmolarity of 285/295 
mosm. Whole-cell recordings were made with an Axopatch 200B (Axon Instruments) 
amplifier and Clampex 9.2.1.9 (Molecular Devices) software. Signals were sampled at 
10kHz with a Digidata 1322a (Axon Instruments) DA converter. Passive membrane and 
AP kinetics measurements were automated using a custom Python program 
(cc_analysis.py) the source code for which is available at 
https://github.com/moriellilab/cc_analysis_46. 
All 7 measures that we investigated in the hypotheses were manually tested-
against script generated values. In all 7 cases, they significantly and positively correlated 
to values determined manually with the threshold peak-detector of Clampfit 10.7 
(Molecular Devices). All analyses used measurements generated by the cc_analysis 
program, with the exception of spiking pattern, which was always determined manually. 
Measure Correlation 
RMP r(7) =0.998, p < 0.001  
AP Threshold r(7) = 0.982, p < 0.001 
Number of APs r(7) = 1.000, p < 0.001 
ISI r(7) = 0.999, p < 0.001 
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Halfwidth r(7) = 0.963, p < 0.001 
Maximum AP Repolarization Rate r(7) = 0.998, p < 0.001 
AHP Amplitude r(7) = 0.921, p < 0.001 
Table 3. Manual measurements positively correlate with script-derived values. We validated the script-
derived values by randomly selecting 3 recordings for validation by using all 3 of their timeslots. 
Therefore, an N = 9 files were analyzed in the script and with manual measurements using Clampfit 10.7. 
In all 7 measurements, values derived with the script were significantly and positively correlated with 
manual measurements. Values compared with a bivariate correlation and tested for significance (two-tailed; 
α = 0.05).  
 
3.2.3 Current-clamp protocol 
We selected neurons for recording that were fluorescent (red), reflecting their exposure to 
AAV-mDlx-NLS-mRuby2 during culturing. We adjusted membrane potentials for a 
junction potential of -11mV. Only neurons with a healthy appearance were selected for 
recording. We generally used neurons that were more hyperpolarized than -45mV for 
recording, though primarily the inclusion criterion was primarily the ability to fire APs 
from their natural RMP after the application of a depolarizing current. 
A diagram of the experiment is illustrated on Figure 15. Upon acquiring a whole-
cell configuration, we recorded for 3 minutes to ensure that the RMP was stable and more 
hyperpolarized than -45mV, and that the neuron was capable of firing APs with a 
depolarizing current from its RMP. The 20 current steps (1s duration) we used to elicit 
APs were adjusted for each recording during this waiting period, because neurons had 
slightly different RMPs, thresholds, and resistances that required modulating the current 
magnitude. Once calibrated for the neuron, we kept that setting constant for all 3 drug 
conditions for all timeslots for that neuron. We subsequently made the pre-drug 
recording, and then we applied these drugs through bath perfusion for 80s to ensure the 
concentration and response was stable. We then made the “post-DAMGO” (slot 2) 
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recording after these 80s of incubation, then applied the next drug buffer for 80s (a 
combination of DAMGO and αDTX), and then made the post-αDTX+DAMGO 
recording (slot 3). Neurons were passively recorded from between timeslots for Vm 
changes, but these data were not considered in the analyses. Coverslips were discarded 
and replaced after a single use.  
We quantified spontaneous APs by counting APs that occurred outside of the 1s 
current pulse. This comprised a noncontiguous period totaling 60 seconds in each 
timeslot. Spontaneous APs were not analyzed beyond counting them because most 
DAMGO-responders stopped firing spontaneous APs after DAMGO. 
3.2.4 Measurements of AP and membrane properties 
APs were evoked with a 1s current pulse of varying amplitude. These pulses occurred 3s 
apart. Resting membrane potential (RMP) was determined from the median Vm measured 
during a 330 ms period immediately before the 1s current pulse. when the 1s current 
pulse was not being applied. This was composed of a noncontiguous period surrounding 
the current pulse, totaling 6.6s. 
AP Threshold was determined from steady-state Vm at the first current 
application that induces an action potential. Mean interspike intervals were likewise 
derived from measuring the mean value for the space between spikes. Number of evoked 
APs was measured by averaging the number of APs also during episodes 15-18. The 




AP kinetic values (halfwidth and maximum repolarization rates) were also 
derived from episodes 15-18 of the 20 current steps. We averaged the values for APs 3-5 
on each of the 4 current steps, and then averaged across the current steps to derive the 
final value. The halfwidth was determined as the width (in ms) of each AP at half the 
height of the AP.  
 
Figure 13. Sample AP diagram. AP kinetics were measured by the script and an example is shown here to 
illustrate the derivation of the measurements (Upward-facing blue arrow) Start of the AP demarcated at 
10% of the maximum depolarization rate. Vm at this point represents AP threshold. (First Green Circle) 
Maximum rate of depolarization of the AP. (Second Green Circle) Maximum rate of repolarization of the 
AP. (Downward-facing blue arrow) 10% of maximum rate of repolarization, marking the end of the AP. 
(Yellow Diamond) Lowest point of the afterhyperpolarization. Afterhyperpolarizations were measured as 
the difference between the y value of the start of the AP with the lowest point of the afterhyperpolarization, 
out to a maximum distance of 2ms from the point where the repolarization phase returns to the same Vm as 
the start of the AP at the upward blue arrow. (Pink Horizontal Line) The halfwidth of the AP was measured 
at half the height of the AP from the threshold Vm of the AP at the upward blue arrow.  
 
3.2.5 Data Display 
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The cc_analysis.py analysis program produced a Microsoft Excel spreadsheet with all 
measurements. To render the spreadsheet compatible with SPSS, we sorted the rows of 
recordings by filename and added in a row of column labels. SPSS syntax is compatible 
with the master spreadsheet included here. Additional columns were added to the excel 
spreadsheet that divided the post-DAMGO (or post-saline) scores by their initial (pre-
drug) condition for each particular measure, which were ultimately graphed on box-and-
whisker plots throughout this text. Every change in the post-DAMGO condition was 
some factor of 1 (initial) to show the fold change. Thus, the changes from baseline were 
determined for the DAMGO recordings and saline controls. While we had either 11 (H-
responders) and 10 (S-responders), we randomly selected a group of comparable size to 
compare changes in the drug condition with entropic changes in the saline controls to 
identify the drug effect. In the box-and-whisker plots where a subset of 10 or 11 saline 
controls were required, we used Excel’s built-in random number generator function was 
used to sort the saline recordings for comparison groups.  
3.2.6 Statistics 
Sample sizes were initially chosen under the expectation that only 5-20% of neurons 
would show a hyperpolarizing effect with DAMGO. We estimated that around 55 
DAMGO recordings should enable us to record from ~10 DAMGO responders. We also 
recorded from 21 saline controls to enable us to compare the changes in DAMGO-
exposed neurons to negative controls; groups are not of matching sizes because we 
expected that the whole DAMGO group would not be compared to the saline controls 
since responders would only compose some of the DAMGO-exposed neurons. 
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Since we were examining for DAMGO or αDTX effects in 7 variables at a time, 
we first tested the combined variables in mixed-model repeated measures MANOVA 
tests first to mitigate the high (30.1%) family-wise error rate to an α = 0.05. If the 
omnibus test failed to produce significant results, we did not test each of the 7 variables 
individually (main hypotheses). However, we made exceptions for data in the post-hoc 
analyses of Table 12, since posthoc tests come with some assumptions of false positives. 
All mixed-model repeated measures MANOVAs were conducted through IBM 
SPSS 27.0.0.0. We defined the independent variable as the timeslot (within-subject 
variable), and the between-subjects factor as the drug group (either saline or the DAMGO 
sequence). For these tests, we compared the 11 DAMGO H-responders (or 10 S-
Responders) against all 21 saline-controls. For DAMGO effects we tested timeslot 1 and 
2 data. For αDTX effects, we analyzed timeslot 2 and 3 data. We only reported 
Slot*Group interaction effects; the effect of Slot (time) most likely reflected entropic 
decay of the neurons over the course of the recording, while the effect of Group likely 
reflected stochastic differences of the neurons between the 2 groups of neurons – neither 
of which were a topic of these analyses. Therefore, in our experimental design, only the 
Slot*Group interaction was relevant to whether DAMGO or αDTX effects were present. 
In instances where the Slot*Group interaction was significant, we followed up by 
individually testing each of the 7 measures.  
Post-hoc analyses (Table 12) were executed similarly with mixed repeated 
measures MANOVAs by testing sets of related variables to provide organizational and 
analytical grouping. APs analyzed in these tests were also measured in episodes 15-18, 
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but first, second, and average (of APs 3-5) were analyzed separately. For instance, the 
first APs in episodes 15-18 were averaged across the episodes and analyzed separately 
from the other (second and later) APs in that episode. We excluded the 7 variables 
previously discussed in the main hypotheses to limit the posthoc analyses to data that 
were not previously analyzed. Results of their individual omnibus tests are noted in the 
figure legend for thoroughness, but we provided posthoc analytical data for individual 
with-subject contrasts regardless of whether their omnibus test was significant. 
Statistical testing portrayed on the box-and-whisker plots and summary tables 
were conducted through in GraphPad Prism version 8.4.3 for Windows, GraphPad 
Software, San Diego CA, USA www.graphpad.com. Statistical testing on fold changes 
proceeded by first testing for skewness and kurtosis using D’Agostino-Pearson omnibus 
K2 test in GraphPad Prism. When the statistic was not significantly different from normal 
(p > 0.05), we conducted an unpaired t-test (one-tailed) to compare the fold changes in 
the DAMGO group with the saline group. When the distribution of either group was 
nonnormal (p < 0.05) we instead did the comparison with a one-tailed Mann-Whitney U-
test. 
3.3 Results 
3.3.1 Identifying responders 
Cortical µOR is expressed only in certain subcategories of interneurons; some studies 
have estimated that only around 3-5% of all neocortical neurons, or 15-25% of 
GABAergic interneurons, express µORs (Férézou et al., 2007; M. C. Lee et al., 2002; 
Taki et al., 2000), though some have reported as many as 2/3rds of prefrontal GABAergic 
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neurons respond to µOR-agonism (Witkowski & Szulczyk, 2006). To identify and target 
GABAergic interneurons in culture, we transformed neurons with an AAV (see Methods) 
that drove expression of the red fluorescent protein mRuby2 under the interneuron-
specific Dlx5/6 enhancer (Batista-Brito et al., 2008; de Lombares et al., 2019; Fazzari et 
al., 2010).  
  
 
Figure 14. Cultured neurons with AAV-mDlx-NLS-mRuby2. (Top Left) Brightfield image of cultured rat 
neurons. (Top Right) Fluorescence of mRuby2 in red. (Bottom) Overlay of both images to show the 
neocortical interneurons in the field. Neurons at DIV 19 at 40x magnification. 
 
Neocortical interneurons generally only constitute between 10-25% of all 
neocortical neurons (with the balance being glutamatergic Pyramidal Neurons), 
depending on the model and methods used to measure the proportions (Beaulieu, 1993; 
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Jones, 1993; Meyer et al., 2011; Ren et al., 1992). To determine whether proportions of 
interneurons occurring in the culture model used here fell within this range, we manually 
counted the number of red and nonred neurons across 110 images in 3 independent 
cultures. We found that red neurons constituted 432 out of 2428 neurons (17.8%). In a 
second approach, we utilized a Python script that automatically counted the neurons. This 
automated approach gave similar results, with red neurons constituting 1037 out of 6461 
neurons (16.1%). With either counting method, our estimations of the proportions of 
interneurons to non-interneurons in these dissociated neuronal cultures are typical for 
previous reports of intact or sliced animal neocortex. 










































































































  Due to DAMGO
(or time)
  Due to DTX
(or time)
Continuous Application of DAMGO
Continuous Application of DTX+DAMGO
 
Figure 15. Time course for patch-clamp recordings. Upon achieving whole-cell configuration, we 
calibrated the amplitude of the current injections to that particular neuron (to factor in its RMP and input 
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resistance) during the waiting and calibration period. (20 µM) CNQX and (50 µM) D-AP5 were constantly 
perfused to block glutamatergic receptors. We performed the “Initial” (slot 1) recording after this period 
and applied (3 µM) DAMGO for 80s of incubation and perfusion. We then performed the “post-DAMGO” 
recording (slot 2) and applied (100 nM) αDTX+DAMGO for another 80s of incubation. After that, we 
finally collected the “post-αDTX+DAMGO” (slot 3) recording. To evaluate for DAMGO effects, we 
compared slot 2 with slot 1. To look for αDTX effects in background of DAMGO, we examined the change 
between slot 3 and slot 2. We also collected recordings from neurons under a saline-control condition to 
account for the effects of time in the drug group. We recorded from these neurons in an identical fashion 
(the timeline is the same), but the saline-control neurons only received vehicle buffer, and not DAMGO or 
αDTX. 
  Within-Subjects Factor (Slot) 




Saline (N = 21) Saline Saline Saline 
Drug Sequence (N = 
55) 
Saline DAMGO αDTX+DAMGO 
Table 4. Control and drug groups for electrophysiology. We included 2 groups in the experimental design; 
a saline-only control and the experimental group that received the sequence of drugs. In both cases, slot 1 
recordings are always pre-drug conditions. Slot 2 is synonymously referred to as “post-DAMGO” or as 
“pre-αDTX” depending on whether we are testing for the effects of (3 µM) DAMGO or (100 nM) αDTX in 
that particular analysis; the αDTX was always delivered in a background of DAMGO. To detect drug 
effects, we analyzed the changes between 2 timeslots in the drug group and compared it to the changes in 
the saline group: slot 1 versus slot 2 for DAMGO effects, and slot 2 versus slot 3 for (100 nM) αDTX 
effects.  
 
 Overall, the DAMGO-exposed neurons (N = 55, M = 1.03, SD = 0.05) were 
significantly more (t(74) = 3.14, p = 0.001) hyperpolarized than saline controls (N = 21, 
M = 0.99, SD = 0.99), which tended to slightly depolarize. However, the µOR is only 
expressed by a subset of cortical interneurons, and therefore was expected to be 
represented in only some of the red-fluorescent Dlx5/6-mRuby2 neurons that we 
recorded from. We anticipated that most neocortical interneurons would be unresponsive 
to DAMGO. Combining data from all interneurons would thus obscure the effects of 
DAMGO (3 µM) and αDTX (100 nM) in neurons that did express had µORs. We 
therefore screened interneurons for responsiveness to DAMGO prior to subsequent 
analyses. Hyperpolarization is a common response to DAMGO in neurons expressing 
opioid receptors (B Chieng & Christie, 1994; Chiou & Huang, 1999; Grudt & Williams, 
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1993; Johnson & North, 1992; Loose & Kelly, 1990; Loose et al., 1990; Madison & 
Nicoll, 1988; R. A. North et al., 1987; Sugita & North, 1993), and in particular those 
expressing µORs (Férézou et al., 2007; Glickfeld et al., 2008; Harris & Williams, 1991; 
Kelly et al., 1990; Lagrange et al., 1994; Lagrange et al., 1995; Madison & Nicoll, 1988; 
E. Tanaka & North, 1994). We therefore first identified responders by detecting a 
hyperpolarizing change in resting membrane potential (RMP) after exposure to DAMGO 
(Figure 16). By comparing the DAMGO-exposed group’s changes in RMP to the changes 
in saline controls, we established a cutoff level to separate neurons most affected by 
DAMGO. We refer to the DAMGO-exposed neurons above this cutoff as 
“hyperpolarizing responders” (H-responders, N = 11). These H-responders 
hyperpolarized significantly (t(20) = 7.61, p < 0.001) when they (N =11, M = 1.10, SD = 
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Figure 16. H-responders hyperpolarize. The efforts to identify DAMGO-responders and measure the 
change of RMP in the H-responders began by graphing resting membrane potential (RMP) after the 80s 
period of incubation with either (3 µM) DAMGO or vehicle saline (a) We plotted the RMP each saline-
control neuron (N = 21) individually and (b) each DAMGO-exposed neuron (N = 55) individually. 
However, these graphs were ineffective in identifying the neurons that hyperpolarized the most under the 
DAMGO condition. To isolate the change (hyperpolarization), we graphed the fold change in RMP instead 
of the raw value (c) We plotted the change in RMP (defined as slot 2 RMP/ slot 1 RMP) in saline and 
DAMGO controls and found a significant hyperpolarization in the DAMGO group compared to the saline 
group (p < 0.05). To identify true DAMGO responders, we established a cutoff at the most hyperpolarized 
saline control (vertical dotted line). DAMGO hyperpolarizers (to the right of the cutoff) are hereafter called 
“H-responders” (N = 11). (d) We extracted these H-responders and a comparison group of random saline 
controls (n = 11) onto a new plot. This represents the change in RMP among the H-responders, which was 
significantly (p < 0.05) more hyperpolarized than the random controls. (e) Subset of random saline controls 
for comparison (n = 11) showing little general trend towards depolarization or hyperpolarization during the 
slot1 to slot 2 period. (f) A plot of the H-responders (N = 11) RMP in their actual values showing a trend 
towards hyperpolarization. (g) The RMP of the nonresponders (N = 34) during the same period. (a,b,e,f,g) 
Dots are values for interneurons and lines connect the same neurons before and after saline or the DAMGO 
(c,d) Edges of box are 1st and 3rd quartiles for values, dots are the change in RMP for the individual 
neurons, and whiskers extend to the largest and smallest values. Statistical testing performed with unpaired 
t tests (one-tailed) after confirming their data had a normal distribution with a D’Agostino-Pearson 
omnibus K2 test (p > 0.05). 
 
During the recording process, we observed that only 3 of the H-responders were 
firing spontaneously at rest and, not surprisingly, their rate of spontaneous APs decreased 
after DAMGO. However, we observed that a sub-population of interneurons in which 
DAMGO failed to produce an above cut-off level of hyperpolarization nevertheless 
underwent reductions in spontaneous APs after DAMGO. We found that 50.0% (22 out 
of 44) of neurons that fell below the H-responder cut-off level exhibited spontaneous AP 
activity before DAMGO (Figure 17). Application of DAMGO resulted in a dramatic 
reduction in the number of spontaneous APs in 45.5% (10 out of 22) of those neurons. 
We define this group of spontaneous AP DAMGO-responders (S-responders) by using an 
arbitrary cutoff of a 50% reduction in spontaneous APs after DAMGO (N = 10). 
Spontaneous APs were measured during a noncontiguous period (cumulative of 60s) in 
between current pulses. 
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Figure 17. Spontaneous APs after DAMGO or saline. Out of the remaining pool of 44 (3 µM) DAMGO-
exposed neurons, 22 were spiking spontaneously. Out of the 21 saline controls, 11 were spiking 
spontaneously. (a) Rate of spontaneous APs after 80s of vehicle saline show no general trend. (b) Rate of 
spontaneous APs in the remaining (non-H-responder) DAMGO-exposed neurons, which appeared to show 
some neurons had reductions in spontaneous APs, and others had not. (c) We therefore graphed the fold 
change in spontaneous APs after DAMGO or vehicle saline. We established a 50% reduction (vertical 
dotted line) in spontaneous APs as a somewhat arbitrary cutoff to distinguish nonresponders from S-
responders. (d) Rate of spontaneous APs in S-responders (N = 10) which had fell below the cutoff, and 
therefore were classified as S-responders. (e) Rate of spontaneous APs in the remaining pool of 
nonresponders (N = 12), which had not achieved that 50% cutoff. Figures (d) and (e) are therefore subsets 
of (b). 
Figure 17 depicts the fold change in number of spontaneous APs (slot 2/slot 1) in 
the saline group (N = 11) and the DAMGO-exposed group (N = 22). Because a saline 
control dropped spontaneous APs to zero, we could not use a “real datapoint” cutoff as 
we did with the H-responders. We therefore established a 50% reduction (0.50; at the 
vertical dotted line in Figure 17c) as a cutoff point for S-responders and nonresponders. 
All DAMGO-exposed neurons to the left of that cutoff were considered to be “S-
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responders” (N = 10). We did not analyze the effect of DAMGO on spontaneous APs 
beyond counting them, because 8 out of 10 S-responders had simply stopped firing 
spontaneous APs after DAMGO. Collectively, 21 out of 55 (38.2%) neurons fell into at 
least one of the two responder categories. Hyperpolarizing responders had an average 
RMP of -54.0 mV (range -50.1 to -62.9 mV). The H-responders had, on average, 
hyperpolarized by -5.6 mV (range -3.5 to -8.6 mV) during the 80s period from slot 1 
(saline) to slot 2 (DAMGO). Most H-responders were silent at rest, with only three firing 
spontaneous APs. On average the S-responders fired around 2.8 APs/s before DAMGO 
when unstimulated. This ranged from 0.17 APs/s to 12.1 APs/s. After DAMGO, 8 out of 
10 S-responders simply stopped firing spontaneous APs, however 2 continued to fire 
spontaneous APs at lower rates after DAMGO. A neuron that was firing spontaneous APs 
at 12.1 APs/s reduced its spiking to 5.75 APs/s after DAMGO, whereas the remaining the 
remaining neuron underwent a nearly four-fold reduction in spontaneous APs (Figure 
17d).  
To further explore whether the H and S-responder classes of DAMGO-responsive 
cells represent distinct cell populations, we determined the pre-drug spiking pattern based 
on the Petilla Interneuron Nomenclature Group’s suggested categorization scheme (The 
Petilla Interneuron Nomenclature Group, 2008). Categorization of H and S-responders 
was determined for based on their firing pattern during the 1s suprathreshold current 
application (Figure 18). Although we characterized their spiking pattern around their 
threshold Vm for the first AP, we observed that discharge patterns could change at higher 
current applications. For instance, fastspiking neurons typically had low firing rates 
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around threshold, but increased at more-depolarizing current steps, which has been 
reported before (Golomb et al., 2007). 
 
Figure 18. Representative Examples of Firing Patterns. We classified the spiking characteristics of 
interneurons by observing the pattern of AP discharges that occurred around their Vm threshold for an AP. 
Note that there is some variability here in their threshold and RMP, which manifests as threshold Vm 
sometimes occurring at different episodes for each neuron. Firing patterns are arranged by row, and their 
episodes by column. (Top row) Adapting neurons tended to fire more frequently at the beginning of the 
current pulses and had steadily increasing interspike intervals through the current application. This pattern 
stayed stable even at high current applications (E-15 and E-20). (Second Row) Irregular spiking neurons 
fired irregular APs, or irregular bursts of APs, at suprathreshold current application. However, this firing 
pattern often transitioned to more evenly spaced APs at higher current applications. (Third row) Fast-
spiking neurons tended to have more distance between their RMP and AP threshold. Most of their APs 
were evenly spaced throughout the current application. At higher current applications (E-15 and E-20) this 
firing pattern tended to fire more frequently, and correlate with the amplitude of the current injection. 
(Fourth Row) Nonadapting, nonfastspiking neurons had evenly spaced spikes throughout the current 
application. This firing pattern tended to have a stable discharge pattern regardless of the current 
application; unlike the neurons we classified as fastspiking which tended to increase their AP frequency 
when more-depolarizing currents were applied. 
We found that S-responders and non-responders were roughly equivalent in their 
distribution of firing patterns. H-responders, in contrast, were notable in having a 
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relatively high frequency of Adapting neurons, a relatively low frequency of non-
adapting neurons and a lack of fast-spiking neurons. Collectively, these data suggest that 
the µOR effects might be heterogeneous and could vary between neuron populations. 
 
Pattern H-responders (N = 11) 
Count (% of column) 
S-responders (N = 10) 
Count (% of column) 
Nonresponders 
(N = 34) 
Count (% of 
column) 
Fastspiking 0 (0%) 2 (20%) 8 (23.5%) 
Nonadapting, 
nonfastspiking 
3 (27.2%) 6 (60%) 16 (47.1%) 
Adapting 6 (54.5%) 1 (10%) 4 (11.8%) 
Irregular Spiking 2 (18.2%) 1 (10%) 6 (17.6%) 
Table 5. Responder groups demonstrate different proportions of spike patterns. We used the PING 
classification system to categorize each group (by hand) based on their spiking pattern in response to a 1s 
depolarizing current at 2-3 steps above threshold, where the trace stabilizes, and multiple APs occur. While 
the proportions of spiking patterns in each pool (in parentheses) are relatively similar, it appears that 
adapting firing patterns are roughly 5 times as common in the H-responder group as S-responders and non-
responders. We did not find fastspiking neurons in the H-responder group, though they were found 
sometimes in S-responders and nonresponders. The PING nomenclature also designates “Intrinsic Burst 
Spiking” and “Accelerating” spike patterns; however, we did not observe these patterns in the sample (N = 
55). 
 
3.3.2 DAMGO effects on action potential activity and kinetics 
Modulation of AP kinetics can affect neurotransmitter release by influencing the kinetics 
and amplitude of calcium influx (Y.-M. Yang & Wang, 2006). Features of AP kinetics 
are shaped by multiple types of ion channels (B Rudy et al., 2009). We therefore evoked 
APs before and after DAMGO and αDTX to assess a potential role of µOR in regulating 
αDTX-sensitive ion channels as a means of governing AP kinetics.  
We analyzed 54 AP parameters, ratios, and membrane properties (Tables 7 and 
9). Of those, seven have been reported to be affected by activation of µORs or αDTX in 
other studies, though not necessarily both. Hyperpolarization was the first measure, 
which is often found with DAMGO stimulation (Loose et al., 1990). Secondly, αDTX-
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sensitive channels are shown to modulate Vm threshold for an AP (AP threshold) 
(Bekkers & Delaney, 2001; Glazebrook et al., 2002; Kirchheim, Tinnes, Haas, Stegen, & 
Wolfart, 2013; Pathak et al., 2016), though the µOR may not change it (Bekkers & 
Delaney, 2001; Faber & Sah, 2004; Glazebrook et al., 2002; Kirchheim et al., 2013; 
Pathak et al., 2016). Both the µOR and αDTX-sensitive channels also suppresses evoked 
AP discharges, and so we investigated whether it decreases the number of evoked APs 
and increases their temporal spacing (interspike interval; ISI) (Faber & Sah, 2004; Mo, 
Adamson, & Davis, 2002). The AP halfwidth (duration) and the AP maximum 
repolarization rate were also measured because there is some evidence to support their 
modulation by αDTX-sensitive channels (W. Wang, Kim, Lv, Tempel, & Yamoah, 
2013). Finally, since many voltage-sensitive K channels contribute to the 
afterhyperpolarization (AHP), we measured the magnitude of afterhyperpolarizations as 
well (W. Wang et al., 2013). 
3.3.3 DAMGO alters AP waveform and pattern of evoked APs in H-responders 
To reduce family-wise errors from running sets of 7 analyses simultaneously, we first 
tested the combined 7 dependent variables (RMP, AP threshold, interspike interval, 
number of evoked APs, AP halfwidth, maximum repolarization rate, and 
afterhyperpolarization amplitude) in the H-responders (N = 11) versus the saline controls 
(N = 21) for a significant Slot*Group interaction (see Table 4) in a mixed-model repeated 
measures MANOVA. When the Slot*Group interaction was significant, we tested the 
changes in the dependent variables individually.  
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We found that the H-responders had statistically significant (F(7,20) = 19.32, p < 
0.001, Wilks’ λ = 0.871) Slot*Group interaction in the 7 combined variables that we were 
tested, which suggested a possible DAMGO effect in those parameters. We therefore 
carried out specific analyses of RMP, AP threshold, number of evoked APs, interspike 
interval, AP halfwidth, max repolarization rate, and afterhyperpolarization magnitude in 
H-responders. 
The αDTX-sensitive channels can modulate Vm threshold for an AP, however the 
µOR does not necessarily change this property (Faber & Sah, 2004; Finnegan et al., 
2006). We analyzed their change in Vm threshold for the first AP (Figure 19a,b,c). We 
found no significant difference (t(20) = 0.42, p = 0.338) in the change in AP threshold for 
the H-responders (M = 0.99, SD = 0.07) versus the saline controls (?̅? = 0.98, s = 0.07) 
after DAMGO. This shows that neocortical µORs do not modulate AP threshold in the H-
responders. 
We then investigated the patterns of AP discharges to determine whether how 
DAMGO had influenced the number of evoked APs and their temporal spacing between 
APs (Figure 19). These H-responders (N = 10, M = 1.35, SD = 0.36) had significantly 
increased interspike intervals (t(18) = 3.01, p = 0.004) when compared to the saline-only 
controls (n = 10, ?̅? = 0.98, s = 0.12). The H-responders (N = 11, Mdn = 0.98) also had 
significantly reduced numbers of evoked action potentials (U = 12, p < 0.001) after 
application of DAMGO when compared to saline controls (n = 11, Mdn = 0.98). These 






























































































































Figure 19. Spike frequency altered in H-responders. We tested whether H-responders had discernible 
changes after (3 µM) DAMGO AP threshold and frequency by comparing them to saline controls. (Left 
column) The saline controls (N = 21) show little systematic changes in their (a) AP threshold, (d) number 
of evoked APs, (g) and mean interspike interval during exposure to vehicle saline. (Middle column) 
Meanwhile the H-responders (N = 11) show little change after (3 µM) DAMGO in (b) AP threshold, 
however they generally show reduced numbers of (e) evoked APs, and (h) larger interspike intervals after 
DAMGO. (Right column) To illustrate and test these changes more precisely, we measured the fold change 
in those parameters against a random group of saline controls (n = 11). We found that (c) AP threshold 
change was unaffected by the DAMGO compared to the change in saline controls, but we found 
significantly decreased (p < 0.05) number of (f) evoked APs in H-responders after DAMGO and 
significantly increased (i) mean interspike interval. One H-responder is excluded because it became single-
spiking after DAMGO (Left and Middle columns) connecting lines bridge the same neuron after an 80s 
period of vehicle or DAMGO incubation. Y axes are true values for those particular measures (Right 
column) isolates the fold change (slot 2/slot1; postdrug/initial) after vehicle saline or DAMGO. Edges of 
the boxes are drawn at the 1st and 3rd quartiles while the “whiskers” connect the largest and smallest values 
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for that group. We performed statistical testing of ISI and AP threshold with unpaired t-tests (one-tailed) 
after first testing for skewness and kurtosis with D’Agostino-Pearson omnibus K2 test (p > 0.05). Only 
number of evoked APs was significantly different from a normal distribution (p < 0.05) and therefore tested 
with a one-tailed Mann-Whitney U test. 
 
We next analyzed the H-responder group to determine whether AP waveform was 
being altered by DAMGO (Figure 20). Among hyperpolarizing DAMGO-responders, we 
found several significant changes in action potential waveforms against the saline-only 
controls; we found significant reductions in AP halfwidth (U = 11, p < 0.001) in the 
DAMGO H-responders (Mdn = 0.91) versus the saline controls, which trended slightly 
towards widening APs over that time period (Mdn = 1.05). The 11 DAMGO H-
responders had increased their maximum repolarization rates (M = 1.29, SD = 0.44) 
significantly (t(20) = 2.91, p = 0.004) compared to the saline controls (?̅? = 0.89, s = 0.11) 
which trended towards slower repolarizations by slot 2. These results show that DAMGO 
was hastening the maximum rates of AP repolarization, and shortening the duration of the 
APs. Lastly, we compared the magnitude of afterhyperpolarizations (AHPs) in the saline 
controls (?̅? = 0.94, s = 0.07) versus the H-responders (M = 1.10, SD = 0.30) and found 
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Figure 20. AP kinetics are altered in H-responders. We analyzed AP kinetics and afterhyperpolarization 
(AHP) amplitude before and after DAMGO or vehicle saline to determine whether DAMGO altered these 
properties. (Left column) Saline controls (N = 21) before and after an 80s period of exposure to the vehicle 
saline. In the saline group, there was little trends in (a) AP halfwidth, and (d) maximum repolarization rates 
(Middle column) DAMGO-exposed H-responders (N = 11) generally show reduced (b) halfwidths and (e) 
larger maximum repolarization rates after DAMGO, but (h) AHP amplitudes are generally stable. (Right 
column) To isolate and statistically test the change after DAMGO, we plotted the fold change after 
DAMGO or vehicle saline. We found that DAMGO exposure in H-responders resulted in significantly 
reduced (c) halfwidths compared to random saline controls (n = 11). This corresponded with significantly 
increased (f) maximum AP repolarization rates. We also found significantly larger (i) AHP amplitudes in 
H-responders relative to controls. (Left and Middle columns) connecting lines bridge the same neuron after 
an 80s period of vehicle or DAMGO incubation. Right column isolates the fold change (slot 2/slot1; 
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postdrug/initial) after vehicle saline or DAMGO. Edges of the boxes are drawn at the 1st and 3rd quartiles 
while the “whiskers” connect the largest and smallest values for that group. We performed statistical testing 
for maximum repolarization rate and AHP amplitude with unpaired t-tests (one-tailed) after testing for 
skewness and kurtosis with D’Agostino-Pearson omnibus K2 test. AP halfwidth change (for saline group) 
was nonnormally distributed (p < 0.05) and therefore tested with Mann-Whitney U tests. 
 
PARAMETER Mean Difference 
(DAMGO-
Saline) 
P value 95% Confidence Interval for 
Difference 
 
Lower        Upper               
RMP  0.12 <0.001 0.09 0.16 
AP Halfwidth -0.21 < 0.001 -0.32 -0.10 
AP Max Repolarization 
Rate 
 0.40  0.004 0.11 0.68 
Interspike Interval  0.37  0.004 0.11 0.62 
Number of Evoked APs -0.35 < 0.001 -0.56 0.14 
AP Threshold  0.01  0.338 -0.05 0.08 
Afterhyperpolarization 
Amplitude 
 0.16  0.045 -0.03 0.35 
Table 6. Summary of DAMGO effects in H-responders. We compiled a statistical summary and effect sizes 
for H-responders in all 7 measures that we were primarily investigating. The change in each property was 
derived by dividing post-DAMGO/pre-DAMGO values (i.e., slot 2/slot 1) to calculate the fold change. 
Here, these fold changes in the saline group (expected to represent the change due to time) was subtracted 
from the fold change in the DAMGO group to derive the effect of DAMGO. Each mean difference is a 
proportion of one (e.g., a mean difference of -0.21 is a reduction of 21% in the DAMGO condition over the 
saline control). Comparisons of the change in saline and DAMGO group were tested first for normality 
with the D’Agostino-Pearson omnibus K2 test. Normally distributed data were tested for significance (α = 
0.05) with one-tailed unpaired t-tests and nonnormally-distributed data were tested with one-tailed Mann-
Whitney U tests. 
 
We classified the H-responders by spiking pattern after DAMGO to determine if 
µORs could change the pattern of discharges, since there were changes in evoked AP 
number and ISI in these neurons (Table 7). Although most H-responders had a stable 
spiking pattern after DAMGO, we did notice a few changes. Three H-responders had 
shifted spiking categories, however the majority (8 out of the 11) H-responders had 
remained in the same spiking pattern after DAMGO. In 2 out of 3 cases where the H-
responder shifted pattern, the neurons transitioned into an Adapting patten, which was 
consistently the prevailing spiking pattern in H-responders. 
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Adapting Irregular Spiking 
Irregular Spiking Irregular Spiking 
Irregular Spiking Adapting 
Non-adapting, Non-fastspiking Non-adapting, Non-fastspiking 
Non-adapting, Non-fastspiking Non-adapting, Non-fastspiking 
Non-adapting, Non-fastspiking Adapting 
Table 7. Few H-responders shift spiking patterns after DAMGO. We identified the spiking patterns of H-
responders based on PING categories before and after DAMGO. Neurons are ordered by row arbitrarily. 
Boldtype rows are neurons that change firing type. The majority of the neurons remained the same spiking 
patterns, though 3 had changed after DAMGO. 
 
3.3.4 αDTX counteracts µOR-agonism in H-responders 
Having found that DAMGO was altering AP waveform and pattern of discharge, 
particularly in hyperpolarizing DAMGO responders, we investigated whether αDTX-
sensitive channels were involved in this effect; µOR elsewhere in the brain has 
previously been found to modulate an α-Dendrotoxin-sensitive channels (Faber & Sah, 
2004; Finnegan et al., 2006). We therefore exposed the neurons to a combination of 
DAMGO + αDTX (3 µM and 100 nM, respectively) after their prior exposure to (3 µM) 
DAMGO to determine if the addition of αDTX could reverse the effects. We once again 
compared this drug group against saline-only recordings to account for stochastic effects 
and the effects of repeated stimulation, and thereby detect the true impact of αDTX in a 
background of DAMGO. For the following comparisons we also isolated the change by 
dividing the post αDTX+DAMGO/pre αDTX-DAMGO; slot 3/slot 2. In this case, the 
post-DAMGO (slot 2) measurements that had been used as the “after-DAMGO” 
recording were used here as the “pre-αDTX+DAMGO” recording (see Figure 15). 
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We tested for a significant Slot*Group interaction in the H-responders versus the 
controls in timeslots 2 to 3 (DAMGO → αDTX+DAMGO). This interaction was 
significant indicating a potential αDTX effect on the 7 variables (F(7,19)= 2.57, p = 
0.048, Wilks’ λ = 0.486). We therefore conducted further analysis on each measure. We 
had previously found significant DAMGO effects in all the measures for H-responders, 
except for AP threshold and afterhyperpolarization amplitude (see Table 6), but we 
expected that αDTX’s effects may not be as extensive as DAMGO’s effect, since this 
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Figure 21. αDTX reverses DAMGO effects on ISI and AP number. We tested for αDTX effects in the H-
responders by applying αDTX in a background of DAMGO and examined these parameters for changes 
that were in opposite polarity as DAMGO. These change ratios were calculated by dividing 
postDTX/preDTX (i.e., slot 3/slot 2). Thus, αDTX in a background of DAMGO. (Left column) Real values 
for saline controls during this period which show stochastic changes in each measure. (Middle column) 
Real values for H-responders before and after exposure to αDTX. (Right column) isolates the fold change 
in a subset (n = 11) of saline controls and the (N = 11) H-responders from their pre-DTX condition. 
Statistical testing was performed by comparing the changes in saline controls (n = 11) with the changes in 
H-responders (N = 11) after αDTX. We found no significant effects of αDTX on (a) RMP, (e,f) AP kinetics 
(halfwidth and max repolarization rate). However, we did find significant effects of αDTX on H-responders 
in a background of DAMGO in (d) interspike interval (c) number of evoked APs, as well as (g) 
afterhyperpolarization amplitude. We also found that αDTX lowered (b) AP threshold, which had not been 
modulated by DAMGO. One neuron was excluded from graph (c), but not statistical comparison, due to a 
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14-fold increase in evoked APs. Edges of the boxes are drawn at the 1st and 3rd quartiles while the 
“whiskers” connect the largest and smallest values for that group. We performed statistical testing with 
unpaired t-tests (one-tailed) after testing for skewness and kurtosis with D’Agostino-Pearson omnibus K2 
test (p > 0.05). 
 
We found no significant effect (t(20) = 0.33, p = 0.374) of αDTX on the RMP of 
H-responders (M = 0.98, SD = 0.03) when compared to saline-controls (?̅? = 0.98, SD = 
0.04). This indicates that although DAMGO had hyperpolarized these neurons, αDTX-
sensitive channels were not responsible for this effect. However, we did find a significant 
(U = 32, p = 0.033) effect of αDTX on the AP Vm threshold of H-responders (Mdn = 
1.04) when compared to the saline controls (Mdn = 1.00). This was a particularly 
interesting finding because DAMGO did not modulate AP threshold (Figure 19 and Table 
6).  
Additionally, αDTX significantly reduced ISI (t(20) = 2.70, p = 0.007) in H-
responders (M = 0.86, SD = 0.13)) versus the saline controls (?̅? = 0.97, s = 0.04)). 
Similarly, αDTX significantly increased (U = 22, p = 0.005) the number of APs in the H-
responders (Mdn = 1.22) versus the saline controls (Mdn = 1.00). Therefore, αDTX has 
an opposite effect to DAMGO, which raises ISI and decreases evoked APs in these H-
responders. This suggests that αDTX-sensitive currents do indeed mediate some of the 
DAMGO effect on suppressing the initiation of APs at suprathreshold depolarizations. In 
a later analysis, we analyzed whether αDTX fully or partially reverted these properties on 
a cell-by-cell basis (Figure 22). 
We next investigated whether αDTX reversed the DAMGO effects on AP kinetics 
through halfwidth and maximum rates of repolarization of an AP. αDendrotoxin failed to 
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reverse (U = 48, p = 0.219) DAMGO effects in AP halfwidth in the H-responders (Mdn = 
1.01) versus the saline controls (Mdn = 1.06). Similarly, we found that αDTX did not 
significantly (U = 57, p = 0.423) alter the maximum rate of AP repolarization (Mdn = 
0.91) when the H-responders were compared to the saline controls (Mdn = 0.96). Thus, it 
appeared that the changes in AP waveform induced by DAMGO are mediated by 
channels other than the αDTX-sensitive channels. 
Finally, we investigated whether αDTX altered AHPs. We found that αDTX 
produced a significant reduction (U = 29, p = 0.020) in AHP amplitude when H-
responders (Mdn = 0.84) were compared to the saline controls (Mdn = 0.98). Therefore, 
DAMGO increased AHP amplitude, while αDTX reduced it. 
PARAMETER Mean Difference 
Δ(αDTX+DAMGO)-
Δ(Saline) 
P value 95% Confidence Interval for 
Difference  
Lower        Upper 
RMP -0.01 0.374 -0.04 0.03 
AP Halfwidth 0.03 0.219 -0.13 0.19 
AP Max Repolarization 
Rate 
0.00 0.423 -0.17 0.17 
Interspike Interval -0.11 0.007 -0.20 -0.03 
Number of Evoked 
APs 
1.51 0.011  -0.91 3.92 
AP Threshold 0.07 0.033  0.00  0.15 
AHP Magnitude -0.14 0.020 -0.27 0.00 
Table 8. αDTX-sensitive channels reverse some DAMGO effects. Mean values in this summary were 
derived by subtracting the mean fold change in the saline group from the mean fold change in the DAMGO 
group. The fold changes for each of the groups were compared with unpaired t tests (one-tailed) for 
significance or Mann-Whitney U-tests. 
 
3.3.5 αDTX and magnitude of reversal 
In H-responders, αDTX affected ISI, number of evoked APs, AHP amplitude, and AP 
threshold (However DAMGO had not changed AP threshold). We next wanted to 
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determine whether αDTX was fully reversing the effects of DAMGO in these parameters, 
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Figure 22. αDTX partially reverses some effects of DAMGO in H-responders. To illustrate the fold 
changes in all 7 parameters across the 3 timepoints, we baselined value for these measures in the (N = 11) 
H-responders by their initial value; therefore, all neurons emanate from “1.00” which marks their original 
values. The dotted line at 1.00 represents baselined starting value for all neurons. These graphs show the 
fold changes over the course of their treatment with DAMGO, and then αDTX+DAMGO. (a) Change in 
RMP, which was the basis of selection for (N = 11) H-responders, and not significantly reversed by αDTX. 
(b) Change in AP threshold, which was not significantly altered by DAMGO, shifted towards 
hyperpolarized Vm after αDTX. (c) Evoked APs in H-responders and (b) ISI changes in H-responders (n = 
10; one neuron was not included because it became single-spiking after DAMGO). Changes in (c,d) had 
before been found to be affected by both DAMGO and αDTX in H-responders. (e) Maximum 
repolarization rate and (f) AP halfwidth, which were both significantly changed by DAMGO, but not 
αDTX. (g) Afterhyperpolarizations were significantly enhanced by DAMGO and reduced by subsequent 
addition of αDTX. Lines on all graphs connect the same neuron’s values across all 3 timepoints. Statistical 
comparisons were made by comparing fold change in H-responders to fold changes in saline controls. 
Changes were compared for significance with unpaired t-tests or Mann-Whitney U tests. 
 
To visualize this variability effects of αDTX in a background of DAMGO, we 
baselined each of the H-responders to their initial starting point and graphed all 7 changes 
over the course of slots 1-3 (Figure 22). These analyses provided insight into the 
direction of the αDTX effect, while also charting each neuron’s course individually. 
From these graphs it is evident that not only did the effect of DAMGO and αDTX varies 
between the interneurons, which can be expected of a heterogenous population of 




Figure 23. Example of αDTX reversal of DAMGO. A trace representing αDTX reversing effects of 
DAMGO in AP number and interspike interval. Respectively, each row represents the initial, post-
DAMGO, post-αDTX+DAMGO timeslots. Each column represents one of the 20 sequential episodes as the 
current applications progressively become more depolarizing. For example, E4 is the 4 th episode of 
stimulation, which generally was around AP threshold, while E20 is the final and most-depolarizing of the 
20 episodes of the stimulation. The blue horizontal bars below the APs represent the period of 1 second 
where the depolarizing current was being applied. (Top Row) This neuron began firing APs in the early, 
less-depolarizing current applications. Application of DAMGO (Middle Row) resulted in the neuron firing 
APs only at later episodes. (Bottom Row) After addition of αDTX, the neuron once again began firing at 
earlier episodes and more frequently than it had after exposure to only DAMGO. A slight RMP 
hyperpolarization after DAMGO is evident here, which was not reversed by αDTX.  
 
3.3.6 DAMGO alters RMP and AP waveform in S-responders 
We began testing for DAMGO effects in S-responders by testing the 7 combined 
variables in a mixed-model repeated measures MANOVA for a significant Slot*Group 
interaction. We found a significant effect of DAMGO in S-responders (F(7,20) = 2.57, p 
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Figure 24. S-responders also hyperpolarize. We compared the fold change in RMP in the (N = 10) S-
responders versus random saline to determine if hyperpolarization is found in this group as well. (a) Real 
values of resting membrane potential in S-responders before and after (3 µM) DAMGO. (b) Fold changes 
in resting membrane potential in S-responders versus random saline controls (n = 10). We found that the S-
responders too underwent a significant hyperpolarization after exposure to DAMGO (p < 0.05) compared 
to the polarization change in saline controls during the same period. Edges of the boxes are drawn at the 1st 
and 3rd quartiles while the “whiskers” connect the largest and smallest values for that group. We performed 
statistical testing by confirming distribution was non-significantly different from a normal distribution with 
the D’Agostino-Pearson omnibus K2 test, and then an unpaired t-test against the fold change of the saline 
controls. 
 
We first compared their change in RMP (M = 1.02, SD = 0.04) against saline 
controls (?̅? = 0.99, s = 0.02). Apparently, although this group fell short of the threshold 
for the H-responder group compared to the saline group (Figure 16) the S-responders too 
had undergone a significant hyperpolarization (t(18) = 2.53, p = 0.011) compared to the 
saline controls. Although these S-responders underwent statistically significant 
hyperpolarization after DAMGO, we classify them as S-responders because they were 
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Figure 25. S-responders have changes in AP waveform. We compared the change in each parameter in a 
sample (n = 10) saline group versus the (N = 10) S-responders. Boxes are drawn around each set of real 
values for each measure (bottom of each box), and the fold change (top of each box). We found that these 
S-responders had significant reductions after DAMGO in (d) halfwidths and significant increases in (e) 
maximum rates of repolarization compared to saline controls (p < 0.05). However, we did not find 
significant differences in the changes in (a) AP threshold, (b) number of evoked APs, (c) mean interspike 
interval, or (f) afterhyperpolarization magnitude (p > 0.05). Edges are drawn at the 1st and 3rd quartiles 
while the “whiskers” connect the largest and smallest values for that group. Prior to statistical testing we 
tested for normality with D’Agostino-Pearson omnibus K2 test (p > 0.05). In most instances, we performed 
statistical testing with unpaired t-tests (one-tailed). However, number of evoked APs and maximum 
repolarization rates were nonnormally distributed (p < 0.05) and we therefore tested those with Mann-





We tested their fold change in AP threshold to find a nonsignificant effect of 
DAMGO (t(18) = 1.11, p = 0.141) when S-responders (M = 0.96, SD = 0.08) versus the 
saline controls (?̅? = 0.96, s = 0.07); there was no effect of DAMGO on Vm threshold for 
an AP in the S or H-responders. 
We did not find a significant difference in their changes in interspike interval 
(t(18) = 1.42, p = 0.086) of these S-responders (M = 1.09, SD = 0.12) relative to the 
saline controls (?̅? = 1.00, s = 0.14). Nor did we find a significant (U = 30, p = 0.072) 
decrease in number of evoked action potentials (Mdn = 0.90) relative to the saline-only 
controls (Mdn = 1.01). Interestingly, we found effects in these 2 properties in the H-
responder group but apparently these effects are absent in the S-responder category; 
although these neurons were selected for on the basis of their decreased spontaneous APs, 
it appears that somatically-evoked APs were not similarly decreased or reduced in 
frequency. 
We next analyzed the AP kinetics of the S-responders to determine whether they 
too had altered AP shapes after DAMGO as the H-responders did. We found that the S-
responders had significantly (t(18) = 2.42, p = 0.013) reduced their AP halfwidths (M = 
0.95, SD = 0.13) after DAMGO compared to saline controls (?̅? =1.07, s = 0.10). These S-
responders (Mdn = 1.07) also had a significant increase (U = 19, p = 0.009) in their 
maximum rate of repolarization when compared with saline controls (Mdn = 0.87). 
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Finally, we analyzed the fold change in afterhyperpolarizations in S-responders 
(M = 1.07, SD = 0.24) versus changes in the saline control (?̅? = 1.00, s = 0.09). However, 
there were no significant differences in the changes of their AHP amplitude (t(18) = 1.72, 
p = 0.051).  
PARAMETER Mean Difference 
(DAMGO-Saline) 
P value 95% Confidence Interval for 
Difference 
Lower            Upper 
RMP 0.03 0.003 0.00 0.06 
AP Halfwidth -0.12 0.013 -0.23 -0.02 
AP Max Repolarization 
Rate 
0.25 0.009 0.02 0.49 
Interspike Interval 0.08 0.086 -0.04 0.21 
Number of Evoked APs -0.03 0.072 -0.03 0.07 
AP Threshold  0.04 0.141 -0.03  0.10 
Afterhyperpolarization 
Amplitude 
0.23 0.051 -0.05 0.52 
Table 9. DAMGO Effect in S-responders. A statistical summary and estimates of effect sizes for the 
spontaneous-AP responders (S-responders). The change in each property was derived by dividing the post-
DAMGO/pre-DAMGO values (i.e., slot 2/slot 1) to calculate the proportion of the change. For instance, a 
change of 0.28 in AP maximum repolarization rate is an average increase of 28% in the DAMGO S-
responders. Comparisons of the change in saline and DAMGO group were performed by unpaired t-tests 
(one tailed). Values for saline were subtracted from DAMGO values to calculate the true effect of the drug 
(and subtract the effect of time). Prior to statistical testing, we tested for normality with D’Agostino-
Pearson omnibus K2 test. In most instances, we performed statistical testing with unpaired t-tests (one-
tailed) (p > 0.05). However, number of evoked APs and maximum repolarization rates were nonnormally 
distributed (p < 0.05) and we therefore tested those with Mann-Whitney U tests (one-tailed) instead. 
 
To summarize, spontaneous AP responders had relatively small 
hyperpolarizations, and changes in AP kinetics compared to H-responders (Table 10). S-
responders lacked the DAMGO-induced ISI increase and reduced evoked AP number, 
which were observed in H-responders (Table 6). Thus, it appears that DAMGO 
influenced their RMP, spontaneous APs frequency, and AP repolarization kinetics, but it 
did not change the somatically-evoked AP frequency, as DAMGO had done in the H-
responders. The effects of DAMGO in S-responders appeared to be smaller in magnitude 
and in the range of affected parameters (Table 10). 
156 
 





RMP  0.12  0.03 
AP Halfwidth -0.21 -0.12 
AP Max Repolarization Rate  0.40  0.25 
Interspike Interval  0.37  - 
Number of Evoked APs -0.35  - 
AP Threshold  -  - 
Afterhyperpolarization Amplitude  0.16  - 
Table 10. Summary of effects for H-responders vs S-responders. To provide a side-by-side comparison of 
H and S-responders and compare their response to DAMGO, we complied data from H-responders (Table 
5) and data from S-responders (Table 6) and re-display them in this table. Numerical values reflect the 
mean fold change in that particular responder group (see top row) for each parameter (left column). Mean 
differences were derived by subtracting fold change in the saline group from the DAMGO responder group 
to isolate the effect of DAMGO from the effect of time. For example, a value of 0.40 for H-responder AP 
max repolarization rate reflects a 40% increase for maximum rate of AP repolarization in H-responders 
compared to the control, which trended larger than the mean 28% change in the S-responders. Only 
significant (p < 0.05) values are shown in the table; cells are intentionally left blank when effects were 
nonsignificant (Unpaired t-test or Mann-Whitney U test, as described in Tables 3 and 6). We found that the 
H-responders had a wider range of detected effects to DAMGO, as well as having larger effect sizes. 
 
3.3.7 αDTX effects absent in S-responders 
We also investigated whether there were αDTX effects in the S-responders, although we 
did not expect a αDTX effect here since data from the H-responder suggested that the 
effects of αDTX were restricted to AP threshold, ISI and number of evoked APs, none of 
which were affected by DAMGO in the S-responders. We found a non-significant 
Slot*Group interaction (F(7,19) = 0.81, p = 0.592, Wilks’ λ = 0.229) in this group for the 
combined variables, indicating that there was not an effect of αDTX in the S-responders. 
We also wanted to determine whether αDTX was reversing the measurement that 
was used to initially identify the S-responders, their spontaneous APs. However, the 
number of spontaneous APs was not significantly changed when αDTX was applied in a 
background of DAMGO (U = 32, p = 0.069). Indeed, after DAMGO exposure, only 3 out 
of 10 S-responders were firing spontaneously, and only 1 out of 7 had resumed firing 
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spontaneous APs after αDTX. Thus, it appears that DAMGO-induced downregulation of 
spontaneous APs was not detectably related to αDTX-sensitive channels. 
3.3.8 Investigating the influence of RMP polarization 
The identification of H-responders to DAMGO involved the selection of neurons with the 
largest hyperpolarization in during those 80s of DAMGO incubation. Under that 
procedure, it was possible that any subsequent differences we observed was simply a 
consequence of that difference in polarity change between the sampling periods. To 
investigate the confound of polarization, we selected the neurons that had hyperpolarized 
the most in the saline control, and we also selected a comparison group of neurons that 
had depolarized the most in the DAMGO group. Although we expected that this 
depolarizing change was merely due to chance (and not a DAMGO effect) it enabled us 
to “flip the sign” so that the saline-control neurons were relatively more hyperpolarized 
than the DAMGO-exposed neurons. If all of these changes were actually a result of 
hyperpolarization, the most-hyperpolarizing saline neurons should actually undergo 
analogous changes as the H-responders. If they fail to do this, significant effects in AP 
parameters are more likely to be caused by differential ion channel regulation by µORs, 
rather than a polarizing shift in the Vm without ion channel regulation by µORs. 
We found a significant Slot*Group interaction (F(7,12) = 2.57, p = 0.048, Wilks’ 
λ = 0.633) in these groups for the combined dependent variables, which included the 
RMP change that they had been selected on. We therefore investigated them further for 
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Figure 26. Polarity shift does not account for other changes. In these analyses, we compared neurons that 
depolarized in the (n = 11) DAMGO condition and neurons that hyperpolarized in the (n = 11) saline 
control. These changes were expected to be due to stochastic fluctuations in their RMP during this period, 
and we therefore expected null results. We selected these neurons based on their changes in (a) RMP 
which, predictably, had significantly depolarized in the DAMGO condition relative to the change in saline 
controls (p < 0.05). However, none of the other changes we tested were significantly different from controls 
(p > 0.05); we did not find significant differences in their changes of (b) AP threshold, (c) number of 
evoked APs, (d) interspike interval, (e) maximum repolarization rates, (f) AP halfwidth, nor (g) magnitude 
of their hyperpolarization when the groups were compared to controls in the same manner as the H and S-
responders were. Comparisons of the DAMGO-depolarizers versus saline-hyperpolarizers were made with 
unpaired t-tests (one-tailed) and summarized on Table 11. Edges of the boxes are drawn at the 1st and 3rd 
quartiles while the “whiskers” connect the largest and smallest values for that group. We performed 
statistical testing with unpaired t-tests (one-tailed) after testing for skewness and kurtosis with D’Agostino-
Pearson omnibus K2 test (p > 0.05). Only halfwidth and maximum repolarization rates were significantly 




PARAMETER Mean Difference 
(DAMGO-Saline) 
P value 95% Confidence 
Interval for Difference  
Lower             Upper 
RMP -0.05 <0.001 -0.07 0.03 
AP Halfwidth -0.02 0.405 -0.08 0.09 
AP Max Repolarization 
Rate 
-0.04 0.245 -0.15 0.08 
Interspike Interval -0.04 0.135 -0.04 0.05 
Number of Evoked APs 0.11 0.154 -0.11 0.32 
AP Threshold -0.03 0.104 -0.08 0.02 
AHP Amplitude -0.01 0.219 -0.12 0.09 
Table 11. Comparisons for the effect of polarity shift. Neurons that depolarized in the DAMGO condition 
were compared against the most hyperpolarizing neurons in the saline condition. This table compares the 
mean changes in each measure for these groups. Statistical testing revealed no significant changes in any 
parameter we compared, other than the RMP which was the basis for their selection to these groups. 
Change in RMP was significantly different from the controls (t(20) = 4.61, p < 0.001), however changes in 
AP halfwidth (t(20) = 0.24, p = 0.405), max repolarization rate (t(20) =0.25, p = 0.245), interspike interval 
(U = 43, p = 0.135), number of evoked APs (t(20) = 1.05, p = 0.154), AP threshold (t(20) = 0.70, p = 
0.245), and AHP (U = 48, p = 0.219) were nonsignificantly (p < 0.05) different from each other. Prior to 
statistical comparisons, distributions were tested with D’Agostino-Pearson omnibus K2 test. Normally-
distributed data (p > 0.05) were tested with unpaired t-tests (one-tailed) while nonnormally-distributed data 
were tested with Mann-Whitney U tests (one-tailed). 
 
Other than the change in RMP that they had been selected on, we did not find 
significant changes in any of the 6 other parameters. These analyses suggest that 
parameters following RMP were not being influenced by the change in the magnitude of 
their polarity that served as the maker for H-responders, but instead were a result of 
differential ion channel regulation that occurs during a DAMGO-response. 
3.3.9 Investigating false negatives 
We next wanted to determine whether there were DAMGO-induced changes in the 
nonresponder group, which would have suggested that these groupings were too 
exclusionary. This could contribute false negatives, i.e., true responders that were 
excluded from the responder groups and passed unanalyzed into the pool of 
“nonresponders.” Out of the 55 neurons that we recorded and exposed to DAMGO, there 
remained 34 recordings that were excluded from the S&H-responder categories. We 
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wanted to investigate this nonresponder pool for the same changes in AP parameters that 
we sought in the S&H-responder categories. We decided to begin to address this issue by 
seeking changes in the nonresponders for the 7 measures we have been testing for. 
We individually graphed the change in polarity (x axis) versus all 7 measures 
tested (y axis). If neurons had undergone changes in those measures without 
hyperpolarization, they can be visually identified by appearing vertically displaced, but 
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Figure 27. Responder categories captured most large changes. To determine whether the changes we were 
attempting to detect had successfully been predicted by the S and H responder groups, we compared 
polarization (x ais) with the changes in AP parameters we were measuring (y axis).Vertical displacement 
on the y axis therefore indicates that the neuron had large changes in the measure being compared and can 
be compared with its polarization (horizontal displacement). Left column only includes the H-responders 
(blue squares), while the right column expands the responder category to both S&H-responders (blue 
squares). Saline-controls (black) are included in these images to illustrate the pattern of stochastic or 
entropic changes that should be considered in interpretations of these graphs. (a,b) AP Threshold versus 
polarization. We previously found no DAMGO effect in this measure, and the distribution shows scattering 
around the origin. (c,d) Number of evoked APs show a downward and right skew, as we expected the 
DAMGO responders were firing fewer evoked APs. (e,f) Interspike interval showed and upwards and right 
skew in the responders, as we expected, since a DAMGO response should reduce spike frequency (and 
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increase temporal spacing). (g,h) AP halfwidth showed a downwards and right skew, particularly in 
DAMGO responders. (i,j) AP maximum repolarization rates show and upwards and right skew in the 
DAMGO responders. (k,l) Afterhyperpolarization amplitude versus polarization shows an upward spread of 
S and H-responders. 
This comparison revealed that these 2 categories of responders had captured most 
of the large changes in those parameters, and yet there seemed to be a small cluster of 
“nonresponders” that seemingly had hyperpolarized and underwent very small reductions 
in halfwidth and small increases in AP repolarization rates. For instance, the saline-
controls never fall in the hyperpolarized and quickly-repolarizing top-right quadrant 
(Figure 26j) and yet 7 nonresponders do. Therefore, examining for hyperpolarization 
seemed to predict the larger changes in these measures, but it left open the possibility that 
weaker responders were being misclassified as DAMGO-nonresponders. 
To investigate false negatives that were overlooked, we tested for a significant 
Slot*Group interaction in the nonresponders with a mixed model repeated measures 
MANOVA (N = 34) versus the saline controls (N = 21). However, the result for the 
combined variables was nonsignificant (F(7,44)= 1.17, p = 0.342, Wilks’ λ = 0.156) 
despite the higher sample size when compared to S and H-responders. While it’s possible 
that some responders with weak effects (Figure 26) may have been misclassified as 
nonresponders, the neurons with the largest changes in measures that we were testing for 
seem to have been identified as H or S-responders and thus were previously analyzed 
here. 
3.3.10 Post-hoc analyses on DAMGO, αDTX and AP kinetics 
Finally, we conducted a post-hoc analysis of 47 other parameters and ratios that have not 
been previously addressed here. This included individually analyzing sequential APs to 
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determine if the drugs had effects only one specific APs in their spike train, as well as 
examining ratios for changes between sequential APs. For these post-hoc analyses, we 
only considered H-responders for the DAMGO and αDTX effects, because only the H-
responders had systematic responses to αDTX and had stronger responses to DAMGO 
(Table 10).  
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Input Resistance 0.064 F(1,28) = 3.71, 
ηp2 = 0.117 
0.512 F(1,27) = 
0.44, ηp2 = 
0.016 
AP Number at Threshold 0.321 F(1,28) = 1.02, 
ηp2 = 0.035 
0.581 F(1,27) = 
0.31, ηp2 = 
0.011 
AP Halfwidth at 
Threshold 
<0.001 F(1,28) = 
23.13, ηp2 = 
0.452 
0.536 F(1,27) = 








<0.001 F(1,30) = 
22.47, ηp2 = 
0.428 
0.917 F(1,29) = 




0.001 F(1,30) = 
13.33, ηp2 = 
0.308 
0.472 F(1,27) = 
0.53, ηp2 = 
0.018 
Time to Max 
Depolarization Rate 
0.001 F(1,30) = 
12.32, ηp2 = 
0.291 
0.612 F(1,27) = 
0.26, ηp2 = 
0.009 
Time to peak 0.003 F(1,30) = 
10.60, ηp2 = 
0.251 
0.785 F(1,27) = 
0.08, ηp2 = 
0.003 
Peak Amplitude 0.084 F(1,30) = 3.19, 
ηp2 = 0.096 
0.172 F(1,27) = 




0.001 F(1,30) = 
14.32, ηp2 = 
0.323 
0.917 F(1,27) = 




0.001 F(1,30) = 
13.65, ηp2 = 
0.313 
0.716 F(1,27) = 
0.14, ηp2 = 
0.005 
Time to max 
Repolarization Rate 
0.014 F(1,30) = 6.75, 
ηp2 = 0.184 
0.949 F(1,27) < 
0.01, ηp2 < 
0.001 
AP1 Halfwidth <0.001 F(1,30) = 
21.79, ηp2 = 
0.421 
0.341 F(1,27) = 
0.94, ηp2 = 
0.031 
AP1 90% Width <0.001 F(1,30) = 
21.79, ηp2 = 
0.421 
0.949 F(1,27) < 




0.042 F(1,30) = 4.53, 
ηp2 = 0.131 
0.043 F(1,27) = 










0.001 F(1,29) = 
14.02, ηp2 = 
0.326 
0.462 F(1,28) = 




0.001 F(1,29) = 
15.56, ηp2 = 
0.334 
0.501 F(1,28) = 
0.47, ηp2 = 
0.016 
Time to Max 
Depolarization Rate 
0.001 F(1,29) = 
13.80, ηp2 = 
0.322 
0.749 F(1,28) = 




Time to peak 0.961 F(1,29) < 0.01, 
ηp2= 0.000 
0.265 F(1,28) = 
1.30, ηp2 = 
0.044 
Peak Amplitude 0.028 F(1,29) = 5.34, 
ηp2= 0.156 
0.110 F(1,28) = 




<0.001 F(1,29) = 
16.45, ηp2 = 
0.362 
0.970 F(1,28) < 




<0.001 F(1,29) = 
15.42, ηp2 = 
0.347 
0.748 F(1,28) = 
0.11, ηp2 = 
0.004 
Time to max 
Repolarization Rate 
<0.001 F(1,29) = 
17.35, ηp2 = 
0.374 
0.438 F(1,28) = 
0.62, ηp2 = 
0.022 
AP2 Halfwidth <0.001 F(1,29) = 
18.04, ηp2 = 
0.384 
0.915 F(1,28) = 
0.01, ηp2 < 
0.001 
AP2 90% Width 0.229 F(1,29) = 1.51, 
ηp2 = 0.049 
0.868 F(1,28) = 
0.03, ηp2 = 
0.001 
Afterhyperpolarization 0.001 F(1,29) = 
13.42, ηp2 = 
0.316 
0.059 F(1,28) = 






0.001 F(1,29) = 
14.11, ηp2 = 
0.327 
0.371 F(1,28) = 




0.001 F(1,29) = 
15.08, ηp2 = 
0.342 
0.445 F(1,28) = 
0.60, ηp2 = 
0.021 
Time to Max 
Depolarization Rate 
<0.001 F(1,29) = 
27.15, ηp2 = 
0.484 
0.716 F(1,28) = 
0.14, ηp2 = 
0.005 
Time to peak 0.332 F(1,29) = 
16.21, ηp2 = 
0.033 
0.440 F(1,28) = 
0.61, ηp2 = 
0.021 
Peak Amplitude 0.023 F(1,29) = 5.76, 
ηp2 = 0.166 
0.098 F(1,28) = 




0.001 F(1,29) = 
14.89, ηp2 = 
0.339 
0.607 F(1,28) = 
0.27, ηp2 = 
0.010 
Time to max 
Repolarization Rate 
0.002 F(1,29) = 
12.02, ηp2 = 
0.293 
0.453 F(1,28) = 
0.58, ηp2 = 
0.020 
AP Multi 90% Width 0.001 F(1,29) = 
12.34, ηp2 = 
0.298 
0.759 F(1,28) = 




ISI Slope 0.016 F(1,26) = 6.71, 
ηp2 = 0.205 
0.184 F(,25) = 
1.86, ηp2 = 
0.069 
ISI Standard Deviation 0.029 F(1,26) = 5.33, 
ηp2 = 0.170 
0.934 F(1,25) = 




Table 12. Posthoc summary of electrophysiological changes.  Our Python script analyzed 44 measures and 
5 ratios, and only 7 have been discussed previously here. We therefore analyzed the 44 remaining measures 
and 5 ratios not presented yet to determine whether DAMGO or αDTX were have significant effects on 
parameters that have not yet been discussed here. Several mixed-model repeated measures MANOVAs 
were repeated for every subcategory (left column) for both DAMGO and αDTX to identify Slot*Drug 
interaction effects which may indicate that those drugs were modulating the properties listed on the left-
side column H-responders (N = 11) were compared with saline controls (N = 21) on various parameters for 
a Slot*Group interaction that would suggest a drug (DAMGO or αDTX) that was independent of 
degradation reflected in the saline control group. Timeslots analyzed were Initial → DAMGO for DAMGO 
effects, and DAMGO → αDTX+DAMGO for αDTX effects in a background of DAMGO. In order to 
determine whether these drugs acted only specifically on certain APs (e.gs., only the first AP, second AP, 
or only APs after that), we analyzed these APs separately for Slot*Group interactions. Boldtype are 
significant effects. 
 
We found that DAMGO was affecting a very wide range of AP kinetic parameters 
across many sequential APs, with the notable exception of spike amplitude. However, 
ISI min 0.001 F(1,26) = 
15.36, ηp2 = 
0.371 
0.001 F(1,25) = 
10.97, ηp2 
= 0.305 
ISI max 0.014 F(1,26) = 6.93, 
ηp2 = 0.210 
0.625 F(1,25) = 
0.25, ηp2 = 
0.010 
ISI covariance 0.114 F(1,26_ = 2.67, 
ηp2 = 0.093 
0.417 F(1,25) = 




<0.001 F(1,26) = 
18.77, ηp2 = 
0.419 





0.002 F(1,26) = 
12.30, ηp2 = 
0.321 
0.003 F(1,25) = 




<0.001 F(1,26) = 
18.95, ηp2 = 
0.422 





0.002 F(1,26) – 
11.28, ηp2 = 
0.304 
0.335 F(1,25) = 
0.97, ηp2 = 
0.037 
Ratios AP2/AP1 Halfwidth 0.237 F(1,26) = 1.47, 
ηp2 = 0.053 
0.492 F(1,25) = 
0.49, ηp2 = 
0.019 
AP3+/AP1 Halfwidth 0.342 F(1,26) = 0.94, 
ηp2 = 0.035 
0.668 F(1,25) = 
0.19, ηp2 = 
0.007 
AP2/AP1 AHP Amplitude 0.463 F(1,26) = 0.58, 
ηp2 = 0.022 
0.916 F(1,25) = 




0.669 F(1,26) = 0.19, 
ηp2 = 0.007 
0.387 F(1,25) = 
0.19, ηp2 = 
0.030 
ISI max/min 0.453 F(1,26) = 0.58, 
ηp2 = 0.022 
0.113 F(1,25) = 




αDTX’s effects were not seen in these parameters (Table 11). Broadly speaking, it 
appears that DAMGO consistently alters many different features, from individual AP 
kinetics, to the probability of firing an AP. Meanwhile αDTX-sensitive channels do not 
seem to contribute the shape of APs in neocortical interneurons, and its effects appear to 
be restricted to the probability of firing an AP and their firing frequency. 
3.4 Discussion 
Previous research indicates that the µOR exerts an excitatory effect on cortical networks 
by suppressing inhibitory neurons (Homayoun & Moghaddam, 2007; C. Jiang et al., 
2019; H. K. Lee et al., 1980; Madison & Nicoll, 1988; Pang & Rose, 1989; 
Zieglgansberger et al., 1979). The experiments here likewise demonstrate that the µOR 
exerts a strong inhibition on many cortical interneurons. We found that over a third 
(21/55; 38.1%) of the sample of interneurons either hyperpolarized (H-responder) or had 
reduced spontaneous action potentials (S-responder). The influence of DAMGO in these 
two populations of interneurons had overlapping characteristics but were distinct. For 
instance, in H-responders DAMGO elicited clear hyperpolarization and affected AP 
kinetics and firing frequency. In contrast, the S-responders exhibited relatively smaller 
hyperpolarizations and small changes in AP kinetics, and no alterations in the probability 
of somatically evoked APs. 
The high degree of variability of neocortical interneurons between and within 
their classes makes identification of interneurons in our system difficult. We did not 
attempt cell-marker identification of the neocortical interneurons since identification 
would have required a thorough multimodal analysis of their characteristics (The Petilla 
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Interneuron Nomenclature Group, 2008). Particularly because our system enabled more 
expeditious data collection at the expense of laminar arrangement - itself an identifying 
characteristic for interneurons. 
We found that most H-responders displayed an Adapting firing pattern, 
characterized by steadily-increasing interspike intervals. This is noteworthy because this 
spiking pattern was found at much lower rates in the non-responders and S-responders 
(Table 5). Other researchers have found interneurons with this firing pattern amongst 
neuropeptide Y-expressing interneurons (Bruno Cauli et al., 1997; B. Cauli et al., 2004; 
Férézou et al., 2007; Toledo-Rodriguez, Goodman, Illic, Wu, & Markram, 2005; Yun 
Wang, Gupta, Toledo-Rodriguez, Wu, & Markram, 2002; Y. Wang et al., 2004). This 
firing pattern in NPY+ interneurons is particularly common amongst Layer I interneurons 
of the neocortex (Karagiannis et al., 2009), which others have found to express high rates 
of µORs and hyperpolarize strongly to DAMGO exposure (Férézou et al., 2007), which 
was the distinguishing feature of H-responders in our study but found in both groups of 
responders. 
Our data also suggest that some of the S or H-responders may have features 
consistent with VIPergic interneurons of the neocortex based on reductions in inhibitory 
postsynaptic potentials that we observed during recording. These experiments did not 
include the use of GABAA and GABAB inhibitors, and IPSPs could therefore persist 
through the spontaneous activity of the interneurons. Although we did not analyze these 
events, we noticed reductions in IPSPs occurring after addition of DAMGO in some 
interneurons, including some H-responders (data not shown, though partially visible off-
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pulse in Figure 23). The VIPergic interneurons tend to inhibit other interneurons, which 
may have been manifesting our data (Fu et al., 2014; Jackson et al., 2016; Pi et al., 2013). 
It is interesting to note that previous research in neocortical slices has found a high 
degree of overlap between VIP and µOR immunoreactivities (Taki et al., 2000). 
Electrophysiological studies have also found high rates of VIP expression amongst 
interneurons that hyperpolarize in response to DAMGO, including neurons that would 
have been classified here as having Adapting spiking patterns (Férézou et al., 2007). 
While speculative, this may hint at a relationship between the H and S responders and 
VIPergic neurons of the neocortex. 
It is also important to point out that H and S-responders may not represent 
discrete populations of interneurons despite the different methodologies to distinguish 
them from nonresponders; numerous effects we found in H-responders fell just short of 
significance in the S-responders (Table 9). For example, many S-responders had 
particularly robust changes in AHP amplitude, which was not captured in the group 
mean. Although the S-responders generally had weaker responses to DAMGO (Table 
10), significant differences in this group may have been more difficult to resolve due to 
lower samples sizes (N = 10), versus the H-responders (N = 11). 
We also found that neurons within the H-responder group possess a variety of 
spiking patterns (Table 5) and also a range of responses to both DAMGO and αDTX 
(Figure 22). Within the hyperpolarizing DAMGO responders, we found a spectrum of 
changes in their AP kinetic parameters; some neurons had pronounced changes in their 
parameters, and some changed barely at all despite their greater hyperpolarization. The 
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assortment of ion channels in each particular neuron may have led to varied responses to 
DAMGO, but variability may also have resulted from the complex intracellular signaling 
cascades of GPCRs; µORs are shown in non-cortical regions to modulate αDTX-
sensitive currents through the Gαi subunit, phospholipase A2 and the lipoxygenase 
pathway (Faber & Sah, 2004; Vaughan et al., 1997), meanwhile upregulation of GIRK 
channels appears to be mediated through direct interaction by activated Gβγ subunits (C.-
L. Huang, Slesinger, Casey, Jan, & Jan, 1995; Inanobe et al., 1995; Logothetis, Kurachi, 
Galper, Neer, & Clapham, 1987; Wickman et al., 1994). It is therefore conceivable that 
neurons have a variety of responses to DAMGO ranging from activating GIRK channels, 
to activating voltage-sensitive currents, based on diverging signaling cascades. 
The neurons in the H and S-responder categories were identified using two 
different measures (RMP and spontaneous APs, respectively), which themselves can be 
manifestations of different target ion channels of µORs, or different localization of the 
µORs among the neuron types. Studies in the cortex suggest that hyperpolarization is not 
always found in a DAMGO response, and that there is incomplete overlap between GIRK 
channels and µORs (S. B. Bausch et al., 1995; Wimpey & Chavkin, 1991). Therefore, 
larger hyperpolarization may not always be seen in µOR+ neurons if GIRK channels are 
not involved. However, the drop in spontaneous APs seen in the S-responders is another 
interesting feature. Studies of this receptor in neocortical interneurons using DAMGO 
have found reductions in non-elicited APs, which appear to originate in distal processes 
of some interneurons (Krook-Magnuson et al., 2011; Norimitsu Suzuki et al., 2014). 
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These mechanisms illustrate that the µOR has several known mechanisms to 
downregulate interneurons which can vary among the interneuronal types. 
We found a range of AP kinetics as well as firing frequency properties (Table 10) 
are altered by the µOR. We found that the AP kinetics were not likely to be mediated by 
the αDTX-sensitive channels, though measures of AP probability (ISI, AP number, and 
AP threshold) were related to the αDTX-sensitive current (Figure 21 and Table 8). We 
found that αDTX frequently reversed (Figure 22) DAMGO-induced changes in spiking 
frequency in the H-responders with a wide spectrum of responses, with neurons that 
underwent DAMGO-induced changes in ISI and evoked APs usually being partially or 
fully reversed to baseline. Interestingly αDTX did seem to have an effect in 2 or 3 
neurons in RMP and AP halfwidth which was not captured by the mean; however, it is 
difficult to say whether this was a genuine reaction to the drug by certain subclasses of 
interneurons, or if they were simply outliers in the data (Figure 22). 
It is interesting that αDTX reversed DAMGO effects in ISI and number of evoked 
APs without reversing any of the AP kinetic features that we measured. The mechanism 
behind the αDTX-sensitive current suppression of follow-up APs is not immediately clear 
considering that changes in AHP magnitude was not significantly changed by DAMGO 
nor αDTX. In other parts of the brain, this current is responsible for modulating spike 
frequency adaptation – a feature that limits follow-up APs during prolonged 
depolarizations (Faber & Sah, 2004). It appears therefore possible that, based on 
DAMGO’s effect and αDTX’s (usually) partial reversal of it (Figure 22) that other 
voltage-sensitive potassium currents are being modulated by µORs. For example, the 
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Kv3 and Kv4 family potassium channels are found in cortical neurons and are implicated 
in modulating these properties (Burkhalter et al., 2006; Carrasquillo et al., 2012; Martina 
et al., 1998; B Rudy et al., 2009). The relationship of AP threshold with the µOR and 
αDTX-sensitive current was a particularly nuanced feature in hyperpolarizing DAMGO 
responders and appears to track with prior findings from the BLA where µORs modulate 
αDTX-sensitive current without changing the Vm threshold for an AP (Faber & Sah, 
2004). Here, αDTX produced a hyperpolarizing shift in AP threshold despite the µOR’s 
apparent noninfluence over AP threshold. Yet the µOR still appears to regulate αDTX 
current; µOR stimulation with DAMGO suppressed follow-up APs, which was partially 
reversed by αDTX. At face value, it appears that µOR+ interneurons have αDTX-
sensitive currents at rest that influence AP threshold, yet these currents can be 
upregulated to suppress APs after µOR-stimulation. One explanation is that αDTX-
sensitive channels are expressed in areas that the µOR is not localized to. For instance, 
αDTX-sensitive channels in axon initial segments of cortical neurons can modulate AP 
threshold (Inda, DeFelipe, & Muñoz, 2006; Kole, Letzkus, & Stuart, 2007), but if the 
µORs localize to soma and dendrites, they may very well modulate somatic channels, but 
not AIS-localized ion channels, where they may be already functioning without DAMGO 
stimulation.  
One drawback of this study is that we did not test the inverse drug exposure of 
αDTX before DAMGO and therefore it is difficult to assess the baseline function of the 
αDTX-sensitive channels in DAMGO-responders to directly relate µOR-stimulation with 
the upregulation of αDTX-sensitive channels. When designing these experiments, we 
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believed it might have been possible that αDTX would block DAMGO-induced 
hyperpolarization (the primary indicator of a positive DAMGO response) and therefore 
prevent us from ultimately identifying H-responders. However, we found that αDTX 
usually failed to reverse DAMGO effects, including hyperpolarization. The inverse drug 
sequence may be the most ideal way to measure baseline αDTX activity in DAMGO 
responders. On the other hand, there were some neurons that did undergo noticeable 
depolarization and had pronounced increases in spontaneous APs, and we may have 
overlooked several H-responders and S-responders had we used inverse drug exposures 
(Figure 22a).  
It may be argued that the hyperpolarizing effect of DAMGO found in the 
hyperpolarizing responders and, to a lesser degree, in spontaneous DAMGO responders 
may have influenced action potential parameters. This is unlikely for several reasons. 
First, most of the action potential analyses were done at several current steps above 
threshold and we used the average values for APs 3-5 in those trains, thereby mitigating 
the influence of hyperpolarized RMP on action potential parameters. In addition, most of 
the APs we observed were initiated from approximately the same Vm regardless of their 
change in RMP. Second, αDTX reversed DAMGO-induced changes in ISI and number of 
evoked APs in hyperpolarizing DAMGO responders despite αDTX’s failure to reverse 
DAMGO-induced hyperpolarization (Table 6 and Figure 21a) and broad range of other 
features in the post-hoc analyses (Table 12). Third, we compared DAMGO depolarizers 
(predicted to have had no µOR response) against neurons that had hyperpolarized slightly 
in the saline group; this comparison “flipped the sign” to the saline group being 
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significantly more hyperpolarized then the DAMGO group. However, in all measures 
resulting from this comparison, we found no significant differences in action potential 
parameters, ISI, and number of evoked action potentials (Figure 25). This analysis 
suggests that the parameters we were investigating during the current steps were not 
being influenced by the neuron’s RMP regardless of if the neuron had depolarized under 
the DAMGO challenge. 
Our data demonstrates that the μOR modulates AP parameters, including the 
halfwidth and maximum rates of repolarization to suppress the excitability of 
interneurons. We observed halfwidth changes of 12% (S-responder mean) 21% (H-
responder mean) and mean maximum repolarization rates of 25% or 40% (Table 10) - 
with also a high degree of variation between neurons (Figure 22). The consequences of 
AP kinetics have been explored in models with large synapses by using real and pseudo 
APs to shown that kinetics have consequences for voltage-gated calcium channel 
(VGCC) activity, calcium entry, and neurotransmitter release (Augustine, 1990; Klein & 
Kandel, 1980; Llinas, Steinberg, & Walton, 1981). Computer simulations and 
developmental data from synapses suggest that most VGCCs are activated by an action 
potential, but further broadening prolongs the kinetics of the VGCCs, and therefore 
contributes to longer duration of Ca2+ entry (Borst & Sakmann, 1998; Geiger & Jonas, 
2000; Sabatini & Regehr, 1997), Additional data from the calyx of Held have added that 
depolarization phases affect the number of VGCCs recruited, while repolarization affects 
their kinetics to influence the amount or duration of Ca2+ entry. Paired recordings have 
shown that both features can modulate the release of neurotransmitter and the amplitude 
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of postsynaptic potentials, depending on stages of development and adaptations at the 
synapse (Chao & Yang, 2019; Y.-M. Yang & Wang, 2006)  
The αDTX-sensitive channels Kv1.1, Kv1.2, and Kv1.6 have previously been 
linked to regulation of cortical interneurons. In the neocortex, they have been found to 
strongly influence firing through their localization at axon initial segments of 
interneurons and excitatory neurons (Bekkers & Delaney, 2001; Guan et al., 2006). The 
have previously been linked to the excitability of cortical interneurons by modulating AP 
threshold and near-threshold spike frequency (Goldberg et al., 2008). In VIPergic 
interneurons, these currents affect the frequency of output (Porter et al., 1998). Genetic 
knockout of Kcna1 (encodes Kv1.1) and Kcna2 (encodes Kv1.2) are linked to seizures 
and ataxia in both humans and rat models (Adelman, Bond, Pessia, & Mayliet, 1995; 
Brew et al., 2007; Heeroma et al., 2009; Robbins & Tempel, 2012). Restoring regulated 
activity of these channels has been proposed as a mechanism underlying a treatment for 
Fragile X syndrome (Y.-M. Yang et al., 2020). Here, our data suggest that the μOR may 
upregulate these currents, as evidenced by αDTX’s attenuation of the DAMGO effect on 
firing frequency (Figure 22). The endogenous opioids of the neocortex are deeply 
involved in reward-seeking and motivated behaviors. Studies in animal models have 
shown enhanced µOR activity correlates with, and causes, binge-eating and drug intake 
(Blasio et al., 2014; Morganstern, Liang, Ye, Karatayev, & Leibowitz, 2012; Unterwald, 
Rubenfeld, & Kreek, 1994). The µOR is believed to reshape neocortical activity by 
releasing Pyramidal Neurons from inhibition by cortical interneurons (Férézou et al., 
2007; Homayoun & Moghaddam, 2007; C. Jiang et al., 2019; H. K. Lee et al., 1980; 
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Madison & Nicoll, 1988; Pang & Rose, 1989; Taki et al., 2000; Zieglgansberger et al., 
1979). Yet despite the supporting evidence for µOR’s disinhibitory role in the neocortex, 
this receptor’s inhibitory influence has rarely been explored beyond its hyperpolarizing 
effects (Baldo, 2016; Férézou et al., 2007). Here, we found that the neocortical µOR has 
far-reaching inhibitory effects in neocortical interneurons that had not yet been described, 
which includes the potential upregulation of αDTX-sensitive channels to modulate 
interneuronal output through firing frequency. 
 
CHAPTER 4: COMPREHENSIVE DISCUSSION 
 
4.1 Overview 
These chapters provide a comprehensive summary of the neurophysiological effects of 
µOR agonism by documenting the electrophysiological effects within cortical 
interneurons, as well as the downstream hyperactivity effects by using spontaneous 
calcium oscillations s as an indicator for bursts of neuronal activity. These findings 
advance our knowledge of the µOR significantly by providing a robust statistical profile 
of DAMGO effects (Table 12) while also showing that most of the µOR’s net excitatory 
effect appears to be secondary to inhibition of cortical interneurons. This dissertation 
sheds light on the mechanisms and effects of the µOR, how opioid drugs dysregulate 




The studies in this dissertation are laid on a foundation of confirmatory evidence 
for research that previous investigators have discovered, while furthering our knowledge 
of the µOR as well. For example, we detected µOR responses in the expected range of 
1/3rd of cortical interneurons, and that hyperpolarization and reduction of spontaneous 
APs is a typical indicator, which has been observed (Férézou et al., 2007). On top of that 
foundation, we show that the µOR has many other effects on cortical interneurons that 
have not been previously described. Additionally, the conclusions and data presented 
here provide numerous other possible research avenues that can be utilized to thoroughly 
understand the target channels of the µOR, as well as to understand the net effects of the 
receptor on neuronal circuits. 
Our calcium imaging studies also corroborate previous reports that investigated 
the receptor – that it reduces GABA release onto both GABAA and GABAB receptors 
(Olah et al., 2007; Tamás, Buhl, Lörincz, & Somogyi, 2000). But our experiments show 
that calcium-imaging and SCOs can be used to detect this relationship as well, and they 
lend a convenient model to studying the network dynamics by visualizing the network 
activity of neurons. Furthermore, this model provided an effective means to assess the 
respective roles of GABAA and GABAB receptors on the SCOs. 
Data from electrophysiology corroborate other studies from neocortical 
interneurons. For instance, we found that DAMGO hyperpolarizes interneurons and 
reduces spontaneous firing. We found that the µOR employs several fascinating 
mechanisms for suppressing interneurons, including hyperpolarization, but it also affects 
AP kinetics – which has not previously been described. Therefore, the µOR utilizes 
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several mechanisms to suppress interneurons, and many of these means have not been 
previously described before the detailed analyses presented here. 
4.2 αDTX-sensitive/insensitive effects 
Our electrophysiology experiments sought to determine whether the µOR positively 
regulated αDTX-sensitive currents, and our results suggest that they do; we observed a 
αDTX-reversible change in AP frequency in H-responders. However, we did not narrow 
this down to specific subunits (e.gs: Kv1.1, Kv1.2, and Kv1.6). It is presently unclear 
which subunits are mediating this effect, though Kv1.1 or Kv1.2 are the mostly likely 
suspects, given their previously-established relationship with the µOR (Faber & Sah, 
2004; Finnegan et al., 2006; Vaughan et al., 1997) and their known localization in 
cortical interneurons (J. Connor & Stevens, 1971; X. Li et al., 2012). 
One of our main findings was that the µOR has far-reaching neurophysiological 
effects and the αDTX-sensitive current mostly modulates firing frequency, and not the 
AP kinetics. Naturally, this does lead to the question of which ion channels are mediating 
these effects since it appears kinetics may be mediated by other channels. The most likely 
suspects are K channel subunits that are more classically known to mediate faster (A-
type) current (B Rudy et al., 2009), even though αDTX-sensitive currents are themselves 
capable of faster kinetics (Casale et al., 2015; Geiger & Jonas, 2000; Pathak et al., 2016). 
Considering the tendency for αDTX-sensitive channels to heterotetramerize when the two 
are coexpressed, it would also be interesting to determine whether this takes place in 
responder neurons (B Rudy et al., 2009). Further identification of subunits mediating this 
effect of DAMGO could therefore be warranted.  
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4.3 Predicting a DAMGO response 
Future studies in this area may require higher response rates than achieved here. Data 
collected from the electrophysiological experiments mostly use random selection of 
mRuby2-positive interneurons to record from and we achieved an average response rate 
of 1/3rd between the H-responder and S-responder criteria. While this response rate may 
be adequate for future studies, there may also be other diagnostic criteria that can be used 
to predict DAMGO responses. Data collected and presented in this dissertation can also 
provide a basis for more targeted experiments directed at understanding the 
electrophysiology of the µOR. 
One of our first attempts to predict DAMGO responses was the use of 
morphology. Unfortunately, we found that neurons in vitro had indiscernible shapes that 
could not be identified; nearly every neuron appears to have a spherical soma with 
indistinct neurites. Shapes such as pyramidal, bipolar/bitufted, or multipolar cannot easily 
be determined in these cultures. However, the use of the mRuby2 AAV improves this 
situation substantially, not only by selectively fluorescing the interneurons, but also 
allowing the viewer to resolve the precise and shape and neurites of each neuron (Figure 
8 and Figure 14). While I did not attempt to use this technique to predict a DAMGO 
response, interneuronal shapes are much more resolvable with mRuby2. Anecdotally, it 
may not be an entirely useful property to predict a DAMGO response, however mRuby2 
makes it exceptionally easy to visualize the shapes of interneurons and, importantly, it 
can be used effectively before committing to the slow step of the recording process: 
sealing and breaking in. 
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Resting membrane potential and membrane resistance tend to be characteristic 
features of neurons as well. However, use of these features to predict a DAMGO 
response would probably be unsuccessful. We found RMP tended to fall in a fairly tight 
range, and membrane resistance is sometimes difficult to consistently determine in real-
time. In addition, these properties can vary over the course of seconds, and spontaneous 
spiking of the neurons also disrupts accurate reading. We typically calculated the RMP 
based on an average value that represented its RMP over a period of seconds, rather than 
being an instantaneous determination. Therefore, these basic properties of neurons were 
not very useful for predicting DAMGO responses when they are put into practice during 
the recording process. This made these properties more problematic to utilize to predict a 
DAMGO response. 
Our electrophysiological data suggest that most H-responders have Adapting 
firing patterns, and that the Adapting firing pattern is less prevalent in the nonresponder 
pool. Future investigations into the µOR should consider using this firing pattern to 
predict a response. However, half of H-responders did not display an Adapting firing 
pattern, and thus using this diagnostic feature may rule out potential H-responders. For 
example, these Adapting neurons likely have unique ion channel profiles that lend them 
their unique firing pattern. Including or excluding them can skew analyses. On the other 
hand, perhaps future investigations may choose to focus on neurons with that firing 
property. In summary, the most useful predictors for DAMGO responses are most likely 
the spiking pattern, which can only be determined after the slow steps of the recording 
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process (positioning and intrusion of the electrode), and also morphology – but only with 
the assistance of the mRuby2 AAV credited in the methods section of those experiments. 
4.4 Identifying responders by subtype 
Cortical interneurons are remarkably diverse and often identified through the use of 
protein-expressional markers (The Petilla Interneuron Nomenclature Group, 2008). To 
expedite the data collection process, we did not identify neurons using protein markers. 
Unfortunately, equipment malfunctions prevented us from collecting images for most of 
the experiment as well. We instead utilized spike patterns to classify interneurons, which 
is also a well-recognized characterizing feature (The Petilla Interneuron Nomenclature 
Group, 2008). However subtyping interneurons by cell marker could assist in making 
inferences about the roles of these interneurons in intact neocortex – in addition to 
perhaps explaining some of the variability that we observed (Figure 22). 
Our experiments grouped neurons into H-responders and S-responders categories 
based on their response to DAMGO. These typings appeared to be necessary, because 
they had been identified based on their drug responses, which were different criteria from 
each other. However, it is possible that interneurons in the 2 groups are actually more 
similar than they are presented, and their neuronal categories and typing by interneuronal 
marker may reveal overlap between the populations. On the other hand, H-responders 
were considerably more likely to be Adapting firing patterns than S-responders or 
nonresponders, and therefore it is quite possible that the H-responder and S-responders 
are composed of different interneuronal populations.  
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4.5 Origin of spontaneous APs 
We used a decreased rate of spontaneous APs as a diagnostic feature of S-responders in 
this study. One interesting area of interest raised by this observation and technique is the 
exact cause of spontaneous APs in this model, and the mechanism by which spontaneous 
APs were produced and reduced. The simplest explanation is that these neurons RMP 
was very close to its AP threshold, and the frequency of APs was simply a matter of 
probability of APs at that Vm. While hyperpolarization was not the diagnostic criterion 
for this group, the S-responders did hyperpolarize on average (Figure 23). Therefore, this 
is a simple and plausible scenario for this observation. 
Another more interesting and complex explanation may be lent by pioneering 
studies in PV+ and neurogliaform neurons, which suggest that APs in these neurons can 
be generated in distal processes, such as their axons and conduct back towards their 
soma. This phenomenon is called retroaxonal barrage firing. These APs may only be 
accompanied by small hyperpolarizations, which possibly indicates a larger 
hyperpolarization in its distant axon. DAMGO has already been shown to reduce these 
tonic APs, and thus this mechanism may apply here as well (Krook-Magnuson et al., 
2011; M. E. Sheffield et al., 2013; M. E. J. Sheffield et al., 2011; Norimitsu Suzuki et al., 
2014). In addition, these tonic APs can occur after depolarizing trains of current, due to 
axonal terminals becoming tonically active and conduction of APs through gap junctions 
which can be conducted into other interneurons; therefore, these are delayed evoked 
action potentials, rather than truly being unevoked and spontaneous APs. The 
involvement of gap junctions suggests that perhaps S-responders may not necessarily 
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indicate a µOR+ neuron, but instead a neuron junctionally-linked to an µOR+ neuron. 
However, this phenomenon has never been demonstrated in neuronal culture models, and 
the frequency of this type of spiking seems to decrease from in vivo to brain slices 
(Krook-Magnuson et al., 2011; M. E. Sheffield et al., 2013; M. E. J. Sheffield et al., 
2011; Norimitsu Suzuki et al., 2014). It’s therefore quite possible this phenomenon may 
not occur in neuronal cultures. 
This phenomenon, however, can be experimentally tested for, as has already been 
done in vivo and brain slices (Krook-Magnuson et al., 2011; M. E. Sheffield et al., 2013; 
M. E. J. Sheffield et al., 2011; Norimitsu Suzuki et al., 2014). In this case a long 
depolarizing current could be applied and the “spontaneous” APs in the minutes that 
follow this train could be counted. By comparing these tonic action potentials before and 
after the current application, it may be possible to test for retroaxonal barrage firing in 
vitro. 
4.6 Drawbacks of whole-cell recording 
Our approach during electrophysiology was establishing whole-cell configuration by 
breaking into neurons for recording. Unfortunately, this may lead to artifactual changes, 
as opposed to cell-attached which would have allowed us to record from neurons without 
breaking into them and thereby altering their intracellular environment. Cell-attached 
recordings were initially attempted during these experiments, but then aborted due to 
spontaneous break-ins during the recording process. It became clear that the sample size 
would have been prohibitively small to allow us to record from enough neurons to have a 
reasonable number of responders, and we switched to whole-cell recording. Therefore the 
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“real” values to AP kinetics may be subjected to artifactual challenges. However, we did 
record from many saline controls as well, and our main data analyses were performed by 
comparing fold changes in DAMGO-exposed neurons with those saline controls. 
Therefore, artifacts were most likely evenly reflected in both groups and fold changes 
that are calculated should still be accurate, even if true values may be subject to some 
deviation. Utilizing this whole-cell recording approach therefore allowed us to collected 
substantial amounts of recordings in a relatively short period, and further enabled the data 
analysis step to identify changes in AP kinetic parameters occurring in responders. In 
many ways, this expedited approach facilitated the robust data analysis and statistical 
profiling shown here. 
4.7 DAMGO and GABARs 
Our experiments with SCOs are a unique approach in determining how DAMGO affects 
GABAergic signaling and identifying the GABARs that are mediating that effect. This 
approach enabled us to record from many (20+) neurons in a single recording, in order to 
understand the dynamics of network activity and how DAMGO affects it. Using this 
model, we reproduced several important findings in µOR research while answering key 
questions about the receptor’s mechanisms. Firstly, this model successfully showed that 
DAMGO does indeed lead to net excitation in neuronal networks, which was well-
indicated by the SCO duration (halfwidth) enhancement by DAMGO. Secondly, our data 
corroborate the well-supported view that DAMGO increases net excitation in neuronal 
circuits by inhibiting GABAergic interneurons, and that net excitation is secondary to 
interneuronal suppression.  
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Our data also advance our knowledge of the field in several important ways; we 
show that not only does DAMGO suppress GABA release onto GABAA receptors, but it 
also suppresses GABA release onto GABAB receptors as well. On one hand, this result is 
well-aligned with the established view that µORs localize to neurogliaform neurons 
which activate postsynaptic GABAB receptors, but our data further suggest that the effect 
of GABAB may be influential for terminating bursts of activity that are indicated by each 
SCO. While extrapolating from these data into in vivo brain structures is inherently 
speculative, these data may suggest that DAMGO enhances net excitation by promoting 
bursts of activity and increasing the lag time before GABAergic interneurons are capable 
of terminating that burst of activity – which clearly seems to be a role of GABAB 
receptors in this model. Whereas our electrophysiological recordings helped us determine 
the effects of DAMGO in single neurons, the SCO model illustrated how networks of 
neurons interact and suggest that there may be a delay in responsiveness to excitation 
within cortical interneurons. This aspect of time lag to inhibit discrete bursts of activity in 
cortical networks could be an interesting topic to explore. 
4.8 DAMGO inhibition and GABA release 
As explained, we observed far-reaching electrophysiological consequences for the 1/3rd 
of interneurons susceptible to DAMGO. But what about the consequences of this for 
synaptic GABA release? This question is largely unanswered by the current data – 
though the data in this dissertation certainly provide a necessary basis for such follow-up 
experiments; we identified AP kinetic changes, but it’s not clear how this relates to 
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GABA release. This topic could be explored by dual electrophysiological recordings to 
record inhibitory postsynaptic potential magnitudes. 
There are likewise similar experiments that could be done to address the neuronal 
networks without the use of CNQX + AP5 at the neuronal network model. For example, 
the cultured neurons could be exposed to DAMGO and concentrations of GABA could 
be quantitatively measured before and after certain timepoints to determine how this 
manipulation affects GABA release. Though, the results from this experiment may be 
difficult to predict or draw conclusions from. For instance, DAMGO may counter-
intuitively increase GABA concentrations due to the greater glutamatergic input on 
GABAergic interneurons; GABA concentrations during the experiment would provide 
little information about whether bursts of GABA release into synapses was happening too 
slowly. Perhaps another important factor to consider, for reasons described later in this 
chapter, is proportionality to their glutamatergic input, i.e., standardizing the GABA 
concentration by glutamate concentration. This may help evaluate not only whether 
GABAergic interneurons are increasing GABA release, but whether their response is 
proportional to glutamatergic input before and after DAMGO. 
4.9 True role of µOR+ interneurons in cortical networks 
Our SCO model for DAMGO responses showed a powerful way to visualize disinhibition 
and cortical hyperactivity. Yet, this was one of the biggest surprises for these experiments 
– why was hyperactivity with DAMGO so common at the circuit level, and yet the 
receptor acted mainly through disinhibition (interneurons), and interneurons expressed 
the receptor uncommonly?  
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There were several striking features about the SCOs that we observed, which 
were surprising given the likely low expression of the receptor. In our early experiments 
with SCOs, we noticed how DAMGO’s enhancement of SCO duration (and sometimes 
amplitude) were particularly prevalent. There may be several explanations for this. 
Firstly, we observed 3 - 11 red interneurons in each imaging field, and our 
electrophysiological experiments suggested that about 1/3rd were inhibited by DAMGO. 
It is therefore possible that an average of 1-3 neurons in every frame were µOR+. We 
also observed that neurites at this stage spanned far distances. Taken together, this 
suggests that the interneurons were highly interlinked with many other neurons in an 
imaging field (Figure 8 and Figure 14). Therefore, despite their low frequency, even one 
µOR+ interneuron in a field could potentially influence many other neurons in a field. 
However, there is a counterargument to this point, which may further reduce the 
number of DAMGO responders that enable DAMGO-enhancement of SCOs; about a 
third of responders (8/21) did not have spontaneous firing, which reduces the 1/3rd 
responder proportion even lower, because many responders were not actively firing at 
rest, and therefore inhibition of those neurons would presumably produce very little 
effect on the network of neurons. To summarize the problem, about 17% of neurons were 
interneurons, 38.1% of them were responders, and 61.9% of them spiked spontaneously. 
This leaves about 4% of neurons which have the µOR+ and spike spontaneously (and 
thus exert effects on the network at rest). Given that an imaging frame only contained 30-




On the other hand, though, about 2/3rds of responders were firing at rest – which is 
a slight majority. Additionally, and importantly, if excitatory activity in the network were 
to increase, then the 1/3rd of responders (8/11 H-responders) may fail to be recruited into 
inhibiting that excitation – because they may have undergone a severe hyperpolarization 
that makes them less responsive (by requiring that they undergo more depolarization to 
close the gap between AP threshold and RMP), in addition to the reduced firing 
frequency and shortened APs that we observed (Figure 19). This model would suggest 
that not only does DAMGO inhibit the spontaneous activity of interneurons, but also 
prevents them from suppressing overexcitation in neuronal networks. In other words, not 
only do µORs provide constant and tonic inhibition, but perhaps the µOR+ interneurons 
also stop neuronal excitation from “snowballing.” Therefore, DAMGO might cause an 
uptick in neuronal excitation due to reduced inhibition, but it may also prevent H-
responders from ameliorating this increased glutamatergic activity. Thus, it is a problem 
of cortical interneurons not being able to mobilize effectively, despite the greater 
glutamatergic stimulation being applied to them. 
Another possible consideration is the interlinkage of interneurons, and the 
influence of neurogliaform interneurons, which are already known to express this 
receptor (Férézou et al., 2007; Krook-Magnuson et al., 2011). These interneurons are 
believed to be powerfully inhibitory in neuronal circuits; they create gap junctions to 
numerous neuronal types and synapse widely (Chittajallu, Pelkey, & McBain, 2013; 
Niquille et al., 2018; Olah et al., 2007; Overstreet-Wadiche & McBain, 2015; A. Simon, 
Olah, Molnar, Szabadics, & Tamas, 2005). Therefore, inhibiting neurogliaform neurons 
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may cause a very disproportionate uptick in excitatory activity relative to their frequency, 
which is very low. While we are not certain about their frequency in this neuronal culture 
model, their postsynaptic target receptors (GABAB receptors) are apparently found in this 
preparation, based on the substantial changes induced CGP55845 (Figure 12). Though 
given the in vitro nature of this model, we cannot be completely certain that this is an 
expressional aberration and perhaps an imperfect indicator of neurogliaform neurons in 
culture, in spite of its congruence to findings in brain slices. We never attempted to 
localize these neurons in this model due to their unfortunate lack of unique and distinct 
cell markers (Conde, Lund, Jacobowitz, Baimbridge, & Lewis, 1994; Niquille et al., 
2018; Overstreet-Wadiche & McBain, 2015). Neurogliaform neurons are often known to 
have late-spiking characteristics (Markwardt, Dieni, Wadiche, & Overstreet-Wadiche, 
2011; Olah et al., 2007; Overstreet-Wadiche & McBain, 2015), and we did not observe 
this firing pattern in any recording. 
While some of the assumptions here are speculative, they do lay some 
groundwork for future studies that explore the roles of µOR+ interneurons in cortical 
network. The experiments in this dissertation not only provide experimental evidence for 
the effects of the µOR in the neocortex, but they provide a substantial basis for this topic 
to be further explored in greater detail. 
4.10 GABAA receptors counteract hypersynchrony 
We observed another interesting drug effect, which may not be obvious in the 
quantitative data we collected. Picrotoxin (100 µM) always caused all neurons to produce 
synchronous SCOs, whereas pre-picrotoxin conditions had some out-of-sync neurons or 
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populations of neurons. It was always very clear in the images whether picrotoxin was 
applied due to the nearly perfect synchrony of neurons in the field. Also, very noticeably, 
picrotoxin dramatically increased amplitude and duration of SCOs (Figure 7). Together, 
this created a profound and bright “blinking” effect as all neurons flickered on and off 
collectively. But what does this tell us about interneurons, and their role in neuronal 
networks? And what does this tell us about the particular roles of GABAA and GABAB in 
neuronal networks? These basic questions have not been raised earlier due to the lack of 
quantitation, but the experiments conducted here do shed some light on the answers to 
these questions. 
I posit that in pre-drug conditions, the interneurons maintained separate and 
discrete populations of neurons, and kept the neurons from achieving perfect synchrony 
with all their neighbors, though neurons started off fairly synchronous (Figure 2). This 
may allow groups of neurons to act as semi-independent units for cortical processing. 
Upon application of picrotoxin, the interneurons lost their ability to segregate the 
neuronal networks, which produced universal SCOs and synchronous excitation in the 
whole network of neurons. This would predict that the fast inhibition of the GABAA 
receptor was primarily responsible for preventing excitation from simply reverberating 
through the culture. Upon applying GABAB receptor antagonist (CGP55845) in a 
background of picrotoxin, this universal synchrony did not seem to change, but instead 
enhanced the durations of the synchronous SCOs (Figure 12). While this model is 
speculative, the synchrony produced by picrotoxin should be noted because it was not 
reflected in the quantitation we did. In addition, it is difficult to extrapolate what this 
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means for in vivo brain circuits. Perhaps the beginning point for testing this would be to 
measure SCOs in brain slices and determining whether picrotoxin likewise causes 
complete synchrony in that model as well.  
4.11 Unknown physiology of SCOs 
One of the more obvious questions that the SCO study raises is the physiological events 
that contribute to SCO duration and amplitude. SCO amplitude may be modulated by 
NMDA receptor ion traffic, which could function to both depolarize the neuron as well as 
conduct inward Ca2+ currents that induce an SCO (Canepari et al., 1997; Penn et al., 
2016; Przewlocki et al., 1999; T. Tanaka et al., 1996). Of the SCO phenomena, amplitude 
remains the most well-studied measurement. However, halfwidth (a measure of duration) 
is a much more complicated matter because few researchers have provided quantitation. 
Of the studies that I cite in Chapter 2, (T. H. Murphy et al., 1992) is the only study I am 
aware that examined it. In that study, function of the NMDAR (modulated through 
manipulations of [Mg2+]out) is shown to strongly modulate SCO duration. However, my 
own results repeatedly demonstrate that function of the GABAB receptor strongly 
modulates SCO halfwidth, and therefore I believe it may also be indicative of 
GABAergic termination of bursts of APs. However, these explanations are non-mutually 
exclusive because both receptors may mediate this effect, and GABAB receptor activity 
inhibits PNs, which may then release glutamate onto NMDARs. 
My speculation is that the proximal cause of SCO halfwidth is the duration of the 
EPSPs, which may allow NMDARs to conduct inward Ca2+ currents for longer periods. 
Evidence for this interpretation is supported by our well-replicated finding that GABAB 
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receptors appear to strongly modulate SCO halfwidth, and their expression on PNs which 
release glutamate (J. R. Chalifoux & Carter, 2010; Jason R. Chalifoux & Carter, 2011; 
Corrêa, Munton, Nishimune, Fitzjohn, & Henley, 2004; Olah et al., 2007). 
On the matter of SCO coupling to calcium-induced calcium release (CICR), we 
did often observe both smaller high-frequency SCOs, as well as much larger ones that 
often showed a refractory period associated with them (Figure 4). My interpretation of 
these data is that the peaks caused by VSCCs, NMDARs and calcium-conducting 
AMPARs might trigger CICR when the peaks are of a certain threshold amplitude or 
duration. This may make tall peaks with a refractory period that tower over smaller 
calcium peaks that have failed to induce CICR. Coupling between extracellular sources 
of calcium and intracellular calcium release could potentially be an interesting study that 
can show how various drug interventions modulate the coupling efficiency between the 
two. However, there are several practical problems that can limit such a follow up. 
Firstly, it may be difficult to identify peaks that are linked to CICR from those that are 
only from extracellular sources and did not induce CICR. Secondly, my experiments 
were unable to determine how the µOR itself couples to intracellular calcium release 
because the µOR is only expected to be expressed in about a third of the interneurons that 
I recorded from. Thirdly, the SCO is a complicated model to study because it involves a 
web of interacting factors. For instance, applying DAMGO often intensifies SCO 
duration and amplitude, yet it happens in too many neurons to be a primary effect of the 
µOR. Instead, the µOR likely enhances glutamatergic outflow which primes NMDARs 
and enables inward calcium current. NMDARs, in turn, may be in an ideal location for 
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coupling smaller SCOs with the larger CICR-induced SCOs. In this scenario the ultimate 
cause may have been µOR agonism, but the proximal cause of enhanced coupling 
between small SCOs and CICR SCOs are the NMDARs, and not any intracellular 
mechanism of the µOR. Although this exact scenario may not be shown to be true, 
follow-up studies should consider alternate possibilities.  
4.12 SCOs: glutamatergic input or neuronal output? 
Our experiments in this dissertation contributed to the field by resolving ambiguity about 
how the µOR exerted its effects by showing disinhibition and not direct excitation. 
However, it also presents another compelling opportunity for future research; 
investigating whether SCOs correspond to (glutamatergic) input or neuronal output 
(through prolonged opening of voltage-sensitive Ca2+ channels). Thus, whether SCOs in 
a given neuron corresponds to its incoming input or its own action potential output. 
In the discussion of Chapter, I previously described how red and nonred neurons 
did not generally react to the various drug combinations differently from each other. I 
speculated that their lack of a difference, even as the various drugs had clear effects on all 
the neurons, may have been due to the origin of the calcium transients; most literature 
suggest that these calcium oscillations are actually a measure of the glutamatergic input 
being applied to the neurons by their neighbors, and therefore that calcium transients are 
not a direct measure of the output of the neurons, i.e., VS Ca2+ channels only constitute a 
small component of the calcium oscillations (Canepari et al., 1997; Dravid & Murray, 
2004; Flint et al., 1999; Penn et al., 2016; Przewlocki et al., 1999; T. Tanaka et al., 1996). 
However, this is not a settled issue, and some authors have proposed that VSCCs are 
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modest or substantial components of SCOs (Bacci et al., 1999; Dravid & Murray, 2004; 
Inglefield & Shafer, 2000). It’s quite possible this is due to variance in neuronal types, 
and experimental conditions. 
While glutamatergic input and output of the neuron are almost certainly positively 
correlated, they are not exactly the same thing. Specifically testing the relationship 
between input and output in the red vs nonred neurons would be an interesting follow-up 
to my experiments, because this would predict that a proportion (maybe a 1/3rd, a 
suggested by my electrophysiology data) may be µOR+. The consequences of a DAMGO 
response may cause them to become relatively suppressed in proportion to their input. 
For instance, these µOR+ interneurons may fire fewer APs, and their APs may be 
hastened in response to DAMGO. In other words, their output given their input may 
become less intense. This output/input ratio may be difficult to measure, because it would 
require calculating an area-under-the curve estimate in the electrophysiological trace (for 
instance, calculating the area of an excitatory postsynaptic potential) and then also 
quantify their (indicator fluorescence) output in the imaging trace, perhaps also through 
an area-under-the curve estimate. Perhaps another way to quantify output is counting 
discrete APs, though bursts of APs appear to have various and irregular amplitudes and 
this method would also ignore the duration of APs. This output/input calculation may 
demonstrate that although excitatory drive increases in µOR+ neurons, their action 
potential output may not be proportional to their excitatory drive, as indicated by the area 
of the SCO. To synthesize the idea into a hypothesis: DAMGO reduces the output/input 
ratio in µOR+ interneurons, which then facilitates disinhibition. Affirming this 
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hypothesis would assist in explaining why interneurons are unable to prevent net 
excitation in spite of their uptick in glutamatergic input. 
While most articles on the topic of SCOs support the view that they are 
visualizations of glutamatergic input, other explanations exist. Some data by other labs 
suggest that voltage-sensitive calcium channels contribute to this affect as well (Dravid & 
Murray, 2004; Robinson et al., 1993). Indeed, while our data show that CNQX+AP5 
combination prevented SCOs from occurring (Figure 3), I also observed that under this 
condition some rare flickering in a few neurons still seemed to occur. This may 
correspond to bursts of tonic activity and voltage-sensitive calcium channels, but it is 
unclear. In addition, application of depolarizing current into neurons could cause a 
calcium oscillation, though these calcium oscillations were frequently not as large as 
SCOs, though, but sometimes they were. It’s possible that VSCCs may contribute to this 
effect as well. In these scenarios, the SCOs may indicate output of the neurons, and not 
necessarily their glutamatergic input. 
4.13 SCOs: AMPARs, NMDRs or mGluRs? 
In our experiments with SCOs, we blocked VS sodium channels with TTX, and we also 
blocked glutamate receptors with the combination of CNQX and dAP5. However, we did 
not separately block AMPARs and NMDARs. Although practically-speaking, these 
experiments would be trivial to conduct using our testing model, the main issue was data 
interpretation and understanding the conclusions that could be drawn from the data since 
these SCOs are spontaneous – not evoked by a constant stimulus. We anticipated that 
decreasing excitatory drive by separately blocking NMDARs or AMPARs may simply 
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reduce excitatory drive in this model, and therefore reducing the proximal factor 
mediating the SCO. For example, blocking AMPA receptors selectively may also lead to 
a substantial reduction in NMDAR activity by reducing the depolarizations produced by 
EPSPs. Similarly blocking NMDARs or AMPARs would likely reduce excitatory drive 
being input into glutamatergic neurons that ultimately release glutamate onto Gq 
receptors.  
4.14 Relationship between SCO halfwidth and interneuronal function 
Using the SCO model to correlate neuronal activity enabled us to identify a particularly 
persistent feature of a DAMGO response: the prominent increase in halfwidth of SCOs. 
This feature was penetrant in the presence or preincubation with picrotoxin and absent in 
the presence or preincubation with CGP55845 (Figure 7). We also found that CGP55845 
could substantially and significantly increase SCO duration (Figure 12). Utilizing this 
model allowed us to effectively measure the effect of DAMGO in this environment and 
determine that it disinhibited cultures and acted through GABAA and GABAB receptors. 
However, going beyond this; what does this feature tell us about interneuronal activity? 
What does halfwidth indicate about GABAergic interneurons in this environment? 
This question is largely unanswered by these data, yet the electrophysiological 
recordings could provide a reasonable starting point, because those data report the effects 
in single neurons. This starting point could be extrapolated from, in order to provide 
theoretical framework for understanding what halfwidth tells us about interneuronal 
function in this mode. 
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Recalling our electrophysiology protocol; we applied depolarizing current over a 
fixed 1s period to measure DAMGO’s effects on interneuronal action potentials. One 
clear metric involved is the latency to spike, which records how quickly a neuron can be 
induced into firing an action potential. However, this is unlikely the whole explanation 
here because it seems unlikely that interneurons firing their first AP can bring an end to 
glutamate release in the network. Instead, a critical amount and duration of GABA might 
be required for glutamate release from PNs to grind to a gradual halt and terminate the 
SCO for that cycle. SCOs did not stop abruptly; they had slow decline phases. This 
suggests that sustained actions of GABAergic interneurons were required to stop SCOs. 
Therefore, The AP halfwidth and spike frequency may modulate this critical amount of 
GABA, and latency to spike is only one feature of this model.  
SCO halfwidth is clearly a complex and multifactorial phenomenon, and given its 
consistent modulation by DAMGO, it warrants more attention. It suggests a complex 
interaction between glutamatergic and GABAergic signaling and it may assay the ability 
of interneurons to respond quickly to bursts of excitation from PNs.  
4.15 Factors other than GABARs can modulate SCO halfwidth 
In the picrotoxin condition, which induced long and synchronous SCOs, the long 
halfwidths likely reflected that only the GABAB receptor was functioning due to the 
block on GABAA by picrotoxin. The GABAB receptors appear to require longer durations 
of GABAergic stimulation to suppress the PNs. There were clear effects of CGP55845 in 
a background of picrotoxin, which supports this idea (Figure 12). Yet, in the combined 
picrotoxin + CGP 55845 condition, the neurons still flickered (albeit slowly, perhaps only 
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2-3 times per 80 seconds); but why did the neurons flicker at all – why did they not 
simply stay “on” since the GABAA and GABAB receptors were blocked? If GABA 
receptors were required to end an SCO for a cycle, the neurons would simply stay 
“flickered on” for the entire duration of the recording, as the PNs release glutamate more-
or-less indefinitely. On one hand, it may be possible that 100 uM picrotoxin and 10 uM 
CGP55845 did not completely block all the GABA receptors. Or perhaps factors other 
than GABA receptors were in play in this condition. One possible explanation is that the 
PNs have internal mechanisms that can terminate SCOs when GABAergic inhibition is 
absent. For example, delayed rectifier K channels, slow inactivation of synaptic terminal 
VSCCs, or calcium-activated K channels. Or perhaps supply of synaptic glutamate 
becomes depleted, due to the seconds-long bursts of APs that PNs appear to undergo. 
Another possibility is that this just a result of calcium stores becoming depleted from 
internal stores and undergoes a refractory period, and thus not necessarily an 
electrophysiological phenomenon.  
It would be interesting to record from PNs in the presence of picrotoxin and 
CGP55845 and observing the neurophysiological events that correspond to the end of an 
SCO in this condition. As mentioned in this paragraph, it may simply be slow actions of 
K channels that terminate bursts of activity from PNs, or depletion of synaptic glutamate. 
If the termination of SCOs in picrotoxin + CGP55845 did not correspond to an abatement 
of electrophysiological phenomena (i.e., the Pyramidal Neuron kept firing even after the 
SCO ends), then depletion of glutamate or calcium stores seems more likely. Though, 
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depletion of glutamate may cause a chain reaction through the culture that terminates the 
SCO by diminishing excitatory drive. 
To provide a more comprehensive summary of factors modulating SCO 
halfwidth; perhaps there are layers of factors that can modulate this feature. Perhaps 
GABAA receptors provide quick modulation and blockading them makes the GABAB 
receptor the next-in-line mitigator. After blockade of both GABAA and GABAB, perhaps 
only the slow action of intracellularly-stored calcium can stop SCOs. It’s fairly clear from 
the data that a multitude of factors can modulate this and that they may come with their 
own temporal range of responses. 
4.16 Sub-threshold calcium oscillations 
We used an all-purpose general peakfinder setting that culled a wide variety of peak sizes 
with a lower cutoff, but virtually no upper cutoff. These settings were chosen after an 
extensive trial-and-error period of peakfinder adjustments, an ensuring that many peaks 
were culled and not overlooked. It also screened out minor fluctuations in baseline that 
could have been culled alongside larger peaks. This separation prevented us from 
conflating miniscule peaks from much larger ones. 
However, some refinements or adjustments may also be made. For example, 
perhaps certain drugs only affect small peaks, and not larger ones. In this case, perhaps 
multiple peak profiles could have been used. Anecdotally, I rarely observed specific drug 
effects in certain peak profiles during the trial-and-error period; drug effects were usually 
consistent. Nevertheless, this topic could be explored further. 
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In addition, analyzing the RMS may be a useful measure, which could 
presumably measure some of the frequent, small-scale calcium fluctuations which were 
not explored here. This perhaps may be a way of analyzing calcium events that are too 
small to induce CICR and may represent scattered synaptic events that are too out-of-
sync to be interpreted as an SCO. 
4.17 Additional peakfinder measures 
In a similar vein, other features of SCOs could have been analyzed as well, analogous to 
the action potential peakfinder. This calcium peak finder could include rate of rise, rate of 
decay, time to maximum rates, 90% width, and maximum rates. These may all be 
important and distinctive features that can inform us on the physiology of SCOs. This 
may lie outside the scope of this dissertation, since we were primarily focused on 
amplitude and duration to find DAMGO effects, but such analyses could provide grounds 
for future studies.  
We sometimes noticed that neighboring neurons had different characteristics, 
including shape and size. One explanation for this is that neighboring neurons have 
different physiological characteristics, which create SCOs of different sizes. Drastic 
differences in peak amplitudes between (and within) neurons may indicate different 
physiological mechanism; for instance; large peaks may indicate CICR, whereas smaller 
peaks may be NMDARs/AMPARs. Perhaps shapes as well indicate different 
physiological mechanisms. For instance, CICR might correspond with sudden upward 
inflections, and slow decays. This may or may not be associated with Gq receptors 
(because membrane calcium channels may also induce CICR). NMDARs, on the other 
202 
 
hand, may be associated with faster kinetics than CICR, but perhaps could also induce 
CICR on top of their own peaks. AMPARs may be similar. Meanwhile, even smaller 
peaks may be simply voltage-sensitive calcium channels. RMS values may capture 
VSCC activity, due to their fast kinetics and constant fluctuations. Perhaps neuronal 
variability and testing systems all contribute to some of the conflicts in the literature (as 
discussed earlier, whether SCO amplitude is due to VSCCs or glutamate receptors). 
While speculative, these can beget testable hypotheses directed at understanding all the 
underpinnings of SCOs. 
4.18 SCOs for drug discovery and assays of glutamatergic activity 
Other labs have proposed the idea of developing a medium-throughput platform for 
measuring and analyzing SCOs as a means of drug discovery and mechanistic studies on 
epilepsy and its treatment (Cao et al., 2015; Pacico & Mingorance-Le Meur, 2014). Our 
lab performed a variety of experiments with other drugs by using SCOs, after we had 
developed the software to analyze them. The data presented here were deemed central to 
the hypotheses presented here, but we applied this testing system more broadly to test 
other drugs. These pilot experiments could have led to other projects and some data is 
therefore shown here. 
As an example, I hypothesized that nicotinic agonism would have opposing 
effects of DAMGO, considering their antagonistic effects in µOR+ interneurons (Férézou 
et al., 2007). I therefore tested the effects of the nicotinic receptor agonist 1,1-Dimethyl-
4-phenylpiperazinium (100 µM; DMPP) on primary neuronal cultures using the same 
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Figure 28. Nicotinic modulation of SCOs. We tested the effects of the nicotinic acetylcholine receptor 
agonist 1,1-Dimethyl-4-phenylpiperazinium (DMPP; 100 µM) using the same slot model (Figure 5). DMPP 
alone significantly enhances SCO halfwidth. But the combination of DMPP + the µOR antagonist D-Phe-
Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP; 1 µM) blocked the effect of DMPP, which was 
significantly (p < 0.05) lower than DMPP alone, but not significantly different from the saline controls (p > 
0.05). 
 
Surprisingly, we found that DMPP actually enhanced SCO halfwidth compared the no-
drug condition, in a manner similar to DAMGO. However, nicotinic agonism could also 
stimulate enkephalin release in cortical neurons (Dhatt et al., 1995), and therefore we 
tested DMPP in the presence of D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) to 
block the µORs. This drug blocked  the effect we observed with DMPP. These results do 
indeed support the notion that DMPP enhancement of SCO halfwidth was due to 
increased enkephalin release, which was blocked in the presence of CTAP. This line of 
evidence was not followed up on further, but these results do show that this testing 
system has broader implications for drug discovery and mechanistic studies. We 
attempted similar experiments with Cannabidiol, but we obtained nonsignificant results; 
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however, we did not troubleshoot potential problems with solubility because it was not a 
necessary part of this dissertation. In conclusion, while this experiment did not contribute 
to the central experiments of this dissertation, testing SCOs using our experimental 
design may provide a platform for future studies that are directed at determining how 
various drugs affect glutamate release.  
4.19 Between SCOs and interneuronal suppression 
The experiments in this dissertation found inhibition of about one third of interneurons, 
and the calcium imaging approach found detectable enhancement of duration of SCOs, 
and often amplitude as well. However, the question remains; how does suppression of 
interneurons produce an enhancement of SCOs? In other words, having found that 
DAMGO inhibits a proportion of interneurons – how do we explain increased durations 
of bursts of activity (SCO halfwidth)? 
Both Chapter 2 and Chapter 3 are congruent insomuch as they both suggest that 
the µOR suppresses cortical interneurons. Yet, these experiments set two points, and it is 
presently difficult to develop a model that relates these points. For example: how does 
reduced AP halfwidth and firing frequency in interneurons produce SCOs of longer 
durations in both interneurons and excitatory neurons? As mentioned earlier, these 
changes may result in interneurons that are simply slower to be recruited to stop bursts of 
excitatory activity. Perhaps the 1/3rd of cortical interneurons that are inhibited by 
DAMGO are too slow to secrete critical amounts of GABA that halts glutamate release. 
However, there may be practical experiments that can be done as well. This idea might be 
tested by tracking SCOs through inhibitory interneurons (using mRuby2) and PNs with a 
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much higher-speed camera. This may allow investigators to resolve the precise timing 
between the two populations of neurons – with glutamatergic neurons causing SCOs to 
move back and forth between PNs and interneurons, and then perhaps allowing 
researchers to determine whether DAMGO alters the temporal delay. However, SCOs 
likely only monitor glutamatergic input, and not neuronal output. Thus, SCOs in a given 
cell will indicate their glutamatergic excitation – not their delay to start spiking. Perhaps 
paired electrophysiological recordings may assist in this determination. 
4.20 Summary 
The calcium imaging studies highlight that DAMGO enhancement of cortical activity is 
likely secondary to inhibition of interneurons, and therefore provides some clarity in a 
field of ambiguities. Additionally, we substantiate findings that the µOR inhibits GABA 
release onto both GABAA and GABAB receptors, and therefore provides evidence that 
the µOR may be found on neurogliaform neurons. Going further than that however, these 
results provide fertile ground for follow-up studies directed at investigating the 
physiological correspondent phenomena that contribute to SCOs and may serve as an 
initial screening test for drug discovery assays. 
Throughout the experiments presented here, I show that the µOR inhibits 
interneurons in numerous ways, and that a spectrum of responses may represent 
interneuronal type. I provide a detailed statistical analysis of these data, and a framework 
of categorizing DAMGO responses for future studies. Our data show that DAMGO not 
only inhibits interneurons through hyperpolarization, but also causes detectable changes 
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in their firing kinetics and AP frequency, which could have consequences for their 
control of network activity.  
As described in this chapter, these studies are built upon a foundation of studies 
that have investigated the µOR. We successfully recapitulated many expected findings 
about the µOR and its excitatory effects on neuronal circuits, hyperpolarizing effects, and 
suppression of spontaneous APs. In doing this, we provide a framework for further 
investigations of the receptor. On top of that foundation, these studies profile many more 
complex effects of the µOR on APs and affirms that the receptor positively regulates 
αDTX-sensitive currents to modulate some of these effects, as well as non-αDTX-
sensitive currents to mediate other effects. 
The experiments presented here significantly promotes our understanding of the 
µOR in the brain. We show how the receptor produces dysregulation of cortical circuits 
by increasing excitatory outflow. These studies shed light on the mechanisms of the µOR, 
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